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CHAPTER 1 
General introduction 
Adapted from: 
Curr Opin Oncol 1996; 8: 143-151: 
Pathology of malignant melanoma, including new markers and 
techniques in diagnosis and prognosis 
INTRODUCTION 
The melanin pigment in the human skin that protects it from the adverse effect of 
sunlight is produced by specialized neural crest derived cells: melanocytes. These 
cells localize predominantly in the basal epidermal cell layer and in the hair 
follicles. Normally the perikaryon of melanocytes are separated from each other 
by about three to ten keratinocytes (68). When benign melanocyte cells 
proliferate and form clusters or nests, these cells have been termed naevus cells 
and the lesions are called "melanocytic naevi" or "naevocellular naevi". Naevi 
may be regarded as benign neoplasms of melanocytes. Malignant neoplasms of 
melanocytic cells are termed "malignant melanoma", synonymously used with 
"melanoma" (42,46,81,99). 
Two principle pathways of tumorigenesis in melanoma have been proposed: it is 
thought that there may be a de novo proliferation of epidermal melanocytes which 
turned malignant, whereas also a more gradual progression can occur via specific 
melanocytic naevi as an intermediate stage. Tumor progression is the concept of 
the evolution from the normal cell to the metastatic phenotype through a series of 
discrete stages with in each further step an additional growth advantage 
(66,98,109). Because cutaneous melanocytic lesions are readily visible and 
accessible, this concept has been extensively studied in melanoma. With respect 
to clinical features and to architectural and cytological characteristics at the 
histological level, an intermediate lesion between the common acquired naevus on 
the one hand and melanoma on the other hand has been recognized and termed 
"dysplastic naevus". This lesion is considered a probably clinically relevant, 
potential precursor of melanoma (45). 
Melanoma and the pathologist 
Cutaneous malignant melanoma is a highly metastatic tumor, disseminating 
already at relatively small sizes. In The Netherlands the age adjusted incidence 
rate per 100.000 is about 8 with a female to male ratio of about 1.5. The age 
adjusted mortality rate per 100.000 is ± 2.5. About 2.5% of all cancers detected 
per year in The Netherlands concern malignant melanomas, mostly men or 
women in their fouxties or fifties. Death due to cancer involves a malignant 
melanoma in less than 1% (37,69,105,144,144). Although these figures indicate 
that malignant melanoma is not a "big killer", in relatively young adults it is an 
important cause of death and next to this, many clinical and basic research 
activities have focussed on melanoma because of several intriguing aspects. From 
a clinical point of view, next to the challenge of the clinical diagnosis and related 
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aspects such as early detection or screening programs, it is one of the few tumors 
which so far show some promising results in immunotherapeutical trials, whereas 
sentinel node procedures and isolated limb perfusion protocols form modern 
surgical therapeutic modalities (10,11,22,74,76,80, 82,90,97,100,112,126,141, 
147,150). With respect to basic research, malignant melanoma and its precursors 
form an attractive model because of the possibility to study molecular aspects of 
tumor progression through a series of discrete stages which can be identified 
histologically (19,25,44,64,121,149). For the general pathologist melanocytic 
lesions form a substantial part of the daily work: many melanocytic lesions are 
being excised and, since melanoma has many faces with a wide variety in 
morphology (the Lues under the tumors) and look-a-likes, a pertained careful 
consideration of every melanocytic lesion is necessary to avoid histopafhological 
misdiagnoses with serious consequences (14,46,81,99,115). 
Although at present malignant melanoma is not a frequently encountered tumor, 
this may change as one of the most worrisome aspects of malignant melanoma is 
its rapid worldwide rise in incidence. A doubling of incidence every ten to 
fourteen years has been described (53,89,92,145). Also in The Netherlands data 
point to a similar increase in incidence, while between 1950 and 1988 also the 
annual age standardized death rates have increased about four fold, despite the 
fact that more melanomas are being detected in an earlier stage 
(37,105,144,145). These trends have concentrated attention to the epidemiology 
of melanoma and to possible etiological factors which can explain the increasing 
incidence (20,57,62,65,72,86,94,104,118,143). Solar and non-solar factors have 
been put forward and recommendations were made, aiming at primary prevention 
(avoidance of too much uv-light) (7,8,38,51). The underlying research data and 
discussions have also led to an increased awareness amongst physicians and in the 
general population, of the fact that when a cutaneous malignant melanoma is 
detected and excised in an early stage, the prognosis is excellent (secondary 
prevention stimulated through campaigns) (18,76,77,93,103,108,146). Probably 
due to this increased interest in recognizing melanoma at a curable stage and in 
recognizing precursor-stages, more pigmented lesions are being removed for 
histological examination (12,24,58,84,88,95,113). So, pathologists nowadays are 
presented with many melanocytic lesions for diagnosis, especially with a high 
proportion of lesions that are diagnostically challenging. 
From a practical point of view the pathologist, when dealing with a melanocytic 
lesion, has to answer three main questions: 1) Is the lesion malignant and if so, 
11 
what is the prognosis? 2) If benign, is the lesion a marker of an increased risk 
for (developing) a melanoma at another site? 3) Is the lesion completely excised 
and with what margin? 
The unequivocal identification of a malignant melanoma, the determination of the 
free margin and the assessment of prognostic factors are important because of 
their clinical consequences with respect to re-excision margins, sentinel node and 
lymph node dissection procedures and follow-up regimens. Inclusion of patients 
in trials investigating the possible benefits of systemic or regional adjuvant 
therapy in high risk patients also requires an unequivocal and correct diagnosis 
(11,80). 
Although the correct categorization of most of the benign cutaneous melanocytic 
lesions does not influence their clinical management, the significance of recog-
nizing the specific benign entity with its clinicopathological characteristics is that 
recognizing the entity as such helps the pathologist to discriminate the lesion in 
question from malignant melanoma (26,28,87,134,136,152). Although at careful 
consideration most melanocytic lesions are readily diagnosed histologically, a 
significant proportion remains difficult to categorize. As documented in Chapter 2 
a substantial part of the problems in this field encountered by pathologists 
consists of the differential diagnosis between malignant melanoma and dysplastic 
naevus and between malignant melanoma and Spitz naevus. Furthermore, the 
correct identification of a dysplastic naevus is important because, like melanoma 
itself, it may indicate an increased risk of developing a (subsequent) melanoma, 
possibly in the context of the dysplastic naevus syndrome, the latter potentially 
also of importance for the family of the patient. Although reexcision of a not 
completely excised naevus is always advocated to avoid the problem of the 
occurrence of a subsequent so-called "pseudo-melanoma", the total excision of a 
dysplastic naevus is mandatory, because of its role as a relevant precursor lesion 
(45,135). 
So, many clinically relevant problems encountered by pathologists in melanocytic 
pathology are related to melanomas, dysplastic naevi and Spitz naevi. Clinico-
pathological characteristics of these lesions are discussed below. 
Clinico-pathological characteristics of melanoma 
As stated, melanomas show a wide variety in clinical presentation, histology and 
biological behaviour and different classification systems for melanoma exist 
(29,30,48,67,133). One system underlines the distinction between radial (horizon-
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tal) growth phase melanomas and vertical growth phase melanomas and is more 
in line with the concept of tumor progression. Its basis is the concept of the 
relevance of the histological recognition of those lesions which have metastatic 
capacity through identification of a vertical growth phase. In contrast, in this 
concept lesions with only a radial growth phase are considered to lack metastatic 
potential. 
The other widely known (conventional) histogenetic classification system is based 
on clinico-pathological characteristics in conjunction with epidemiological 
properties and is more derived from concepts on the etiology of melanoma. Thus, 
both classification systems seem to have additional value. The most characteristic 
aspects of both classification systems of melanoma are summarized in Tables I 
and II. 
The histological diagnosis of melanoma depends on the recognition of a constel-
lation of histological features, no single feature being diagnostic of melanoma. 
Both architectural and cytological characteristics are important (14,46,81,99). 
Table I: Main clinico-histological features in four histogenetic subtypes of 
melanoma 
Age 
Race 
Relative fre-
quency" 
Localization 
Actinic skin-
damage 
History of 
sun-exposure 
RGP-pattern 
Usual cell 
type 
Epidermis 
Desmoplasia 
Neurotropism 
SSM* 
fourties 
mainly whites 
65% 
all sites 
uncommon 
intermittent 
pagetoid 
epithelioid 
hyperplasia 
common 
uncommon 
uncommon 
NM 
fifties 
mainly whites 
10% 
all sites 
uncommon 
intermittent 
not applicable 
epithelioid 
hyperplasia 
uncommon 
uncommon 
uncommon 
LMM 
sixties 
only whites 
10% 
mostly head 
and neck 
present 
cumulative 
lentiginous 
spindle 
atrophy 
common 
common 
ALM 
sixties 
all 
5% 
nailbeds, 
soles.palms 
absent 
lentiginous 
spindle 
marked 
hyperplasia 
common 
common 
* SSM: superficial spreading melanoma; NM: nodular melanoma; LMM: lentigo 
malignant melanoma; ALM: acro lentiginous melanoma; RGP: radial growth phase 
10% unclassifiable 
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Table II: Radial growth phase versus vertical growth phase invasive 
melanoma 
RGP (microinvasive) 
- Single cells and small aggregates 
(usually < 5-10) of melanoma cells 
of similar size invading in papillary 
dermis (no growth preference) 
- Dermal nests are no larger than 
intraepidermal nests, and do not 
distort the surrounding tissues 
- Cells are similar to the 
intraepidermal melanoma cells 
- Mitoses are rare in dermal part 
- Usually prominent lymphocytic in-
filtrate 
- Almost always thinner than 1 mm 
VGP 
- Single cohesive cellular nodule or 
plaque or multiple nests (usually 
> 15-25 cells in diameter) in pa-
pillary dermis (growth preference) 
- Individual cellular nests are larger 
than nests in RGP, and distort the 
surrounding tissues 
- Dermal melanoma cells differ 
from those in the RGP 
- Mitoses common in dermal part 
- Lymphocytic infiltrate less 
prominent 
- Often thicker than 1 mm 
Architectural characteristics include asymmetry of the mainly relatively large ( > 
6mm) lesion with a poor circumscription of the melanocyte proliferation and 
variation in size and shape of the nests. Further, ascent of atypical cells is an 
important hallmark: upward migration of atypical melanocytes in a random 
pattern, with single cells or groups of a few cells reaching the granular layer 
(pagetoid growth). Lack of so-called maturation is mostly found. Cytological 
atypia (present in the majority of cells) include nuclear changes with nuclear 
enlargement, pleomorphism, hyperchromasia and one or more prominent nucleoli 
and also cytoplasmic changes often including abundant eosinophilic cytoplasma in 
epithelioid cells and so-called dust-like melanin. Mitoses are usually found, also 
in the deeper parts of the lesion where there is an expanding pattern without 
respect for surrounding tissues. Also atypical mitoses and necrosis may be found. 
The histological differential diagnosis of malignant melanoma versus other 
clinico-pathological entities includes a large number of benign and malignant 
tumors both of melanocytic and non-melanocytic origin (Table III). In most cases 
where non-melanocytic lesions are considered in the differential diagnosis, the 
non-melanocytic character can be identified by careful attention to histological 
details in routinely stained sections. Histochemistry and immunohistochemistry 
can be helpful (36,130). 
With respect to the differential diagnosis of the conventional subtypes of 
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Table Ш: Differential diagnosis of malignant melanoma* 
Superficial spreading melanoma 
Melanocytic tumors 
Lentigo malignant melanoma 
Dysplastic melanocytic naevus 
Halo naevus 
Spindle and epithelioid cell naevus 
Pigmented spindle cell naevus 
Recurrent melanocytic naevus 
Other melanocytic naevi with 
prominent pagetoid spread 
Nonmelanocytic tumors 
Squamous cell carcinoma 
Paget's disease, mammary or 
extramamma ry 
Sebaceous carcinoma 
Cutaneous T-cell lymphoma 
Epidermotropic eccrine carcinoma 
Metastatic carcinoma, other 
Angiosarcoma 
Kaposi's sarcoma 
Leiomyosarcoma 
Atypical fibroxanthoma 
Malignant fibrous histiocytoma 
Nodular melanoma 
Melanocytic tumors 
Metastatic melanoma 
Spindle and epithelioid cell naevus 
Pigmented spindle cell naevus 
Cellular blue naevus 
Nonmelanocytic tumors 
Squamous cell carcinoma 
Atypical fibroxanthoma 
Malignant fibrous histiocytoma 
Cellular neurothekeoma 
Malignant peripheral nerve 
sheath tumors 
Angiosarcoma 
Nodular melanoma (continued) 
Kaposi's sarcoma 
Histiocytoid hemangioma 
Leiomyosarcoma 
Lentigo malignant melanoma 
Melanocytic tumors 
Solar lentigo 
Dysplastic naevus 
Pigmented spindle cell naevus 
Superficial spreading 
melanoma 
Nonmelanocytic tumors 
Squamous cell carcinoma, 
spindle-cell type 
Atypical fibroxanthoma 
Cellular neurothekeoma 
Malignant peripheral nerve 
sheath tumor 
Acrolentiginous melanoma 
Melanocytic tumors 
Melanocytic naevi of aerai 
skin 
Lentiginous melanocytic 
proliferations of aerai skin 
Pigmented spindle cell naevus 
Nonmelanocytic tumors 
Squamous cell carcinoma, 
spindle-cell type 
Atypical fibroxanthoma 
Cellular neurothekeoma 
Malignant peripheral nerve 
sheath tumor 
Angiosarcoma 
Kaposi's sarcoma 
Histiocytoid hemangioma 
Leiomyosarcoma 
'After Barnhill and M ihm, reference 14, page 54 
melanoma, it can be difficult to discriminate one subtype from another, and it is 
accepted that about 10% of melanomas is not further classifiable. Although 
important from a clinico-epidemiological point of view and also for the diagnostic 
work of the pathologist because the different conventional subtypes have in part 
their specific benign look-a-likes, the specific subtype of melanoma does not 
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seem to be of prognostic significance. Based on a vast literature, prognostic 
factors are clinical and pathological tumor stage, site of the primairy lesion, age 
and sex of the patient, tumor thickness measured according to Breslow, level of 
invasion according to Clark, presence and extent of ulceration, mitotic rate and 
presence of satellites. Of these the Breslow-thickness (in millimeters) is the most 
important and robust prognostic factor in localised disease. The 5 year survival 
percentage is more than 95% in very thin (<0.76 mm) melanomas whereas in 
thick melanomas (_>. 4 mm) this drops to around 50%. Melanomas of an 
intermediate thickness show survival rates in between (23,39,52,85,113). 
So, as most thin (mostly radial growth phase) melanomas will not metastasize, 
the correct classification of a melanocytic lesion as either benign or malignant is 
especially important with increasing thickness because the prognosis and clinical 
management of a thick melanoma on the one hand or of a thick naevus at the 
other hand is totally different. As stated, in the experience of many pathologists 
two specific differential diagnostic problems are relatively frequently encountered 
i.e. melanoma versus dysplastic naevus and melanoma versus Spitz naevus. 
The dysplastic naevus 
Histologically, a melanocytic naevus is a focal area of increased melanocytic 
cellularity with nested growth of mostly non-atypical melanocytes. Clinically, 
except for cosmetic significance, naevi are important only for their relation to 
melanoma. Different forms of naevi have been described with more or less 
specific clinical and histopathological characteristics. Most of these naevi are only 
important for the pathologist because the various subtypes should be recognized 
as the specific look-a-likes of the various types of malignant melanoma, since 
melanoma is known for its wide variation in histomorphological presentation (16, 
26,87,134,138,152). 
The significance of dysplastic naevi can be summarized as being clinically 
relevant potential precursors of melanoma, being markers of an increased risk for 
melanoma and being simulants of melanoma (41,45). Potential precursors are 
lesions in which the rate of cancer development is greater than that found in 
normal tissue. The clinical importance is that by excision of melanocytic precur-
sors death from melanoma (which would have evolved if the lesion was left 
alone) can be prevented (120). For most types of naevi neither a clinical nor a 
histopathological role as a precursor of melanoma or as a marker of an increased 
risk for melanoma is known at present. For giant congenital naevi however, an 
increased risk of the occurrence of a melanoma in the naevus is known and 
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surgical excision is therefore advocated (91,142). Also malignant change at the 
site of an acquired naevus is a clinically and histologically documented 
phenomenon (47). If at microscopic examination a melanoma is found together 
with remnants of a benign melanocytic naevus, its histological aspect almost 
always is that of a common acquired naevus or that of a dysplastic naevus. The 
estimation of the frequency of progression through naevi to melanoma has been 
based mainly on such histological evidence of naevus remnants in melanoma. 
Between 5% and 39% (median 22%) of melanomas exhibit a dysplastic naevus 
remnant whereas a part of a common acquired naevus is reported in an additional 
10% to 21% (median 15%) of cases (45). 
Based on the histomorphology of naevus-remnants in melanomas and following 
the concept of tumor progression, all common acquired naevi in the general 
population may be potential very early precursors of melanoma. It is not jus-
tifiable and clearly impractical to remove all these naevi because everybody of 
Caucasian complexion has about 10-30 such lesions and the annual incidence of 
melanoma for instance in The Netherlands is about 8 per 100.000. Calculated in 
a crude theoretical model approximately 2% of common acquired naevi may 
progress to dysplastic naevi (131). The dysplastic naevus was described as a 
subtype of naevus carrying a higher, possibly clinical significant risk of malignant 
transformation to melanoma. 
In the late seventies melanoma kindreds were reported with many, clinically 
atypical naevi that were common among family members (Table IV). These 
clinical atypical naevi where referred to as B-K-moles (after the initials of the 
index-families), later as large atypical naevi whereas in 1980 it was suggested 
that the atypical moles should be called dysplastic naevi (31,32,55,56,60,71,83, 
119). The atypical moles as well as the melanomas were considered to be part of 
a syndrome. It was referred to as familial atypical multiple mole melanoma 
(FAMMM) syndrome and later also as dysplastic naevus syndrome (DNS) 
(83,102). Lesions similar to dysplastic naevi in the familial hereditary dysplastic 
naevus syndrome were also reported in non-familial (sporadic) melanoma patients 
(sporadic dysplastic naevus syndrome) (43,106). Persons with the dysplastic 
naevus syndrome (either familial or sporadic) have a highly increased risk of 
developing a melanoma, so that their identification is of clinical importance 
(78,79). Further studies demonstrated that dysplastic naevi occurred also in 
individuals who neither had melanoma, nor were members of hereditary 
melanoma kindreds (9,61,65). Now, clinically atypical naevi are considered not 
uncommon, there reported incidence ranging from 5% to 20% (median 13%) 
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Table IV: Dysplastîc naevus, clinical characteristics 
- 5 mm or more in largest diameter 
- Macular, sometimes with papular central 
- Asymmetrical shape 
- Irregular border 
- Ill-defined border 
- Irregular pigmentation 
- Red hue 
part 
(45). The occurrence of clinically atypical naevi is associated with an increased 
risk for melanoma for persons who are not members of hereditary melanoma 
kindreds also after adjustment for the total number of naevi on the body and for 
other risk factors. An increasing risk for melanoma has been described for an 
increasing number of total naevi and also for an increasing number of clinically 
atypical naevi (128). Cohort studies indicate that the recognition of clinically 
atypical naevi permits the identification of high risk groups, especially individuals 
who have a personal or family history of melanoma, large numbers of atypical 
lesions or a complex phenotype of multiple risk factors. In high risk patients, 
melanomas can be detected in an earlier stage (27,50,54,55,95,123,124,146). So, 
the detection of a high risk phenotype depends primairly on (family)history and 
physical examination (45). Although therefore preferably prior to the excision of 
a suspect melanocytic lesion a total skin examination and a specific family history 
should always be obtained, in our experience this is not always done and possibly 
impractical in current clinical practice. Here is a role for the histopathologist 
who, next to excluding melanoma, by reporting melanocytic dysplasia may 
trigger the search for clinical risk factors associated with an increased melanoma 
risk. 
Few studies have attempted to evaluate the epidemiological significance with 
respect to melanoma risk of just dysplasia as determined histologically. Although 
it is not yet known whether or not independent of clinical atypia, dysplasia seems 
to be associated with a higher melanoma risk (9). An emerging question is how 
many naevi of what (histological) type in connection with which other factors 
determine a significant increased risk (13,15). This question is somewhat 
artificial since both on clinical and histological grounds as well as emerging from 
the concept of tumor progression there probably is a biological continuum 
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between common acquired naevi without atypia towards dysplastic naevi with 
evident architectural and cytological atypia. This continuum probably also feeds 
the discussion on the criteria needed for a histological diagnosis of dysplastic 
naevus, and in line with this the basic discussion about the reproducible recog-
nition of the lesion. Also the bare existence of a clinicopathological entity defined 
by clinical atypia and histological dysplasia has been questioned because the 
borders defining the lesion are under discussion (1,2,3,4). To solve the problem, 
such discussions on matters at the interpretation and defenition level seem only 
part of the solution (33,34,35,40,49,63,75,101,107,116,117,122,125,127,129, 
132,137,140). Because the scoring of the individual features forms the basic 
material from which the pathologists starts to interpret, it seems more important 
to see whether the features contributing to "dysplasia", can be recognized 
reproducibly. Subsequently further studies can determine whether, to what extent 
and how these features are associated with increased melanoma risk, whether 
they are independent of clinical atypia and whether the association is stronger for 
one or more (specific combinations of) features. From there, boundaries of parts 
of the spectrum can be proposed arbitrarily based on clinical pathological 
correlation and clinical relevance: as also melanoma risk so far seems to be a 
continuum related to the "naevus-phenotype" the discussion tends towards the 
question what relative risk and thus what degree of atypia/dysplasia is taken as 
the boundary from which level upwards physicians and health authorities consider 
it worth of taking patients into surveillance programs. Based on these con-
siderations, it was felt worthwhile to study and describe the reproducibility of the 
histological features generally scored in melanocyte lesions, with emphasis on 
dysplastic naevi (Chapter 3). 
The dysplastic naevus as a high-grade simulant of melanoma is a known his-
topathological problem. In this differential diagnosis, next to morphological 
features, other phenotypical and genotypical characteristics may be of value, 
although also here the gradual accumulation of "markers" along the line of tumor 
progression blurs the boundaries: that is, no single marker will problably exactly 
discern between two histologically defined neighbouring stages of disease along a 
line of tumor progression. Although such a problem is frequently encountered in 
the differential diagnosis between a dysplastic naevus and a thin radial growth 
phase melanoma, the biological and clinical significance of these lesions is stated 
to be similar as they are both regarded as lesions without capacity for metastasis. 
The clinically more relevant problem is the differentiation between the deeper 
19 
Table V: Naevus cells versus small melanoma cells in the deeper parts of 
melanomas 
Naevus cells of preexisting naevus 
- No mitoses 
- Small non-atypical nuclei 
- No nucleoli at base 
- Single cells between collagen at 
base 
- Lymphocytes absent 
- Little or no pigment 
- Small uniform nests at base 
Deeply invading small melanoma cells 
- Mitoses sometimes present 
- Larger atypical nuclei 
- Prominent nucleoli 
- Nests and fascicles rather than single 
cells 
- Lymphocytes present 
- Irregularly scattered pigmented cells 
at base of lesion; dusty pigment 
- Larger variable nests at base 
dermal part of a malignant melanoma versus the naevus remnant underlying a 
micro invasive, radial growth phase melanoma (Table V). This differentiation has 
major impact on the Breslow thickness and thus on prognosis and clinical 
management. As a basis towards an application in this differential diagnosis, we 
studied the epidermal growth factor receptor as a possible progression-marker 
(chapter 4 of this thesis). 
Spitz naevus 
The name "Spitz naevus" pays tribute to Sophie Spitz who in 1948 first described 
histological criteria to distinguish the Spitz naevus from malignant melanoma 
(6,139). When the term "Spitz naevus" is used, it refers to a group of melano-
cytic naevi, most often acquired, composed of large epithelioid and/or spindle 
cells (21,73,96,110,111,114,148,149). Another frequently used name is spindle 
and epithelioid cell naevus. Most Spitz naevi are diagnosed in Caucasian children 
and young adults, often involving the legs and the face although the lesion may 
occur anywhere on the body. Although the Spitz naevus is typically a cir-
cumscribed, non-pigmented, asymptomatic, dome-shaped nodule less than 1 cm 
in diameter, there is a large variation in the clinical presentation. A correct diag-
nosis on clinical parameters alone is very difficult. On the other hand the clinical 
features of Spitz naevus, especially the age of the patient and the body-site of 
occurrence should always be taken into account together with the histological 
appearance to reach a final diagnosis. 
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Table VI: Histological features commonly found in typical Spitz naevi* 
- Hyperplasia of the epidermis 
- Overall symmetry 
- Lateral borders sharp 
- Retraction spaces between intraepidermal nests of melanocytes 
and adjacent epidermis 
- Ascending melanocytes absent or rare 
- Kamino bodies present, often confluent 
- Regular architecture of dermal component 
- Infiltrating margins at base non-disruptive 
- Maturation with increasing depth 
- Mitoses in superficial parts, but very rare in deep parts 
'After Mooi and Krausz, reference 99, page 171. 
Histologically, most Spitz naevi are compound lesions, whereas approximately 
10% are solely junctional and a further 15% purely intradermal. The lesion 
consists typically of a proliferation of large epithelioid and/or spindle-shaped 
melanocytes (Table VI). The epithelioid melanocytes are mostly oval or 
polygonal cells with distinct borders. The cytoplasm is often abundant and stains 
mostly homogeneous eosinophilic. The nuclei of epithelioid cells are large and 
centrally located. The chromatin is usually finely dispersed. Typically there is a 
distinct, single round large nucleolus, centrally located in the nucleus. Multi-
nucleated or bi-nucleated cells are commonly observed. The spindle-shaped 
melanocytes are large and often rather plump in appearance. The chromatin of 
the usually oval nuclei is finely stippled. Distinct nucleoli are typical. 
The described features can be encountered in typical Spitz naevi. However, Spitz 
naevi may also show features more generally associated with melanoma. Thus, 
architectural disorder and cytological atypia may be encountered which is 
insufficient for a diagnosis of melanoma but also not consistent with a diagnosis 
of typical Spitz naevus (16,17,136,152). This reflects the experience of most 
pathologists that based on the discussed criteria one can confidently distinguish on 
histological grounds between a typical Spitz naevus and a typical melanoma but 
that difficult cases are encountered regularly. Here, as a first step a scrupulous 
scoring of the clinical and histological parameters can be of help to reach a 
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Table VII: Spitz naevus versus nodular melanoma 
Spitz naevus 
- Symmetrical 
- Epidermal hyperplasia 
- Ovoid nests of cells, perpendicular 
to epidermis 
- Pagetoid spread rare 
- Uniform nests at base 
- Kamino bodies usually present 
- Mitoses absent or rare and very 
rare at base 
- Cellular symmetry/uniformity 
- Maturation with descent to base 
- Single cells between collagen at 
base 
Nodular melanoma 
- Asymmetrical 
- Epidermal hyperplasia uncommon 
- Nests variable in size, shape, and 
orientation 
- Pagetoid spread common 
- Larger nests at base (different size) 
- Kamino bodies rare 
- Mitotic rate often high, mitoses 
common at base 
- Asymmetry 
- Maturation rare 
- Fascicles/nests in the reticular der-
mis at base 
correct diagnosis (26,28,70,138). Important differential diagnostic features to be 
scored are listed in Table VII. A second step may be to ask for the opinion of a 
colleague, more experienced in this particular field of pathology. A further 
approach to minimize the number of "impossible cases" may be the application of 
additional techniques. To this end, we performed DNA-in situ hybridization and 
allelotyping experiments (chapters 5-7 of this thesis). 
OUTLINE OF TÍOS THESIS 
This thesis deals with several aspects of specific differential diagnostic problems, 
regularly encountered in the field of melanocytic pathology. 
Chapter 2 documents the character and relative extent of difficult areas in 
melanocytic pathology encountered in general practice as deducted from the cases 
submitted to the Pathology Panel of the Dutch Melanoma Working Group, the 
bimonthly meetings of which the author of this thesis has been attending for the 
past seven years. The results give guidance to the focussing on the problems 
regarding the dysplastic naevus and the Spitz naevus: histomorphological, as well 
as immunohistochemical, DNA-in situ hybridization and allelotyping approaches 
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were used. 
Chapter 3 describes the attempt made, through an interobserver study among 
experts in the field of melanocytic pathology in Europe, to come up with a set of 
best reproducible histomorphological parameters in melanocytic lesions leading to 
the highest chance of obtaining a reproducible, although still arbitrary histological 
"boundary" between the group of dysplastic naevi and common naevocellular 
naevi. 
Chapter 4 presents a study on the expression of the epidermal growth factor 
receptor on melanocytic cell lines and tissues at the protein and mRNA level and 
its use as a possible progression marker. 
In chapter 5 a study on the feasibility of the application of the DNA-in situ 
hybridization technique on melanocytic cell lines and tissues is described, 
especially on tissue sections from routinely processed, formalin-fixed, paraffin-
embedded tissues. 
Chapter 6 describes a study on the possible implementation of the DNA-in situ 
hybridization technique in the histological differential diagnosis between Spitz 
naevus and malignant melanoma. 
In chapter 7 a pilot study is described in which routinely processed tissues were 
used as starting material to perform allelotyping experiments on Spitz naevi and 
malignant melanomas in order to investigate whether the phenomenon of loss of 
heterozygosity may be used for diagnostic purposes. 
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ABSTRACT 
Some cutaneous melanocyte lesions are notoriously difficult to diagnose by 
histopathology. For that reason the Pathology Panel of the Dutch Melanoma 
Working Party was instituted and is regularly approached to provide an expert 
opinion on problem cases. In order to identify the most common diagnostic 
problems, 1069 consecutive referral cases of submitted lesions (1992 to 1994 
inclusive) were analysed. 
About 60% of the requests came from small laboratories, with up to three consultant 
pathologists. Two-thirds of the lesions reviewed concerned women and nearly 50% 
of the patients were 30 years of age or younger. 
In 8% of the cases the referring pathologists felt unable to make a confident 
diagnosis, in 14% melanoma was suspected and in 12% a differential diagnosis only 
had been formulated. The panel felt able to provide an unequivocal diagnosis in 93 % 
of the requests. 
Of the 158 lesions classified as invasive melanoma by the referring pathologists, 22 
were considered to be benign by the panel. Conversely, 108 invasive melanomas 
(panel diagnosis) had originally been considered as benign lesions, dysplastic naevus 
or melanoma in situ. 
These high numbers of discordancies reflect the intrinsic difficulty of the differential 
diagnoses in this selected material submitted to the panel. Diagnostic difficulties 
were most often encountered with Spitz naevi and dysplastic naevi. 
Although the rate of overdiagnosis and underdiagnosis is quite high, in the majority 
the diagnosis of the referring pathologist matched the diagnosis of the panel. This 
may reflect a proper awareness of difficult melanocytic lesions in pathology practice. 
The activities of the Pathology Panel of the Dutch Melanoma Working Party 
contribute to the improvement of the quality of diagnosis in cutaneous melanocytic 
lesions as they increase the number of unequivocal diagnoses and reduce the number 
of incorrect diagnoses. On the basis of the systematic comparison of the diagnosis 
by the referring pathologist and the panel, postgraduate teaching and quality control 
can be more focused on specific diagnostic problems. (J Pathol 1997; in press). 
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INTRODUCTION 
Quality assurance is of great importance in the diagnosis and treatment of cancer 
patients. This is underscored by the current policy of various international 
organizations which stimulate quality control projects in different aspects of the 
management of cancer patients. As an example, in the field of cutaneous melanoma, 
quality control within the framework of the EORTC (European Organization for 
Research and Treatment of Cancer) Malignant Melanoma Cooperative Group, is 
executed in the context of clinical trials, i.e. by means of site visits by an expert 
surgeon to centres which have entered patients treated with isolated perfusion 
therapy (1). With regard to the histological diagnosis and micro-staging of lesions 
from patients entered in such studies and others, quality assurance is pursued by the 
reviewing of the slides by expert pathologists. 
High quality standards within the framework of international collaboration are not 
possible without a continuous effort to maintain and improve the care of melanoma 
patients at the national and regional level. Thus, melanoma working parties are now 
active in several countries, including The Netherlands. The Dutch Melanoma 
Working Party was founded in 1986. It consists of a multi-disciplinary forum of the 
various specialties involved in melanoma management, aiming at improving of the 
prevention, early diagnosis and treatment of melanoma. Three consensus texts on 
melanoma were prepared by the group under the guidance of the National 
Organization for Quality Assurance in Hospitals (2). Members of the working party 
also act as consultants for colleagues with less experience in melanoma. In addition, 
the working party provides continuous education in melanoma pathology. In order 
to be able to make such an effort to be as effective as possible, insight is required 
gained into the problems encountered by pathologists. This is of importance since 
it provides subjects for targeted training. 
About 300 cases are sent annually to the Pathology Panel of the Dutch Melanoma 
Working Party for expert opinion. The purpose of this article is to report on a 
consecutive series of 1069 such cases, with emphasis on the specific diagnostic 
problems and major discrepancies between the diagnoses of referring pathologists 
and panel pathologists. Recommendations are made with respect to targeted quality 
control and continuous education. 
MATERIALS AND METHODS 
Working methods of the Pathology Panel and materials 
The Pathology Panel of the Dutch Melanoma Party consists of three pathologists 
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(WJM, DJR and ES). It operates on a consultative basis: pathologists who have 
difficulties in making an unequivocal diagnosis of a lesion may send representative 
slides and/or paraffin blocks of the lesion along with a tentative diagnosis to a 
member of the panel. The referring pathologist receives a written report from the 
panel member within one week. Where doubt remains, the panel member may send 
the slides to other panel members. The cases are discussed among the panel 
members at regular bi-monthly meetings. Just occasionally, this panel discussion 
leads to a clinically relevant change in the original panel diagnosis which is then 
promptly communicated in an additional report. 
Requests are received from pathologists throughout the country and occasionally 
from abroad. Each consultation is recorded in the national computerised system on 
pathological diagnoses (Pathologisch Anatomisch Landelijk Geautomatiseerd Archief, 
PALGA) which facilitates retrieval of follow-up data. Also from each consultation 
data are collected by registering items through a standard list: gender, date of birth, 
site of the lesion, name of the hospital/department of the referring colleague, name 
of the consulted pathologist, diagnosis of the referring pathologist, available material 
and panel diagnosis. The panel members use information mentioned in the report 
and the accompanying letter from the referring pathologist to complete this list. 
The diagnoses of the referring pathologists and the panel pathologist(s) are registered 
as standard entities listed in Table I. For this study, these entities were grouped in 
the following categories: no diagnosis, common acquired naevus, Spitz naevus, other 
special type of naevus, dysplastic naevus, melanoma in situ, suspect melanoma, 
invasive melanoma, and others. The category "differential diagnosis" was also 
included. 
Methods used for evaluation of data 
Comparison of the referring pathologists' and the panel's diagnoses was made in 
terms of overdiagnosis and underdiagnosis. 
Overdiagnosis was defined from the perspective of clinical relevance, including 
therapeutic consequences. The following situations were regarded as overdiagnosis: 
the diagnostic category of the referring pathologist was "suspect melanoma" or 
"invasive melanoma" while the diagnostic category of the panel was "common 
acquired naevus", "Spitz naevus", "special type of naevus", "dysplastic naevus" or 
"melanoma in situ". 
Underdiagnosis was defined as the situation in which lesions were classified as 
"common acquired naevus", "Spitz naevus", "special type of naevus", "dysplastic 
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Table I: Categorization of separate diagnoses into diagnostic categories 
Separate diagnosis 
No diagnosis 
Common acquired naevus 
Spitz naevus 
Congenital naevus 
Pigmented spindle cell naevus 
Blue naevus 
Combined naevus 
Dysplastic naevus 
Lentigo maligna 
Melanoma in situ 
Melanoma in situ with dysplastic naevus 
Suspicion of malignant melanoma 
Superficial spreading melanoma 
Nodular melanoma 
Lentigo maligna melanoma 
Acrai lentiginous melanoma 
Melanoma unclassified 
Melanoma in congenital naevus 
Melanoma in pre-existent naevus 
Melanoma metastasis 
Differential diagnosis 
Other diagnosis 
Category 
No diagnosis 
Common acquired naevus 
Spitz naevus 
Other special type of naevus 
Other special type of naevus 
Other special type of naevus 
Other special type of naevus 
Dysplastic naevus 
Melanoma in situ 
Melanoma in situ 
Melanoma in situ 
Suspect melanoma 
Invasive Melanoma 
Invasive Melanoma 
Invasive Melanoma 
Invasive Melanoma 
Invasive Melanoma 
Invasive Melanoma 
Invasive Melanoma 
Invasive Melanoma 
Differential diagnosis 
Other 
naevus" or "melanoma in situ" by the referring pathologist and as "suspect 
melanoma" or "invasive melanoma" by the panel. 
RESULTS 
The Pathology Panel examined a total number of 1069 cases over a three year 
period: 333 in 1992, 359 in 1993, and 377 in 1994. 
Referring pathologist 
The requests came from pathologists working in hospitals or institutes throughout 
The Netherlands and from some pathologists abroad (8 cases in 1992, 24 cases in 
1993 and 24 cases in 1994). Number of requests per institute varied from 1 to 35 
per year. Four institutes sent 15 or more cases per year. The institutes were grouped 
according to the number of pathologists and categories were made: small institutes 
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(1-3 pathologists), intermediate (4-6 pathologists), large ( > 6 pathologists) and 
unknown. Thirty-five small institutes over the three years period submitted 614 cases 
(median: 30; range: 1-88), 14 "intermediate" institutes sent in 194 cases (median: 
13; range: 2-33) and 10 large institutes sent in 179 cases (median: 12.5; range: 2-
61). Thus, small institutes with fewer pathologists sent in more cases. 
Age and gender of the patients 
In Table II the distribution of gender and age of all submitted cases and of the cases 
with a panel diagnosis of "invasive melanoma" are presented. About two-thirds of 
all submitted cases concerned women and nearly half of the patients were 30 years 
of age or younger. The younger the age, especially in children, the more lesions that 
were submitted, but few invasive melanomas were identified by the panel in 
childhood cases (Table II). Nevertheless, the percentage of invasive melanomas in 
young individuals amoung the invasive melanomas diagnosed by the panel was high 
when compared to the age distribution in the general population. In the panel's 
series, about one fourth of invasive melanomas were from patients of 30 years or 
younger while in the Dutch cancer registry about 10% of invasive melanoma patients 
are under the age of 30 (3). This reflects the particular difficulties encountered by 
pathologists in diagnosing lesions in especially younger patients, as well, perhaps, 
a reluctance to diagnose invasive melanoma in a young patient without seeking a 
second opinion. Of the submitted cases in male patients younger than sixteen years 
of age 9% (7 of 74) were diagnosed as invasive melanoma whereas this was 67% 
(12 of 18) in patients over 75 years (Table II). 
With regard to gender, the panel diagnosed more cases of invasive melanomas in 
females than in males as compared to the general population: 34% males and 66% 
females diagnosed by the panel against 41% and 59% respectively, in the general 
population (3). This may be due to the overall surplus of lesions from females 
submitted for consultation. 
Site of the lesion 
The site of the lesion was recorded in 692 cases. The most common sites, in 
decreasing order of frequency, were: legs 34% (234), trunk 33% (226), head/neck 
region 17% (115), arms 12% (85) and other sites 5% (32). Other sites included 
conjunctiva (11), external genitals (10), juxtacutaneous mucosa (5), hip (1), 
abdominal cavity (3), lumbal spinal column (1) and lymph node (1). 
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Table Π: Age and gender of the patients 
age" 
0-15 
16-30 
31-45 
46-60 
61-75 
75 + 
unknown 
total 
gender 
all cases submitted0 
male female 
74 (19%) 56 (9%) 
101 (26%) 215 (33%) 
95 (25%) 201 (31%) 
62 (16%) 107 (16%) 
36 (9%) 59 (9%) 
18 (5%) 14 (2%) 
3 6 
389(37%) 658 (63%) 
panel diagnosis 
invasive melanoma0 
male female 
7 (6%) 5 (2%) 
20 (17%) 49 (21%) 
38 (32%) 78 (33%) 
28 (24%) 58 (24%) 
14 (12%) 37 (16%) 
12 (10%) 10 (4%) 
1 0 
120 (34%) 237 (66%) 
*: in years 
b
: gender unknown: 22 
c
: gender unknown: 7 
Of the 364 lesions diagnosed by the panel as invasive melanoma, the sites were: 
trunk 35% (83), legs 32% (76), head/neck region 19% (44), arms 10% (24) and 
other localizations 3% (8). The site was unknown in 129 cases. 
The body distribution of the invasive melanomas diagnosed by the panel was 
compared with the lesions coded in 1993 as invasive melanoma in the national 
computerised system PALGA. The distribution of the sites of the lesions in PALGA 
was: legs 43% (98), trunk 30% (67), head/neck region 13% (30) and arms 14% 
(32). Compared with the distribution seen in the general invasive melanoma 
population, the panel invasive melanoma cases were somewhat less often localized 
on the legs and more often in the head/neck region. This may reflect a tendency to 
seek confirmation of the pathology diagnosis invasive melanoma in the head/neck 
region since its impact in terms of surgical treatment and cosmetic consequences is 
greater than at other sites. 
Diagnosis 
Table III presents the diagnoses of the refering pathologist versus the diagnoses of 
the panel, after categorization. Relatively many of the lesions referred were 
diagnosed by the panel as Spitz naevus or other special types of naevus. The 
referring pathologists submitted many lesions with suspicion of malignancy, but few 
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lesions with a diagnosis of "melanoma in situ". 
From the total number of lesions categorized as "other" by the referring pathologist 
or the panel (22+27), a substantial number were classified as non-melanocytic soft 
tissue tumour (20), melanocytic lesion of the conjunctiva (8), or melanocyte tumour 
not specified in the other mentioned categories (8). A final group of 13 lesions 
consisted of various other diagnoses such as "scar" and "dermatitis". 
The total number of lesions in which the panel felt unable to arrive at a diagnosis 
was 7; five lesions concerned a punch biopsy, two lesions had been mechanically 
damaged. 
In 23 cases in which the panel had not reached an unequivocal diagnosis; the 
following differential diagnoses were given: Spitz naevus versus invasive melanoma 
(7), (dysplastic)naevus versus invasive melanoma (6), other special type of naevus 
versus invasive melanoma (5), melanoma in situ versus invasive melanoma (1). In 
four cases, other differential diagnoses were reported. 
Of the 90 lesions without a referring pathologist's diagnosis the panel made an 
unequivocal diagnosis in 81 cases (including 21 invasive melanomas). Of the 131 
lesions with a differential diagnosis by the referring pathologist, the panel had an 
unequivocal diagnosis in 122 cases (including 51 invasive melanomas). Of the 151 
lesions with the referring diagnosis "suspect melanoma" the panel made an 
unequivocal diagnosis in 129 cases (including 71 invasive melanomas). 
Overdiagnosis and underdiagnosis were defined and calculated from a perspective 
of clinical relevance including therapeutic consequences (see Materials and 
Methods). 
Overdiagnosis 
Of the 151 lesions classified by the referring pathologist as suspect melanoma, 55 
lesions were overdiagnosed (Table III). Here it was taken into account that lesions 
classified in a pathology report as "suspect melanoma" will probably be regarded 
and treated by clinicians as if they were invasive melanoma. The panel classified 11 
cases as common acquired naevus, 25 as Spitz naevus, 8 as other special type of 
naevus, 8 as dysplastic naevus and 3 as melanoma in situ. Of the 158 lesions 
classified by the referring pathologist as invasive melanoma, 22 lesions were 
overdiagnosed. The panel classified 3 cases as common acquired naevus, 10 as Spitz 
naevus, 4 as other special type of naevus, 2 as dysplastic naevus and 3 as melanoma 
in situ. 
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Underdiagnosis 
Of the 84 lesions classified by the referring pathologist as common acquired naevus, 
12 were classified by the panel as "suspect melanoma" or invasive melanoma (Table 
III). The numbers of the other underdiagnosed lesions were: Spitz naevus 25 of 157, 
other special type of naevus 7 of 54, dysplastic naevus 44 of 176 and melanoma in 
situ 20 of 46. 
Table IV presents a summary of the diagnostic categories of referring pathologists 
versus panel pathologist(s) with the further grouping of diagnoses based on clinical 
relevance. 
Table Г : Summary of the diagnostic category of the referring pathologist 
versus the diagnostic category of the panel 
Diagnosis of 
Referring 
pathologist 
No diagn. 
Benign/DN/MISa 
Diff. diagn. 
Suspect mei. 
Invasive mei. 
Total 
Pathology Panel 
No Benign/ Diff. Suspect Invasive 
diagn. DN/MIS diagn. mei. mei. 
1 56 2 6 21 
3 391 11 23 85 
1 69 5 3 51 
2 55 4 16 71 
0 22 1 2 133 
7 593 23 50 361 
Total 
86 
513 
129 
148 
158 
1034" 
* lesions included: common acquired naevus, Spitz naevus, other special type of 
naevus, dysplastic naevus (DN) and melanoma in situ (MIS) 
" lesions classified as "other" were excluded in this table 
DISCUSSION 
Although the large majority of melanocytic tumours of the skin do not present 
significant diagnostic problems, a small minority of lesions are very difficult to 
diagnose (4,5,6). An expert pathology diagnosis of such cases may be of great 
clinical importance. In the present study, in 8% (90) of the lesions submitted, the 
referring pathologists could not provide a confident diagnosis, in 14% (151) there 
was suspicion of melanoma while in a further 12% (131) only a differential 
diagnosis, had been formulated. In these 372 lesions the panel was able to make an 
unequivocal diagnosis in 332 cases. The panel classified 7% (25) as suspect 
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melanoma and 38% (143) as invasive melanoma. 
It is unclear how many cases of overdiagnosed invasive melanoma really occur in 
practice. In the present study overdiagnosis as "suspect melanoma" was found in 55 
of 151 cases and as "invasive melanoma" in 22 of 158 cases. In the case of a 
diagnosis "suspect melanoma", a second opinion is always likely to be requested, 
as no certainty is given. In contrast, an incorrect but unequivocal diagnosis of 
invasive melanoma will not usually be submitted for pathology review, generally 
leading to overtreatment of the patient. Still, although an unequivocal diagnosis of 
invasive melanoma was reported by the referring pathologist in 22 cases, there must 
have been some element of doubt with regard to the diagnosis: otherwise, the case 
would not have been submitted for consultation. 
Although the number of discordant diagnoses is quite high, the majority of diagnoses 
of the referring pathologists matched those of the panel. This might indicate a proper 
awareness of difficult cases in practice. Still, the only approach to come up with 
hard data is a systematic comparison of all diagnoses. In a documentation study of 
melanomas in one regional Dutch Comprehensive Cancer Centre East (Integraal 
Kankercentrum Oost, IKO), all invasive melanomas and melanomas in situ are 
reviewed by a member of the panel (DJR). Of the first 152 lesions, only one case 
diagnosed as lentigo maligna was classified by the panel member as common 
acquired naevus and three cases reported as melanoma in situ were diagnosed by the 
panel member as superficial spreading melanoma. These numbers are quite 
reassuring regarding the quality of the diagnosis. At the national level the use of the 
Dutch PALGA system makes it possible to review at a later stage cases of "thick" 
invasive melanomas which had not metastasized (7). Since most of the metastatic 
lesions will be verified histologically, a proportion of those thick invasive 
melanomas without documented metastases may be overdiagnosed naevi. These 
approaches may become a part of an integrated quality control programme in the 
future. 
Underdiagnosis of invasive melanoma as benign lesion was noted in this study in 13-
25% of the cases: 12 of 84 common acquired naevus, 25 of 157 Spitz naevus, 7 of 
54 other special type of naevus, 44 of 176 dysplastic naevus and 20 of 46 melanoma 
in situ. Again, although these figures on discordant cases are quite high, the majority 
of the cases were concordant. This probably reflects a low threshold to submit cases 
to the panel and a proper identification of the group of difficult lesions. 
A major problem in estimating the true number of underdiagnosed melanocytic 
lesions in general practice is the fact that most thin misdiagnosed invasive 
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melanomas will not metastasize and remain undetected as misclassified lesions. In 
a recent search for underdiagnosed cases covering about ten years in The 
Netherlands using the PALGA system, only a few cases of truly proven invasive 
melanomas "misdiagnosed" as Spitz naevus were uncovered (8). However, it 
remains unclear how many cases may have been given another key-diagnosis in the 
computerized system, after a case being recognized as a "mis-diagnosis", e.g., after 
metastasis. 
Many lesions were diagnosed by the panel as Spitz naevus or as another special type 
of naevus. Also, of the 23 lesions with a differential diagnosis given by the panel, 
7 lesions concerned the diagnosis Spitz naevus versus invasive melanoma, 6 lesions 
the diagnosis (dysplastic) naevus versus invasive melanoma and 5 lesions the 
diagnosis other special type of naevus versus invasive melanoma. Obviously, both 
referring pathologists and panel pathologists have difficulties in diagnosing such 
lesions (4,5,6,9,10). In terms of improving the general level of accuracy in 
melanoma diagnosis, it would appear to be most effective to concentrate 
postgraduate education on the specific problems concerning dysplastic naevus and 
Spitz naevus. A teaching slide set composed of difficult cases could be circulated 
among laboratories and discussed with an expert. During such discussions the 
technical quality of histological slides could also be addressed. At a later stage, test 
slide sets could be circulated in order to evaluate the diagnostic skill of the 
participating pathologists. Also quality monitoring may focus on the problems 
mentioned. Local laboratories can, together with consultation with more experienced 
colleagues in difficult cases, select representative lesions (i.e., not classical, but 
without a reason for consultation) for a second opinion (intra- or interinstitutional). 
The procedure of consultation by individual panel members only is a result of the 
relatively large number of cases submitted and the need for a rapid response. A 
prompt response is greatly appreciated by the referring pathologist and the clinician. 
For this reason an independent opinion by all panel members on all cases is not 
feasible. As a compromise, only selected cases, which are considered difficult by 
the reviewing panel member, are sent to the other members for further evaluation. 
In addition, the regular panel meetings prove very useful in order to fine-tune the 
histopathological criteria and their interpretation. In almost every case a consensus 
could be reached, although this does not always mean an unequivocal diagnosis. In 
fact the panel, for mainly technical reasons, was not able to make a diagnosis in 7 
cases and could make a differential diagnosis only in 23 cases and a diagnosis 
"suspect melanoma" in 50 cases. Here, additional techniques may provide relevant 
diagnostic information. 
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In this article the diagnosis of the panel is assumed to be the correct diagnosis. We 
realise that the panel too is subject to misinterpretation or observer bias. However, 
based on the specific experience acquired in this particular field of pathology the 
panel is more likely to change wrong diagnoses into correct ones than the other way 
around. Cases diagnosed as melanoma in situ or invasive melanoma are monitored 
through the cancer registry which will enable a clinical validation of the panel 
diagnosis. In addition, cases diagnosed as benign with a later presentation of 
melanoma metastasis, can be traced systematically through the Dutch pathology data 
bank PALGA. 
So far, there has been no opportunity to perform an interobserver study among all 
panel members on submitted, or otherwise selected, difficult cases. However, in a 
recent extended interobserver study on melanocytic lesions among 10 
(dermato)pathologists in the melanocytic field in Europe, the best overall inter-
observer agreement was between two members of the panel who participated in that 
study (11). Furthermore, in an earlier independent review of a set of 104 
melanocytic lesions (not especially difficult cases), the pair-wise interobserver 
agreement among the three panelmembers was good (agreement > 95 % and kappa 
> 0.80; unpublished results, PEJdW) compared to other studies. Even so, an 
interobserver study on the lesions, received for consultation as described here, needs 
to be performed as this is a specific subgroup of cases. The lesions are difficult to 
diagnose, more often located in the head and neck region and the patients tend to be 
younger. Such a study may yield more specific information on the problems 
encountered in this area of pathology. 
In this paper the diagnoses of referring pathologists and the Pathology Panel of the 
Dutch Melanoma Working Party were compared. The rates of overdiagnosis and 
underdiagnosis (together with incorrect treatment) are shown to be quite high. There 
is no reason to believe that such rates of diagnostic problems exist only in The 
Netherlands. Difficulties in diagnosing melanocytic lesions are well known in the 
international literature (4,5,6,9,10) but they are described in a more qualitative 
manner. In the three years analysed, the panel received some requests from 
pathologists abroad, amongst which misdiagnoses were also found. 
In summary, our data indicate that a second opinion given by pathologists, 
experienced in the diagnosis of cutaneous melanocytic lesions, is useful for the 
quality assurance of the pathology diagnosis. Uncertainty in the assessment of 
diagnoses and over- or underdiagnosis are serious problems that deserve to receive 
continuous attention. The quality of melanoma pathology can be improved by expert 
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review and by continuing education targeted at the specific problems signalled. 
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ABSTRACT 
Ten (dermato)pathologists studied fifty cutaneous melanocyte lesions including 
common naevocellular naevi, dysplastic naevi (D.N.), melanomas in situ and 
invasive primary melanomas, with emphasis on the histological criteria of D.N. 
Using a standardized form, 20 defined histopathological features were scored 
(semi)quantitatively. Concordance of diagnosis, efficacy and reproducibility of 
features were investigated. D.N. were distinguished well from the other entities 
(mean P0 0.87). Agreement on the degree of atypia of D.N. was low. The 
reproducibility of the scoring was best for the following features: "irregular 
nests, lymphohistiocytic infiltrate, marked junctional proliferation and large 
nuclei". The overall values of these features to discriminate between D.N. and 
non-dysplastic naevi were better than for the other features studied. 
Using the presence of at least 3 of the 4 features as a condition for the diagnosis 
of D.N., values for sensitivity, specificity, positive and negative predictive values 
were 0.86, 0.91, 0.96 and 0.73, respectively. On the basis of the results these 
features seem best suited as histological criteria for the diagnosis of D.N. (Eur J 
Cancer 1993; 29a: 831-839). 
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INTRODUCTION 
The dysplastic naevus (D.N.) is considered a precursor to cutaneous melanoma. 
In addition, it may serve as a marker of an increased risk of developing 
melanoma. Clinical hallmarks often encountered are a largest diameter of 5 mm 
or more, asymmetry, irregular borders and a variegated colour (1). His-
topathological examination of selected lesions is needed to confirm a clinical 
diagnosis of D.N. and to detect or exclude early melanoma. Elder et al have first 
described the histopathological criteria for the diagnosis of D.N. (2,3). They 
consist of features of cytological atypia, architectural atypia and stromal changes. 
Later, these features were debated and others were added (4-19). At present, it is 
not settled which of the histological criteria are obligatory for the diagnosis, and 
if so, to what degree and extent a feature should be present. Issues related to this 
problem are differences in the appreciation of the concept of D.N. as an entity 
and differences in the final interpretation of the observations. Basically however, 
the selection and weight of a feature for a diagnostic purpose rests on its validity 
in terms of the discriminatory value (efficacy) and the reproducible recognition 
among observers. With regard to D.N., research into the latter matter is sparse 
and concerns only some histological features (16). As it is important to provide 
clinicians with a consistent histopathological diagnosis the pathology subgroup of 
the EORTC Malignant Melanoma Cooperative Group, under the auspices of the 
E.C. Concerted Action on Melanoma, commenced the present study. The validity 
of the morphological features which have been propagated was investigated in 
relation to their interpretation in terms of concordance of diagnosis among 
observers. The results obtained are compared with other studies with respect to 
reproducibility (16) and efficacy (13) of features and concordance of diagnosis 
(19). Although this work may be considered a pilot study, provisional guidelines 
are given on the histopathological classification of D.N., which also may direct 
future research among (dermato)pathologists in a routine setting. 
MATERIALS AND METHODS 
Histological slides 
A set of 50 histological slides was used, taken from the files of the Pathology 
Panel of the Dutch Melanoma Working Party. Based on their individual diag-
noses on all 50 slides, the set consisted of nine non-dysplastic benign melanocytic 
lesions, 25 dysplastic naevi, seven melanomas in situ and nine invasive 
melanomas. Thus, a wide spectrum of melanocytic lesions was included although 
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enriched for certain categories. As the distinction between benign versus malig-
nant can serve as a quality check of the observers, rather a lot of premalignant 
and malignant lesions were included. D.N. were the lesions of principal interest 
in this study. According to the Dutch Panel, following the criteria of Steijlen et al 
(13), the set of D.N. consisted of approximately equal numbers of lesions with 
slight, moderate and marked atypia. 
Observers 
Ten (dermato-)pathologists participated as an observer. The same slides were sent 
to each observer and evaluated independently within a period of three weeks. 
Morphological features and histopathological evaluation 
A standardized form for histopathological evaluation was used, listing morpholo-
gical features based on the literature and personal experience. In addition, criteria 
for melanoma in situ and invasive melanoma were listed (Appendix I). A lesion 
could be diagnosed as common naevocellular naevus, common naevocellular nae-
vus with minor abnormal features, D.N., melanoma in situ, superficial spreading 
melanoma, other lesion. In order to facilitate a consistent appreciation of the 
morphological features a list with detailed definitions of the criteria used was 
added (Appendix II). No set of criteria for the diagnosis D.N. or other diagnoses 
was proposed. The form was discussed and accepted by the observers before 
circulation of the histological slides. One slide per lesion was studied. In most 
cases several sections were mounted on the slide. No clinical data were provided. 
Statistical methods 
The interobserver agreement was studied by calculating the proportion of agree-
ment (P0) and the Kappa-coefficient (the proportion of agreement in excess of 
what is expected by chance, see Appendix III). The measures of agreement in 
diagnosis were also calculated when certain categories were combined. Both the 
mutual agreement in diagnosis of all observers and the agreement with the panel 
diagnosis were determined. The EORTC-panel diagnosis was considered to be the 
diagnosis of a majority of the 10 observers. The reproducibility of the features 
was studied by calculating Pearson correlation coefficients and by applying Kappa 
statistics. The discriminating value of the features was described using discrimi-
nant analyses and Fisher exact tests. Sensitivity, specificity, positive and negative 
predictive value for the features with respect to the panel diagnoses were cal-
culated. 
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RESULTS 
Results reported here mainly concern the issues related to the diagnosis of D.N. 
Concordance of diagnosis 
Before further analysis of the data, the observers' diagnoses were a posteriori 
classified in one of the six categories mentioned in Table I. 
Table I: A posteriori classification of the observers' diagnoses 
Category 1 
- Benign proliferations of melanocytes, except "Spitz naevus" and "freckle". 
It includes: common naevocellular naevus 
congenital naevus 
lentigo 
blue naevus 
combined naevus 
Category 2 
- Common naevocellular naevus with minor abnormal features. 
Category 3 
- Dysplastic naevus. 
Category 4 
- Melanoma in situ. 
It includes: in situ SSM" 
in situ ALM 
Category 5 
- Invasive melanoma. 
It includes: SSM 
NM 
LMM 
ALM 
unclassified melanoma 
aerai SSM 
cutaneous melanoma metastasis 
Category 6 
- "Other diagnoses", including Spitz naevus (8x), freckle (7x), hyperpig-
mentation of basal keratinocytes (lx), functional hyperpigmentation (2x), 
pigmented Bowen's disease (lx), mastocytosis (lx), no diagnosis (4x). 
SSM: superficial spreading melanoma; NM: modular melanoma; LMM: lentigo 
maligna melanoma; ALM: acrolentiginous melanoma 
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All observers agreed on 10 slides, while at least eight observers agreed on 23 
slides, and at least five observers agreed on 46 slides. The distribution of the 
diagnoses per observer is given in Table II. It illustrates the interobserver 
variation in the diagnoses made. All observers scored one or more lesions in 
category 2 (mean 6.5), but only in one case did a majority agree on this diag­
nosis. 
Table Π: Distribution of observers' diagnoses 
Observer 
a 
b 
с 
d 
e 
f 
g 
h 
i 
j 
a-j mean 
s.d. 
EORTC 
panel* 
Number of slides per diagnostic 
1 2 3 4 
13 8 13 2 
8 10 17 4 
7 4 21 4 
7 1 25 5 
11 9 14 2 
5 2 27 4 
8 11 12 6 
19 5 4 10 
15 6 12 7 
9 9 15 6 
10.2 6.5 16 5 
4.3 3.4 6.8 2.4 
9 1 23 6 
category 
5 
10 
9 
12 
11 
12 
10 
11 
10 
7 
7 
9.9 
1.8 
9 
6 
4 
2 
2 
1 
2 
2 
2 
2 
3 
4 
2.4 
0.8 
2 
The diagnosis of a majority of the 10 observers 
As is shown in Table ΠΙΑ the mean P0 and Kappa values for the comparison of 
benign vs. malignant lesions are high, i.e. 0.90 and 0.76, respectively. Also, 
mean values for the comparison II are relatively high, i.e. 0.79 and 0.58. These 
figures represent the means of 45 interobserver comparences. When the diag­
noses of one observer were compared to the diagnoses of a majority of the 10 
observers ("panel diagnoses"), the values were higher (Table HIB). Stratification 
of the diagnostic categories coincides with a decrease of the P0 and Kappa values, 
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but for all diagnoses taken separately (analysis V) mean P0 and Kappa values are 
acceptable: 0.70 and 0.61, respectively. A low level of agreement (P0 mean = 
0.28; s.d. = 0.16; 45 observer pairs) was found on the degree of histopathologi-
cal atypia between pairs of observers. This comparison was made if both 
observers of a pair classified the lesion as either common naevocellular naevus 
with minor abnormal features or as a D.N., thus constituting 4 levels of atypia, 
that could be scored (appendix I, items 38 and 39). 
Discriminative value 
The sensitivity, specificity, positive and negative predictive value of the features 
discriminating between a non-dysplastic naevus and a D.N. are given in Table 
IV. Highest values for sensitivity were found for the following features: per-
centage of melanocytic cells with at least one feature of cytological atypia, 
irregular nests, lymphohistiocytic infiltrate, large nuclei, elongated rete ridges 
and nuclear pleomorphism. Highest values for specificity were found for the 
following features: abnormal distribution of melanin, marked junctional proli-
feration, irregular nests, neovascularisation, lamellar fibroplasia and shoulder 
phenomenon. Highest values for positive predictive value were found for: 
irregular nests, marked junctional proliferation, lamellar fibroplasia, nuclear 
polymorphism and shoulder phenomenon. Highest values for negative predictive 
value were found for: irregular nests, % melanocytic cells with at least one of the 
cytological atypia features, large nuclei, nuclear polymorphism, and lymphohis-
tiocytic infiltrate. For these analyses panel diagnoses were used. Scoring of the 
features was dichotomized. Dichotomization, other than into present vs. absent, 
resulted in lower figures. From two observers some data were missing, which 
prohibited a meaningful analysis. 
Discriminant analysis showed that using more than three to four features had no 
further discriminating value. Although the most discriminating features varied 
from observer to observer, certain features were more often among the top four. 
Table V shows the overall hierarchy of the best discriminating features. The 
average Revalues for these features varied from 0.65 (for irregular nests) to 0.30 
(for large cytoplasma). The hierarchical order obtained by discriminant analysis 
correlated well with the order obtained when applying a Fisher exact test, ranking 
the features according to significance (best P-values). Features not listed, but 
with a relatively high discriminating value in a single observer were: bridges of 
melanocytes, lymphohistiocytic infiltrate, lamellar fibroplasia, dust-like melanin 
and elongated rete ridges. 
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Table III: Reproducibility of diagnosis expressed in P0 and Kappa values* 
A. Means and s.d. of 45 P0 values and Kappa values of 45 comparisons of 
two observers (ab ij) 
mean 
s.d. 
I 
0.90 
.06 
II 
.79 
.09 
Po 
III 
.69 
.10 
IV 
.63 
.09 
V 
.57 
.09 
I 
0.76 
.13 
Kappa 
II III 
.58 .57 
.17 .12 
IV 
.50 
.10 
V 
.45 
.10 
B. P0 and Kappa of comparisons between observer and "panel" diagnosis for 
each of observers a-j 
a-panel 
b-panel 
c-panel 
d-panel 
e-panel 
f-panel 
g-panel 
h-panel 
i-panel 
j-panel 
mean 
s.d. 
I 
0.94 
.96 
.82 
.98 
.94 
.94 
.96 
.92 
.92 
.96 
.93 
.04 
II 
.90 
.86 
.82 
.92 
.86 
.90 
.94 
.70 
.82 
.98 
.87 
.08 
Po 
III 
.82 
.86 
.72 
.82 
.78 
.82 
.88 
.62 
.74 
.92 
.80 
.09 
IV 
.70 
.76 
.76 
.82 
.66 
.84 
.72 
.54 
.66 
.78 
.72 
.09 
V 
.70 
.70 
.70 
.80 
.62 
.80 
.70 
.54 
.66 
.78 
.70 
.08 
I 
0.85 
.90 
.58 
.95 
.85 
.85 
.91 
.82 
.80 
.90 
.84 
.10 
II 
.80 
.72 
.64 
.84 
.72 
.80 
.87 
.38 
.68 
.96 
.74 
.16 
Kappa 
III 
.75 
.79 
.59 
.73 
.68 
.73 
.83 
.52 
.64 
.88 
.71 
.11 
IV 
.60 
.67 
.66 
.74 
.54 
.76 
.63 
.43 
.55 
.70 
.63 
.10 
V 
.62 
.61 
.59 
.71 
.54 
.71 
.62 
.45 
.57 
.71 
.61 
.08 
* Comparisons based on clustering of diagnoses (categories of Table I): 
I : [1,2,3,6] vs [4,5] benign/malignant 
Π : [2,3] vs [1,4,5,6] 
ΠΙ : [1] vs [2,3] vs [4] vs [5] vs [6] categories 2 and 3 together 
IV : [1,2] vs [3] vs [4] vs [5] vs [6] categories 1 and 2 together 
V : [1] vs [2] vs [3] vs [4] vs [5] vs [6] all diagnoses separately 
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Table IV: Sensitivity, specificity, positive and negative predictive value of 
histopathological features in "dysplastic" vs. "non-dysplastic" 
naevi* 
Feature 
- large nuclei 
- nuclear hyperchromasia 
- nuclear polymorphism 
- prominent nucleoli 
- large cytoplasm 
- % melanocytic cells with at 
least one of the cytological 
atypia features 
- irregular nests 
- marked junctional 
proliferation 
- dust-like melanin 
- elongated rete ridges 
- loss of preference for rete 
ridge tips 
- "shoulder phenomenon" 
- abnormal distribution of 
pigment 
- lymphohistiocytic infiltrate 
- lamellar fibroplasia 
- neovascularisation 
sensi-
tivity 
0.87 
.72 
.87 
.67 
.81 
.94 
.89 
.71 
.62 
.87 
.67 
.70 
.33 
.88 
.70 
.51 
speci-
ficity 
0.67 
.71 
.67 
.80 
.74 
.45 
.84 
.84 
.75 
.17 
.77 
.80 
.88 
.52 
.81 
.83 
positive 
predictive 
value 
0.87 
.86 
.87 
.89 
.88 
.81 
.93 
.91 
.86 
.71 
.80 
.89 
.87 
.81 
.90 
.88 
negative 
predictive 
value 
0.68 
.51 
.68 
.50 
.62 
.76 
.76 
.55 
.45 
.35 
.63 
.53 
.36 
.65 
.53 
.42 
* panel diagnoses were used (category 1 and 2 vs. 3); for each feature the total of the 
data from eight observers was used to calculate sensitivity, specificity, positive and 
negative predictive value; scoring of features was dichotomized (present vs. absent); 
data from two observers were incomplete. 
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Table V: Overall hierarchy in discriminating value of histopathological 
features for the discrimination between "normal" naevi and 
"dysplastic" naevi* 
- irregular nests 
- marked junctional proliferation 
- large nuclei 
- shoulder phenomenon 
- nuclear hyperchromasia 
- loss of preference for rete ridge tips 
- nuclear polymorphism 
- large cytoplasm 
* Hierarchy based on discriminant analyses and Fisher exact tests. Some features not 
listed had a relatively high value in a single observer e.g. bridges of melanocytes, 
lymphohistiocytic infiltrate, lamellar fibroplasia, dust-like melanin, elongated rete 
ridges 
Reproducibility of feature scoring 
The concordance in the non-dichotomized scoring of the features among eight 
observers can be found in Table VI. From two observers some data were mis-
sing, which prohibited a meaningful analysis. The results of the analysis of all 
diagnoses (category 1 to 6) did not differ from those of the analysis restricted to 
category 1, 2 and 3 only. Highest mean Pearson correlation coefficients ( > 0.65) 
with also the highest minimum values for a single observer (see range), were 
found for the following features: lymphohistiocytic infiltrate, irregular nests, and 
marked junctional proliferation. Counting of the number of "bridges of 
melanocytes" was hardly reproducible (not shown). 
Based on the foregoing results features were selected and Kappa values calculated 
for the agreement on their presence or absence in benign lesions (i.e. categories 
1, 2 and 3). Best values were obtained for: irregular nests, lymphohistiocytic 
infiltrate, marked junctional proliferation, and large nuclei. The results are shown 
in Table VII. The highest Kappa value was found for the first feature mentioned. 
Values were not higher when another dichotomization then present vs. absent was 
used. The histopathological features are illustrated in Figs 1 and 2. Figs 3 and 4 
show photomicrographs of lesions which were classified as common naevocellular 
naevus and melanoma in situ, respectively. 
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Table VI: Comparison of the scoring of histopathological features among 
eight observers using Pearson correlation coefficients" 
Feature 
large nuclei 
nuclear hyperchromasia 
nuclear polymorphism 
prominent nucleoli 
large cytoplasm 
% melanocyte cells with at least 
one cytological atypia feature 
irregular nests 
marked junctional proliferation 
dust-like melanin 
elongated rete ridges 
loss of preference for rete ridge 
tips 
"shoulder phenomenon" 
abnormal distribution of pigment 
lymphohistiocytic infiltrate 
lamellar fibroplasia 
neovascularization 
Correlation coefficient 
Ab 
mean 
0.53 
.45 
.57 
.43 
.53 
.52 
.72 
.65 
.41 
.53 
.48 
.60 
.46 
.79 
.56 
.28 
range 
0.42-.68 
.10-.59 
.34-.71 
.27-.67 
.26-.79 
.19-.80 
.56-.81 
.50-. 80 
.00-.77 
.31-.78 
.06-.74 
.22-.74 
.18-.73 
.63-.89 
.43-.69 
.00-.55 
В 
mean 
0.53 
.46 
.58 
.43 
.53 
.52 
.72 
.65 
.41 
.53 
.48 
.60 
.46 
.79 
.56 
.28 
range 
0.42-.69 
.10-.59 
.34-.71 
.27-.Ö7 
.26-.79 
.19-.80 
.56-.81 
.50-,88 
.00-.77 
.31-.78 
.06-.74 
.22-.74 
.18-.73 
.63-.89 
.43-.69 
.00-. 55 
1
 Per observer the score (not dichotomized) of that observer was compared to the 
mean of the score of seven other observers; data from two observers were in-
complete; per feature the mean and range of the results from eight observers is 
presented. 
b
 A: all categories of Table I included; B: limited to categories 1, 2 and 3. 
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Table П: Kappa values for the agreement on presence/absence of four 
features* 
Observer 
a 
b 
с 
d 
e 
g 
h 
j 
mean a-j 
s.d. 
feature 
irregular 
nests 
0.60 
.65 
.52 
.60 
.38 
.67 
.54 
.68 
.58 
.10 
lymphohistio-
cytic infiltrate 
0.38 
.49 
.40 
.56 
.50 
.45 
.56 
.38 
.47 
.07 
marked 
junctional 
proliferation 
0.36 
.40 
.46 
.28 
.47 
.55 
.31 
.47 
.41 
.09 
large 
nuclei 
0.40 
.44 
.28 
.46 
.37 
.48 
.19 
.33 
.37 
.10 
* - Per observer the mean of kappa's of that observer compared with each of seven 
others is presented. 
- Provided the own diagnosis of the two compared observers was 1, 2 or 3. 
- Dichotomized: present vs. absent 
DISCUSSION 
A first condition for a reliable diagnostic test is that the result is reproducible on 
a given specimen. As the scoring of multiple histopathological features in 
diagnosing melanocytic lesions is such a test, we investigated the reproducibility 
of the scoring. No clinical data were provided. The four best reproducible 
features were: irregular nests, lymphohistiocytic infiltrate, marked junctional 
proliferation and large nuclei. Although the Kappa values of these features are 
not very high, they are still better than those of the other features examined. The 
fact that, when another dichotomization or further stratification was used, values 
became lower, indicates that reproducibility is best when a simple present versus 
absent dichotomization is used. Similarly, Ahmed et al (16) found low Kappa 
values, using four levels that could be scored for junctional activity, irregular 
nests, dusty melanin and large melanocytic nuclei. 
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Figure 1: Dysplastic naevus. 
Photomicrograph of a dysplastic naevus, showing marked junctional activity, irregular 
nests, and lymphocytic infiltrate. At this magnification, large nuclei cannot be appreciated 
properly. 
Figure 2: Dysplastic naevus. 
Higher magnification of the lesion shown in Fig. 1. Note several melanocytic nuclei that 
are larger than those of adjacent keratinocytes. 
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Figure 3: Common naevocellular naevus. 
Photomicrograph of a common compound naevocellular naevus, showing slight architec­
tural abnormalities. 
Figure 4: Melanoma in situ. 
Photomicrograph of a melanoma in situ: pagetoid growth of atypical melanocytes. 
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Given these basic values on the reproducibility of the scoring, examination of the 
validity of each of the four features to discriminate between dysplastic naevi and 
common naevi, showed that three of them scored the highest in the discriminant 
analysis. Also, their values for sensitivy, specificity, positive and negative value 
were among the best. This is in agreement with the study by Steijlen et al (13), 
who found the best efficacy for irregular nests, marked junctional activity, large 
melanocyte nuclei and dust-like melanin. 
In 21 of the 23 lesions that in the present study were diagnosed as D.N. (panel 
diagnoses), all four best reproducible features were present, as determined by the 
score of the majority of the observers. However, features were "missed" in a 
number of cases by individual observers, illustrating the suboptimal reproducibi-
lity of the feature scoring. Based on these data and the fact that the discriminant 
analysis showed no further value in the discrimination between "common" and 
"dysplastic" naevi when using more than four features, we examined the 
discriminative value of combinations of these features to distinguish D.N. from 
common normal naevi. Using the presence of all four features as a diagnostic 
prerequisite for D.N., values for sensitivity, specificity, positive and negative 
predictive value were 0.53, 0.93, 0.95 and 0.45 respectively. Thus, the missing 
of one feature by an observer would imply that D.N. would not be diagnosed as 
such. 
However, using the presence of at least three of the four features as a diagnostic 
prerequisite for D.N., values for sensitivity, specificity, positive and negative 
predictive values were 0.86, 0.91, 0.96 and 0.73, respectively. This implies that 
a very acceptable efficacy can be reached with a limited set of reproducible 
criteria, which has advantages in terms of leamibility and applicability. For this 
practical reason we propose lesions be diagnosed as D.N. if at least three of the 
four features mentioned are present. In the lesions diagnosed as D.N. by the 
panel, nuclear atypia was nearly always scored as present by the individual 
observers. In our opinion lesions with one or two of the features should be 
classified as a common naevocellular naevus, while mentioning the minor 
abnormal features in the detailed microscopic report or note. They should not be 
diagnosed as a separate entity. For the 10 observers, the mean value for the 
correct classification with respect to the panel diagnosis in either category 1 and 
2 or in category 3 was 88%, using the proposed approach summarised in Table 
VIII. The morphological features mentioned are shown in Figures 1 and 2. In 
this approach grading of atypia in D.N. is not recommended since it is not 
reproducible. The features relevant for the differential diagnosis of D.N., 
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Table VIII: Proposed diagnostic approach 
Morphological features 
No or less than three of the features 
mentioned below for dysplastic naevus 
Three or more of the following 
features 
- marked junctional proliferation 
irregular nests 
- large nuclei 
- lymphohistiocytic infiltrate 
Pagetoid growth 
Continuous junctional proliferation 
Pagetoid growth 
Continuous junctional proliferation 
Invasion of markedly atypical 
melanocytes into the dermis 
Diagnosis 
Common naevocellular naevus 
Dysplastic naevus 
Melanoma in situ 
Superficial speading melanoma 
melanoma in situ and superficial spreading melanoma are also included in Table 
VIII. 
"Marked junctional activity" and "irregular nests" both reflect architectural 
atypia, "large nuclei" reflects cytological atypia and "lymphohistiocytic infiltrate" 
reflects stromal changes. Comparing our study with that published by Clemente 
et al (19), we feel that "marked junctional activity" is similar to their major 
criterion "basilar proliferation of atypical melanocytes (extending at least three 
rete ridges or "pegs" beyond any dermal naevocellular component)". In addition, 
our "irregular nests" is comparable to their other major criterion "organisation of 
the melanocytic proliferation in a lentiginous or epitheloid-cell pattern". Our 
feature "large melanocytic nuclei" is included in their first mentioned criterion, as 
the term "atypical melanocytes" is used. Of their minor criteria, i.e. "lamellar 
fibrosis or concentric eosinophilic fibrosis", "neovascularisation", "inflammatory 
response", and "fusion of rete ridges", the feature "lymphohistiocytic infiltrate" 
was most reproducible in our study. Clemente et al (19) found good concordance 
of diagnosis, using a previously agreed upon set of criteria. In the present study, 
no set of criteria was suggested by and to the observers. Emphasis was put on the 
defenition of the features, which were scored. The interpretation was left to the 
62 
observers. Doing so, we also found a very acceptable concordance of the 
diagnosis for most observers. 
In the present study the matter of the preferred nomenclature of D.N. was not 
addressed. The most important issue to our opinion is that dermatologists, 
pathologists and dermatopathologists formulate a reproducible scheme for 
diagnosing and reporting these naevi. We feel that studies on the efficacy and 
reproducibility of histopathological features for diagnosing D.N. are more 
instrumental to solve this issue than semantic discussions on the nomenclature of 
the lesion. 
In conclusion, our study indicates that it is possible to reliably diagnose D.N. by 
histopathological examination. A reproducible set of criteria with, in theory, good 
discriminating value can be compiled. Our study was set up as a first step to 
standardize the histopathological diagnosis of D.N. among European centres. 
Further studies should reveal whether our proposed diagnostic approach can add 
to a consistent diagnosis of D.N., among pathologists and dermatopathologist in 
centers, who may coordinate continuing education and quality control, and, more 
important, among those in a routine setting. 
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APPENDIX I 
EORTC-MMCG PATHOLOGY FORM ON THE DIAGNOSIS OF 
DYSPLASTIC NAEVUS 
SLIDE NUMBER 
Date (day, month, year) 
Reader (write or stamp) 
Ш 1-2 
I I I I I I I 3-е 
E D 9-ю 
HISTOPATHOLOGICAL EVALUATION 
General remarks: 
1) The criteria for cellular and architectural atypia ad A concern the intra-
epidermal (including the junctional) component only. 
2) If asked for, the proportion of atypical structures (e.g. melanocytic cells, 
nests) as part of the total in the lesion, is given in a percentage estimated in 
one of the following classes: 
0% (code: 0), 1-10% (code: 1), 11-50% (code 2), 51-100% (code 3). 
3) Further definition of the criteria: see addendum. 
A) MAJOR CRITERIA 
1) Cytological atypia 
large nuclei (percentage code) 
nuclear hyperchromasia (percentage code) 
nuclear polymorphism (percentage code) 
prominent nucleoli (percentage code) 
large cytoplasma 
What is the estimated percentage of melanocytic cells with at 
least one of the cytological atypia features? (percentage code) 
2) Architectural atypia 
irregular nests (percentage code) 
marked junctional proliferation (yes=l, no=0) 
B) MINOR CRITERIA 
3) Cytological change 
dust-like melanin (percentage code) Q 19 
4) Architectural changes 
elongated rete ridges (yes = l, no=0) 
bridges of melanocytes (maximal no. per section) 
loss of preference for rete ridge tips (yes=l, no=0) 
"shoulder" phenomenon (yes = l, no=0) 
abnormal distribution of pigment (yes = l, no=0) 
lymphohistiocytic infiltrate (see addendum) 
lamellar fibroplasia (yes = l, no=0) 
neovascularisation (yes=l, no=0) 
Π 
D 
D D 
D 
D 
D 
D 
11 
12 
13 
14 
15 
16 
17 
18 
D 
1 1 1 D 
D 
D 
D 
D 
D 
20 
21-22 
23 
24 
25 
26 
27 
28 
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SLIDE NUMBER E D 29-30 
Reader (write or stamp) : Γ I I 31-32 
С CRITERIA FOR MELANOMA (IN SITU) 
- continuous atypical melanocyte proliferation (yes = 1, no=0) Q 33 
- pagetoid cells present (yes=1, no=0) Q 34 
- ascension of atypical melanocytes reaching granular layer | | | 35-36 
(mention maximal number found in one section) 
- lack of maturation (yes = 1, no=0) Q 37 
(no decrease in nuclear size of dermal melanocytic cells as 
compared to junctional component) 
DIAGNOSIS (according to your own criteria) • 38 
Common naevocellular naevus = 1 
Common naevocellular naevus with minor abnormal features = 2 
Dysplastic naevus = 3 
Melanoma in situ = 4 
SSM = 5 
Other, please specify = 6 
If a dysplastic naevus please indicate degree of atypia: Q 39 
(according to your own interpretation) 
not applicable = 0 
slight = 1 
moderate = 2 
marked = 3 
CONTEXT OF LESION • 40 
Not applicable = 0 
Dysplastic naevus ass. with common naevocellular naevus = 1 
Melanoma in situ ass. with common naevocellular naevus = 2 
Melanoma in situ ass. with dysplastic naevus = 3 
SSM associated with common naevocellular naevus = 4 
SSM associated with dysplastic naevus = 5 
If the lesion would not have been completely resected, would you Q 41 
consider re-excision? (yes = l, no=0) 
COMMENTS; 
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APPENDIX Π 
ADDENDUM TO THE EORTC-MMCG PATHOLOGY FORM ON THE 
DIAGNOSIS OF DYSPLASTIC NAEVUS 
Further definition of the criteria 
Large nuclei 
Nuclear hyperchromasia 
Nuclear polymorphism 
Prominent nucleoli 
Large cytoplasma 
Irregular nests 
Marked junctional proliferation 
Dust-like melanine 
Elongated rete ridges 
Bridges of melanocytes 
Loss of preference for rete 
ridge tips 
Shoulder phenomenon 
Abnormal pigment distribution 
Lymphohistiocytic infiltrate 
Lamellar fibroplasia 
Neovascularization 
Pagetoid cells 
nuclear size > nuclei of basal keratinocytes 
nuclear density > nuclei of lymphocytes 
irregular size/shape/orientation 
nucleolar size > one-third of erythrocytes 
as compared to melanocytes in perilesional 
skin 
irregular size/shape 
number of melanocytes (either as single cells 
or loose aggregates) > number of basal 
keratinocytes, along at least three adjacent 
rete ridges (nestlike or lentiginous) 
finely and equally dispersed grey-brown 
pigment 
as compared to those in perilesional 
epidermis 
rete rigdes connected by bridging nests of 
melanocytes 
arrangement of solitary units and/or nests of 
melanocytes at the lateral side of the rete 
ridges and/or over the top of dermal papillae 
extension of junctional component over at 
least three rete ridges beyond the dermal 
naevocellular component 
retention of melanin throughout dermal 
naevocellular component 
0=no; l=slight, perivascular; 2=moderate, 
aggregate-like; 3=marked, band-like 
as compared to the papillary dermis in 
perilesional skin 
as compared to the papillary dermis in 
perilesional skin. 
abnormal melanocytes with abundant pale 
cytoplasma containing dusty melanin 
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APPENDIX ΠΙ 
ADDENDUM TO THE EORTC-MMCG PATHOLOGY FORM ON THE 
DIAGNOSIS OF DYSPLATIC NAEVUS 
The observer aereement for categorical data* 
P 0 : represents the observed proportion of agreement between two observers (the 
observed proportion of subjects with equal diagnosis for the two observers). 
K: represents the proportional excess of agreement beyond what is to be ex­
pected under independence. The coefficient kappa is defined by 
0 - e 
К = 
1 -e 
о = observed proportion of agreement 
e = expected proportion of agreement 
* Cohen, J. 
A coeficient of agreement for nominal scales. 
Educational and Psychological Measurement 1960; 20: 37-46. 
Quality of Kappa** 
< 0.20 poor/slight 
0.21 - 0.40 fair 
0.41 - 0.60 moderate 
0.61-0.80 substantial 
0.81 - 0.99 almost perfect 
1.00 perfect 
** Landis J.R. and Koch G.G. 
The measurement of observer agreement for categoria] data. 
Biometrics 1977; 33: 159-174 
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CHAPTER 4 
Increasing epidermal growth factor receptor 
expression in human melanocytic tumor 
progression 
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ABSTRACT 
Different results have been reported on the expression of epidermal growth factor 
receptor (EGFR) in human melanocyte lesions, which may be due to different 
methodological approaches. Therefore, we compared EGFR expression in six 
human melanoma cell lines by utilizing the monoclonal antibodies 2E9, 425 and 
225, applying four immunocytochemical staining procedures. The results were 
compared with those obtained by a multiple point ligand binding assay. In 
addition, Northern blot analysis was performed. 
A three-step immunoperoxidase method using the monoclonal antibody 2E9 
proved the most sensitive. Staining intensities, estimated semiquantitatively, 
correlated well with the quantitative data obtained by the ligand binding assay. 
Expression on the mRNA level was also in agreement with these results. 
Immunohistochemical staining of a large series of human cutaneous melanocyte 
lesions using the method selected showed differential EGFR expression in various 
stages of melanocyte tumour progression: 19% of common nevocellular nevi, 
61% of dysplastic nevi, 89% of primary cutaneous melanomas and 91% of 
melanoma metastases showed staining of the melanocyte cells. Intralesional 
heterogeneity of EGFR expression was present. Although the mean percentage of 
positive melanocyte cells in positive lesions did not increase with progression, 
mean staining intensity was stronger in malignant lesions compared to benign 
lesions. 
Ligand binding assays showed that EGFR expression in the highly metastasizing 
cell lines MV3 and BLM was at least 40 times higher than in the cell lines IF6, 
530, M14 and Mel57 which do not or only sporadically metastasize after sub-
cutaneous inoculation in nude mice. Although the differences between the various 
stages of progression are not absolute, we provide further evidence that EGFR 
expression increases in human melanocyte tumour progression (J Invest Der-
matol 1992; 99: 168-173). 
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INTRODUCTION 
Antigens associated with tumour progression of human melanocytic cells have 
been identified and are detectable immunohistochemically (1-7). Different results 
have been reported on the expression in human melanocytic lesions of one of 
these antigens, the epidermal growth factor receptor (EGFR) (7,8). 
The EGFR is a 170 kD transmembrane glycoprotein (9). The cytoplasmatic 
domain of the receptor is in structure similar to the v-erbB oncogene protein 
(10). Binding of epidermal growth factor (EGF) or transforming growth factor a 
to the external domain of EGFR can result in the activation of a mitogenic 
pathway (11). In vitro, overexpression of the human EGFR confers an EGF 
dependent transformed phenotype to NIH 3T3 cells (12). 
Elder et al (7) reported that the EGFR shows the distribution of a progression 
antigen in human melanocytic lesions. However, in another series of human 
melanocytic lesions studied immunohistochemically by Real et al. (8) no EGFR 
expression was found. As these authors used different immunohistological 
techniques and different monoclonal antibodies (MoAb), we wondered whether 
this could explain the dissimilar results. Therefore, we first compared the 
sensitivity of four routinely applied immunohistochemical methods using a panel 
of six human melanoma cell lines with different levels of EGFR expression. The 
MoAbs used by Elder et al. (MoAb 425) (13) and by Real et al. (MoAb 225) 
(14) were compared with a third one, MoAb 2E9 (15), which appeared very 
sensitive in a pilot study. In addition, the level of EGFR expression in the cell 
lines was quantified using a multiple point ligand binding assay. Furthermore, 
EGFR-mRNA expression was determined. Based on these results the most 
sensitive immunohistochemical method was chosen for further study of EGFR-
expression in a large series of melanocytic lesions. We provide further evidence 
for a differential expression of EGFR, both in human lesions of various stages of 
melanocytic tumour progression and in human melanoma cell lines with a 
different metastatic behavior in nude mice. 
MATERIALS AND METHODS 
Cell lines 
Human melanoma cell lines used, included the following: IF6 (16), 530 (17), 
Mel 57 (18), M14 (19), BLM (16) and MV3 (20). Cell lines IF6, BLM and 
MV3 were developed in our laboratory. BLM is a subline of the BRO line (21) 
with a higher metastatic potential in nude mice than the parental line. Further-
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more, the vulval carcinoma cell line A431 was used (22). All cell lines were 
grown as monolayer in culture flasks on Dulbecco's Modified Eagle's Medium 
supplemented with 10% Fetal Calf Serum, glutamine, penicillin G and Strep-
tomycin. Cells were harvested by short trypsinization and processed for cytospin 
preparation or RNA isolation. 
Human melanocytic lesions 
Subcentral representative slices of 16 common nevocellular nevi (NN), 13 
dysplastic nevi (DN), 48 primary cutaneous melanomas (PM) and 22 melanoma 
metastases (MM) were snap-frozen in liquid N2 and stored at -70°C until use. 
The histopathological diagnosis was made on corresponding paraffin sections and 
the representativity of the samples of the frozen sections was ascertained. 
Primary melanomas were divided into three categories according to the Breslow 
thickness (23): < 0.76 mm (PM1), between 0.76 and 3 mm (PM2), > 3 mm 
(PM3) in thickness. The degree of atypia in DN was assessed (24). 
Monoclonal antibodies and immunocytochemical techniques 
MoAb included: 1) 2E9 (ascites fluid) (15), 2) 425 (tissue culture supernatant) 
(13), 3) 225 (1 mg/ml purified immunoglobulins)(14). All three murine MoAb 
recognize an antigenic determinant of the protein core of the EGFR. Cytospin 
preparations of the cell lines were dried, fixed in acetone and incubated for 60 
minutes with MoAb 2E9 (1:25), MoAb 425 (undiluted) or MoAb 225 (1:12.5). 
The further procedure consisted of one of four different immunoperoxidase 
techniques; 1) a two-step method: incubation with peroxidase-labeled rabbit anti-
mouse Ig serum (RAMPO, Dakopatts, Denmark), 2) a three-step method: 
incubation with RAMPO followed by incubation with peroxidase-labeled swine 
anti-rabbit Ig serum (Dakopatts, Denmark), 3) a PAP method: incubation with 
rabbit anti-mouse Ig serum (Cappel, Belgium), followed by incubation with swine 
anti-rabbit Ig serum (Dakopatts, Denmark) and incubation with rabbit PAP 
complex (Dakopatts, Denmark), 4) an avidin-biotin-complex (ABC) method 
(Vector Laboratories, USA). All incubations were performed at room 
temperature for 30-60 minutes. Between incubations sections were rinsed with 
PBS. Visualization of the immunoperoxidase reactions was performed with 3-
amino-9-ethylcarbazole as substrate. Preparations were counterstained with 
hematoxylin. Titration experiments with the MoAbs were performed using 
method 2. 
Based on the staining results of the cytospin preparations, air-dried and acetone 
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fixed frozen 4 ¿im sections of melanocyte lesions were processed using MoAb 
2E9 and the three-step immunoperoxidase technique (method 2). 
Score 
The intensity of staining in the melanocyte cells was scored semiquantitatively 
as: -(no), ±(weak), + (moderate), ++(marked). In the cytospin preparations of 
the cell lines the percentages of positive cells and the average staining intensities 
were estimated. In the frozen sections of human melanocyte lesions the per-
centages of positive melanocyte cells were estimated. Lesions were regarded 
EGFR positive if 5% or more of the melanocyte cells in the lesion stained. 
Ligand binding assay 
Cells were harvested with a rubber policeman and homogenized by means of 
ultrasound bursts (MSE Soniprep-150: nominal frequency 23 kHz., amplitude 10 
μτή) for 10 seconds, on ice, in EGFR assay buffer (0.02 M phosphate buffer, pH 
7.4, containing 0.15 M NaCl and 70 ¿¿g/ml Bacitracin). 
The homogenates were centrifuged for 10 minutes at 800xg, 4°C, to spin down 
nuclei and other coarse cell fragments. The supernatants were recentrifuged for 
60 minutes at 105,000xg, 4°C. The cell membrane pellets thus obtained were 
resuspended in 1.1 ml of EGFR assay buffer by means of ultrasound bursts. 
EGFR assays were performed in a manner similar to that described previously 
(25). To summarize: eight times 100 μ\ aliquots of cell membrane preparation 
were incubated with 125I-mouse-EGF (mEGF) tracer at concentrations ranging 
from 0.15 to 3.5 nM. Aspecific binding was assessed in duplicate using 1 nM 
l25I-mEGF and a 250-fold excess of unlabelled mEGF. Receptor-bound and free 
ligand were separated using hydroxy apatite. Receptor values were calculated by 
Scatchard analysis and expressed in fmol/mg of membrane protein. 
Northern blot analysis 
Total RNA of the cell lines was isolated by the LiCl/urea method (26). Ten /tg 
aliquots of total RNA were glyoxylated (27) and size fractionated on a 1% 
agarose gel followed by blotting on hybond-N-membrane according to the 
procedure recommended (Amersham, UK). Hybridizations were performed as 
described (28). To detect EGFR mRNA the 0.8 Kb EcoRI fragment of Lambda 
HER A 64 was used as a probe (29). For control hybridizations on the amount of 
RNA a 28S rRNA probe was used. Both probes were radio-labelled using the 
multiprime labelling method (Amersham, UK). 
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RESULTS 
Immunocytochemistry of the cell lines 
Table I (columns A) summarizes data on the EGFR expression in the melanoma 
cell lines and cell line A431 as obtained by applying different MoAb and 
immunocytochemical staining techniques. 
Table I: Expression of EGFR-protein and EGFR-mRNA in human melanoma 
cell lines and cell line A431 
Cell 
line 
IF6 
530 
M14 
Mel 57 
BLM 
MV3 
A431 
Aa 
two-step method 
425 
-
-
-
-
-
-
ND 
225 
-
-
-
-
-
-
ND 
2E9 
-
-
-
-
+ 
+ 
ND 
three-step methodb 
425 
-
-
-
-
+ 
+ 
ND 
225 
-
-
-
-
+ 
+ 
ND 
2E9 
-
± 
+ 
-
+ + 
+ + 
+ + + 
В 
-
10 5 
33.9 
-
1436 
1480 
17271 
С 
-
± 
± 
-
+ + 
+ + 
+ + + 
' A EGFR expression as detected immunohistochemically using the monoclonal an­
tibodies 425, 225 and 2E9. 
Explanation of symbols; - : no staining; ± : weak staining; + : clear staining; 
+ + : marked staining; + + + intens staining; ND. not determined. 
В EGFR expression in fmol per mg of cell membrane protein as determined with a 
ligand binding assay. - = not detectable (< 6 fmol/mg) 
С EGFR mRNA expression determined by Northern blot analysis. 
- = not detectable; ± faint-signal; + + marked signal; + + + strong signal. 
b
: same scores were obtained using the three-step-, the PAP- or the ABC-method. 
For each separate MoAb, the intensities of the staining signals were similar when 
comparing the three-step immumunoperoxidase technique, the PAP technique and 
the ABC technique. The two-step technique was less sensitive. With regard to the 
MoAb used at the indicated dilutions, a less sensitive or negative staining result 
was obtained with MoAb 425 and MoAb 225, compared with MoAb 2E9. 
Titration experiments showed similar staining signals for the MoAb 2E9, 425 and 
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Figure 1: EGFR expression in human melanoma cell lines and lesions. 
Α-G: EGFR expression in human melanoma cell lines (Α-C, cytospin preparations) and 
human melanocytic lesions (D-G, frozen sections). Immunocytochemical staining using the 
monoclonal antibody 2E9 and a three-step detection method. Scale bar = 50 μπι. A: cell 
line IF6 showing no staining, as also found in cell line Mel 57; B: cell line M14 showing 
weak staining, as also found in cell line 530; C: cell line BLM showing marked staining, 
as also found in cell line MV3; D: common nevocellular nevus; negative control; the 
primary MoAb 2E9 was omitted; E: common nevocellular nevus; nevus cells show no 
staining, the epidermis shows a marked staining; F: common nevocellular nevus; nevus 
cells show a weak staining in a diffuse pattern, the epidermis shows a marked staining; the 
mean staining intensity observed in positive dysplastic nevi was similar to the staining 
shown here; G: primary cutaneous melanoma; diffuse intermediate to marked staining of 
melanoma cells; the mean staining intensity observed in the positive melanoma metastases 
was similar to the staining shown here. 
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225, when used diluted 1:300, undiluted and diluted 1:12.5, respectively. Using 
the MoAb 2E9 (1:25) and the three-step immunoperoxidase detection method cell 
lines IF6 and Mel 57 were negative, 530 and M14 weakly positive and BLM and 
MV3 markedly positive (Fig. ΙΑ-C). The positive reference cell line A431 
showed a very strong staining. In the positive melanoma cell lines 80-100% of 
the tumour cells stained. 
Ligand binding assay of the cell lines 
In Table I (column B) and Fig. 2 the level of EGFR expression in the cell lines, 
as quantified by radio-ligand binding assays is shown. Cell line A431 showed a 
very high expression. Cell lines MV3 and BLM showed a high, cell lines M14 
and 530 a low and cell lines IF6 and Mel 57 no measurable level of expression. 
All the EGFR containing melanoma cell lines showed one single class of high 
affinity EGFR binding sites. In contrast to this, the A431 cell line, containing 
high levels of EGFR, showed a curvilinear Scatchard-plot (linearized in Fig. 2), 
indicating the presence of two EGFR binding sites with different affinity. The 
quantitative ligand binding assay data on EGFR expression in the cell lines 
correlated well with the semiquantitative immunocytochemical results obtained 
with the MoAb 2E9 using a three-step detection method. This correlation was not 
found with the MoAb 425 and the MoAb 225 (Table I). 
Northern blotting of the cell lines 
EGFR gene transcripts (10.5 and 5.8 Kb) were present in four out of six human 
melanoma cell lines tested [Fig. 3 and Table I (lane C)]. Cell lines BLM and 
MV3 showed a high ( + + ) , M14 and 530 a low ( ± ) , and IF6 and Mel 57 no 
detectable (-) level of EGFR-mRNA expression. Cell line A431 showed a very 
high EGFR mRNA expression (not shown). 
The results on the EGFR expression in the cell lines, as detected with the MoAb 
2E9 using the three-step technique correlated well with the EGFR-mRNA levels 
in the same cell lines. 
Immunohistochemistry of melanocytic lesions 
The expression of the EGFR in frozen sections of the melanocytic lesions as 
assessed immunohistochemically is summarized in Table IIA. For the different 
categories it shows the percentage of lesions in which > 5 % of the melanocytic 
cells stained. As in the cell lines M14 and 530 there was a good correlation 
between the weak immunocytological staining, the ligand binding assay data and 
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Figure 2: EGFR expression in human melanoma cell lines. 
A and B: EGFR expression in human melanoma cell lines and cell line A431. Scatchard 
plot of data obtained with a ligand binding assay. The ordinate intercept depicts the level 
of EGFR expression in fmol/ml. Note the scale difference between A and B. 
Table П: Expression of EGFR in human melanocyte lesions" 
Ac 
В 
category0 
NN 
19 
45 
DN 
61 
67 
PM1 
87 
56 
PM2 
85 
36 
PM3 
95 
42 
MM 
91 
60 
a
: EGFR expression as detected immunohistochemically (MoAb 2E9, three-step 
method). 
b
: Abbreviations: NN: common nevocellular nevus, DN: dysplastic nevus, PM1: 
primary melanoma (Breslow <0.76 mm), PM2: primary melanoma (Breslow 
between 0.76 mm and 3 mm), PM3: primary melanoma (Breslow >3 mm), MM: 
melanoma metastasis. 
c
: A: Percentage of positive lesions per category. 
B: Mean of percentages of positive melanocytic cells in positive lesions per 
category. 
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the mRNA level, weak staining in the sections was regarded as relevant and 
taken into account. A clear difference was seen in EGFR expression, when 
comparing benign and malignant lesions (Table II). The percentage of positive 
lesions was 19 for common nevocellular nevi, 89 for primary melanomas and 91 
for melanoma metastases. The dysplastic nevi hold an intermediate position 
(61%). In primary melanomas there was no clear increase in the number of 
positive lesions with increasing Breslow thickness. 
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Figure 3: EGFR mRNA expression in human melanoma cell lines. 
Northern blot analysis of EGFR mRNA expression in human melanoma cell lines using 
the 0.8 Kb fragment of lambda HER 64 as a probe. Two bands (10.5 and 5.8 Kb) are 
visible in cell lines BLM and MV3 (intense) and in cell line 530 and M14 (faint). No band 
could be detected with the cell lines IF6 and Mel 57. As a control on the amount of RNA, 
the blot was re-hybridized with a 28S rRNA probe. As molecular weight marker lambda 
DNA digested with endonuclease Hind ΠΙ was used. 
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Within the group of dysplastic nevi there was no correlation between a history of 
dysplastic nevus syndrome or the histological degree of atypia and EGFR expres-
sion. Heterogeneity of EGFR expression was observed in most lesions. In each 
category of lesions the percentage of positive melanocytic cells per lesion varied 
(Fig. 4). With regard to this parameter there was no correlation with the stage of 
progression (Table IIB). Comparing the different categories, the average staining 
intensity in positive nevi was weak, in primary melanomas and metastatic 
melanomas intermediate to marked (Fig. 1D-G). 
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Figure 4: Heterogeneity of EGFR expression in human melanocytic lesions. 
Diagram showing heterogeneity of EGFR expression in human melanocytic lesions, based 
on immunohistochemical staining using the monoclonal antibody 2E9 and a three-step 
detection method. Each dot represents the estimated percentage of melanocytic cells 
stained in one lesion. Lesions are ordered by category. NN: common nevocellular nevus; 
DN: dysplastic nevus; PM1: primary melanoma (Breslow á0.76 mm); PM2: primary 
melanoma (Breslow between 0.76 mm and 3 mm); PM3: primary melanoma (Breslow S3 
mm); MM: melanoma metastasis. 
DISCUSSION 
In this study we have compared the level of EGFR expression in six human 
melanoma cell lines using three Mo Ab, four immunocytochemical techniques, a 
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multiple point ligand binding assay and Northern blot analysis. The level of 
EGFR expression in cell line A431, used as a control, was very high, which is in 
agreement with earlier reports (8,15,29). A relatively low expression of EGFR 
could be detected immunocytochemically only, when MoAb 2E9 and a three-step 
staining method were used. Semi-quantitative data obtained with this most sen-
sitive approach correlated well with the quantative data obtained with the ligand 
binding assay. Northern blotting results were also in concordance. 
We quantified the differences in EGFR expression between melanoma cell lines 
with a different metastatic behavior in nude mice (16). Cell lines which fre-
quently give rise to spontaneous lung metastases (BLM and MV3) had a high 
level of EGFR expression, whereas those with no (IF6 and 530) or only a low 
(M14 and Mel 57) metastatic potential had no detectable or a low level of 
expression. These data suggest that an increased level of EGFR expression may 
be relevant in melanocyte tumour progression. Supporting data, obtained with 
other cell types, come from studies by Di Fiore et al (12) and Velu et al (30), 
who found a transformed phenotype of NIH 3T3 cells after induction of EGFR 
overexpression by transfection experiments and from a report by Wells et al (31) 
who described a transformed phenotype of NR6 cells expressing a transfected 
non-intemalizing mutant EGFR. 
Because of the good correlation with the ligand binding assay results, we 
considered a weak immunocytochemical staining, as obtained in the cell lines 530 
and M14 with MoAb 2E9 and a three-step method, as specific and relevant. This 
is underscored by the fact that cell lines IF6 and Mel57 were EGFR negative 
with both techniques. 
By doing so, we found differential EGFR expression in benign, premalignant and 
malignant human melanocytic lesions. About 20% of common nevocellular nevi, 
60% of dysplastic nevi and 90% of primary and metastatic melanoma lesions 
showed staining in at least 5% of the melanocytic cells. Two previous reports 
have dealt with EGFR expression in human melanocytic lesions (7,8). Although 
Real et al (8) were able to detect EGFR expression in 19 out of 36 melanoma cell 
lines by resetting assay analysis, they could not detect EGFR expression in five 
of five primary melanoma lesions and seven of seven metastases immunohis-
tochemically, using MoAb 225 and an ABC-procedure. Elder et al (7) detected 
EGFR immunohistochemically in two of eleven dysplastic nevi, in three of 
sixteen radial growth phase primary melanomas, in eight of nine vertical growth 
phase primary melanomas and in eight of ten metastases, using a PAP procedure 
and MoAb 425. Mature dermal nevi were found negative. 
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The discrepancy between our results and those of Real et al. (8) might be due to 
the different antibodies used, as equally sensitive immunohistochemical 
procedures for the detection of EGFR were applied. Our results suggest that the 
Mo Ab 225 may have a lower avidity than Mo Ab 2E9. A factor which may be of 
major importance is the fact that the two MoAb recognize different epitopes (32). 
For the detection of the EGFR expression in melanoma cell lines Real et al. used 
a highly sensitive resetting assay and found a positive reaction in about half of 
the lines, which is in agreement with our results. The differences in tissue 
distribution of EGFR, reported by Elder et al (7) and in the present study might 
also be explained by the fact that different MoAb were used. In our comparance 
of MoAb and detection methods on a panel of melanoma cell lines, we found for 
the equally sensitive three-step- and PAP-procedures that the staining signal 
obtained using MoAb 2E9 was stronger than that of MoAb 425. In addition, the 
positive correlation between the staining signal obtained with MoAb 2E9, the 
EGFR level as determined by ligand binding analysis and the level of mRNA 
expressed was not found for MoAb 425. MoAb 2E9 was used as ascites fluid and 
the MoAb 425 as tissue culture supernatant. We assume that the concentration 
and the avidity of the MoAb used have influenced the staining results. Further-
more, the MoAb may recognize different epitopes (13,15). The outcome of our 
study of melanocyte lesions was not altered essentially when a 10% margin was 
applied to score a lesion as "positive". If only the lesions showing a staining 
intensity of + or more would be regarded relevant, thus excluding the weak 
staining signals, no benign and fewer premalignant lesions would be scored 
positive. However, we were unable to detect differentia] staining in horizontal 
growth phase primary melanomas as compared to vertical growth phase primary 
melanomas, as reported by Elder et al (7). 
From this study we conclude that, although the differences between the various 
stages of progression are not absolute, we provide further evidence that EGFR 
expression increases in human melanocyte tumour progression. 
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CHAPTERS 
In situ detection of supernumerary aberrations of 
chromosome-specific repetitive DNA targets in 
interphase nuclei in human melanoma cell lines and 
tissue sections 
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ABSTRACT 
The use of non-radioactive in situ hybridization (ISH) with chromosome specific 
repetitive DNA probes to study genomic changes, aneuploidy and heterogeneity 
during melanocytic tumour progression, relies on its applicability to non-mitotic 
interphase nuclei, present in cell suspensions and tissue sections. Therefore, we 
studied the feasibility of detecting numerical aberrations with respect to the 
(peri-)centromere regions of chromosomes 1 and 7 in intact nuclei of two human 
melanoma cell lines with different metastatic behavior in nude mice. In addition, 
we used paraffin sections from xenograft lesions, obtained by inoculation of these 
cell lines in nude mice (subcutaneous tumours and spontaneous lung metastases). 
Paraffin sections from the original primary cutaneous melanoma (with a 
subepidermal and a dermal part) and two loco-regional metastases were also 
studied, one of which was the source for the cell lines. These cells and tissues 
represent examples of materials used in different approaches to study melanocytic 
tumour progression. 
Regarding the targeted sequences, ISH analysis showed that both cell lines were 
heterogeneous and aneuploid. The results correlated well with those obtained by 
ISH on metaphase spreads. Differences between the lines, which could not be 
detected by flow-cytometric or conventional karyotyping analysis, included data 
suggestive of a polyploid subpopulation and an extra copy of chromosome 7 in 
the metastasizing cell line. The polyploid population could be detected also in the 
paraffin sections of the corresponding subcutaneous xenografts and lung metas-
tases in the mice. Both areas in the patients' primary melanoma could be 
evaluated separately and showed similar supernumerary aberrations of the 
chromosome specific targets. These abnormalities matched those found in both 
metastases. 
Our results demonstrate that ISH can be used to visualize genomic abnormalities 
at the single cell level in melanocytic nuclei in their natural context, which makes 
it a promising tool in the histopathology of melanocytic lesions and in the study 
of melanocytic tumour progression (J Invest Dermatol 1992; 98: 450-458). 
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INTRODUCTION 
In human melanocyte tumour progression (1), the identification of genomic 
changes is based on the comparison of cells from different stages. Regarding the 
total DNA content of tumour cells, flow-cytometric studies have highlighted the 
correlation between aneuploidy and tumour progression in melanocytic lesions 
(2), whereas Southern blotting and restriction fragment length polymorphism 
analysis have been used in the study of single genes (3). Cytogenetic studies in 
particular have directed attention to specific chromosomes of interest in malignant 
melanoma (for review see Ref 4). Most karyotyping studies reported are confined 
to melanoma metastases or metastasis derived cell lines: alterations of chromo-
some 1, chromosome 6 and chromosome 7 have been encountered most often in 
these late stages (4). Due to the low mitotic index and the limited amount of 
tissue available, it is difficult to obtain metaphases from early (precursor) lesions 
(5-11). Consequently, data on cytogenetic aberrations in subsequent stages of 
melanocytic tumour progression from one patient are sparse (4,6-10). Therefore, 
it is worthwhile to study these changes in cell preparations and tissue sections. 
Furthermore, the latter allows the study of genomic aberrations in cells in their 
natural context and thus enables a direct in situ comparison of DNA alterations 
and phenotypical characteristics. 
Non-radioactive in situ hybridization techniques (ISH) enable the visualization of 
DNA targets in interphase nuclei, a method that has been called interphase 
cytogenetics (12). DNA probes, which hybridize to the (peri-)centromeric region 
of a specific chromosome (13), have been reliably used to detect numerical 
chromosomal aberrations in interphase nuclei in neoplasms (14-24). The ap-
plication of ISH to tissue sections (25), provides a tool to link cytogenetic to 
morphological characteristics (19,23,24). 
In this paper we examine the feasibility of applying ISH to melanocytic inter-
phase nuclei, in order to trace and compare heterogeneity and numerical changes 
with respect to centromere regions of chromosomes 1 and 7. First, we used two 
human melanoma cell lines, derived from one lymph node metastasis, with 
different metastatic behavior in nude mice (26, 27). In addition, paraffin sections 
from corresponding xenograft lesions in mice (subcutaneous tumours and spon-
taneous lung metastases) were studied. Finally, we applied ISH to paraffin 
sections from the patients' primary cutaneous melanoma and the loco-regional 
lymphnode metastases. These cells and tissues represent examples of the 
materials often used to study melanocytic tumour progression. As we concen-
trated in this study on the feasibility of detecting numerical changes, we focussed 
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on chromosome 1 and 7 because, in malignant melanoma, numerical changes of 
these chromosomes are most frequently reported (4). 
MATERIALS AND METHODS 
Clinical data and tissue specimens 
A pigmented cutaneous nodule was removed from the chin of a 76 year-old male. 
Conventional histopathological examination revealed a primary cutaneous 
malignant melanoma of nodular type, Clark level IV, Breslow thickness 6 mm. 
After five months, lymph node metastases were found in the homolateral neck. A 
fragment from one metastasis was used for subcutaneous implantation in nude 
mice, while other fragments were snap-frozen and stored at -70°C. The 
remainder of the specimen was processed for routine histology, i.e., formalin 
fixation and paraffin embedding. The patient died of pulmonary metastases 15 
months after diagnosis. 
Cell lines MV1 and MV3 
Parts of one lymph node metastasis were implanted subcutaneously into nude 
mice. Cell line MV1 was established from part of the subcutaneous outgrowth of 
the first passage. Cell line MV3 was isolated from part of the outgrowth of the 
third passage. Both cell lines were cultured as described for MV3 (26,27). Cell 
lines MV1 and MV3 consistently give rise to local tumours after subcutaneous 
inoculation in nude mice. Mice inoculated with MV3 show spontaneous lung 
metastases in 90% of cases, compared to 10% after inoculation with MV1. The 
subcutaneous tumours and the corresponding spontaneous lung metastases were in 
part processed for routine histology and in part snap-frozen. To prepare ethanol 
fixed suspensions of the cell lines, we trypsinized cultured cells, washed them 
with phosphate-buffered saline (PBS), resuspended in ethanol 70% (-20°C), and 
stored at -30°C. As a control, an ethanol-fixed suspension of cultured normal 
melanocytes derived from normal human foreskin was used. 
Flow-cytometric and karyotypic analysis of the cell lines 
To determine the cellular DNA content, we used suspensions of trypsinized 
cultured cells of MV1 and MV3 for flow-cytometric analysis, as described (28). 
Chicken red blood cells and human lymphocytes were used as standard control 
cells. 
For karyotyping, subconfluent tumour cell cultures of MV1 and MV3 were 
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incubated with colchicine (l^g/ml) for 90 minutes, trypsinized, subsequently 
treated with a pre-warmed (37°C) hypotonic 0.075 M KCl solution for 10 
minutes, and finally fixed with a mixture of methanol and glacial acetic acid 
(3:1). Air-dried slides were prepared according to routine cytogenetic procedures. 
Fifty metaphases were photographed after conventional Giemsa staining and 
chromosome numbers were counted from the photographs. Ten mitoses were 
studied in more detail after G-banding of the chromosomes. Three cells were 
fully karyotyped. At least 5 metaphases from both cell lines were studied after Q-
banding and subsequent C-banding. Stored air-dried preparations were used for 
ISH on metaphases, using the same method as described below for ISH on cell 
suspensions. 
Pretreatment of ethanol-fixed cell suspensions for ISH 
Ten microliters of an ethanol suspension were dropped on a poly-L-lysine 
(Sigma, St. Louis, USA) coated glass slide (29), air-dried and heated for 60 min 
at 80°C. Cells were pretreated by enzyme digestion with pepsine (2500-3000 
units per mg protein; Sigma) at a concentration of 100 /¿g/ml in 0.01 N HCl for 
10 min at 37°C (17). After washes with H20 and PBS, post-fixation with 1% 
formaldehyde in PBS for 20 min at 4°C, and further washes with PBS and H20, 
nuclei were equilibrated at room temperature with hybridization buffer [60% 
formamide in 2x SSC (Standard Saline Citrate, 0.3 M NaCl, 30 mM Na-citrate), 
0.05% Tween, pH 7.O.]. 
Pretreatment of paraffin sections for ISH 
Six-micrometer paraffin sections were floated on water (40°C) and mounted on 
glutaraldehyde-activated poly-L-lysine coated glass slides (29). Sections were air-
dried and heated for 16 hours at 56°C, dewaxed in xylene (3x10 min) and rinsed 
in methanol (100%, 2x5 min). Endogenous peroxidase activity was blocked in 
methanol/1% H202 for 30 min, followed by rinsing with methanol (2x10 min), all 
at room temperature. Sections were air-dried and nuclei were, prior to enzyme 
digestion, pretreated either by incubation with 1 M NaSCN at 80°C for 10 min 
and two subsequent washes with H20 (5 min) or by incubation with H20 for 20 
min at 37°C (23,24). 
Enzyme digestion was performed with pepsine (as described above) at a con-
centration of 4 mg/ml in 0.2 N HCl at 37°C. Digestion was "tuned" to obtain an 
optimal balance between morphology preservation and ISH signal. The digestion 
time ranged from 5-60 minutes. After pepsine treatment, slides were dip-washed 
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in H20, dehydrated with ethanol and heated for 30 min at 80°C. 
Probes 
The satellite III DNA probe for chromosome 1 (pUC 1.77) recognizes a tandem 
repeat of 1.77 Kb in the (peri-)centromere region of chromosome 1 (30). The 
alphoid probe for chromosome 7 (p7dl) recognizes tandem repeats in the 
centromere region of chromosome 7 (31). 
Biotinylation of the probes was performed using Bio-11-dUTP (Sigma, St. Louis, 
USA)(32,33) in a nick translation reaction as recommended by the supplier 
(BRL, Gaithersburg, USA). 
Conditions of ISH 
Hybridization conditions of high stringency were applied (17-19). Five to fifteen 
microliters of the hybridization mixture (2-6 ng chromosome-specific biotinylated 
probe DNA, 50ng herring sperm DNA and 50 ng baker's yeast RNA per Ιμΐ 
hybridization buffer containing 10% dextran sulphate) was added to the 
nuclei/metaphases on the slide under a coverslip and sealed with rubber cement. 
Simultaneous denaturation was performed on a heating plate: 3 min at 70°C for 
the metaphases and the isolated cells from the suspensions, and 10 min at 80 °C 
for paraffin sections. Hybridization was performed overnight at 37°C. Post-
hybridization washes were done with hybridization buffer at 42°С (2x 5 min). 
Visualization of hybrids 
Based on procedures described before (21,34), after the post-hybridization 
washes, slides with cells/metaphases were subsequently washed with 2x SSC (pH 
7.0, 2x5 min at 42°C) and 4x SSC/0.05% Tween (pH 7.0, 1x5 min at room-
temperature), followed by pre-incubation with 5% non-fat dried milk in 4x 
SSC/0.05% Tween (pH 7.0, 10 min at room temperature). Biotin-labelled DNA 
was detected by incubation with FITC-conjugated-avidin (Vector, Burlingame, 
USA; 1:500 in 4xSSC/ 0.05% Tween, pH 7.0) for 20 min at 37°C. Signal 
amplification was obtained by incubation with biotinylated goat-anti-avidin serum 
(Vector, Burlingame, USA; 1:100 in 4xSSC, 0.05% Tween, pH 7.0) for 20 min 
at 37°C followed by a second incubation with FITC-conjugated avidin. Finally, 
after rinsing with PBS and H20, preparations were dehydrated with alcohol and 
mounted with PBS/glycerol (1:9 v/v) containing 2.3% 1,4-di-azobicyclo-(2, 
2,2)octane (DABCO, Merck, Darmstadt, Germany) and 0.05 % 4,6-diamidine-2-
phenylindole dihydrochloride (DAPI, Boehringer Mannheim, Mannheim, 
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Germany). 
After the post-hybridization washes, paraffin sections were washed with 
PBS/0.05% Tween (2x5 min at room temperature) and pre-incubated with normal 
rabbit serum (NRS, 2% in PBS/0.05% Tween) for 10 min at room temperature. 
Slides were then incubated with mouse-anti-biotin serum (Dakopatts, Glostrup, 
Denmark; 1:100 in PBS/2%NRS/0.05% Tween) for 45 min at 37°C. After 
washes with PBS/0.05% Tween (2x5 min at room temperature) slides were 
incubated with peroxidase-labelled rabbit-anti-mouse serum (Dakopatts, Glostrup, 
Denmark; 1:100 in PBS/2%NRS/0.05% Tween) for 45 min at 37°C. After 
washes with PBS (3x5 min) visualization of the probe was performed using di-
amino-benzidine (DAB, Sigma, St. Louis, USA; 0.5 mg/ml in PBS/0.1 M 
imidazol) as the substrate in a peroxidase reaction. Preparations were 
counterstained with hematoxilin solution (Merck). 
Evaluation of signals in the cells and sections was performed as described 
(14,16,19,23). 
RESULTS 
Flow-cytometric and karyotypic analysis of the cell lines 
The analysis of the total DNA content of MV1 and MV3 cells by flow-cytometric 
analysis of propidium iodide stained nuclei showed aneuploidy in both cell lines 
with a DNA-index (DI) in the triploid region (DI-MV1 = 1.43; DI-MV3 = 1.46). 
No tetraploid or polyploid subpopulation could be detected (Fig. 1A, C). 
Karyotyping of the cell lines with respect to chromosome counts revealed an 
over-all aneuploidy, resembling a hypotriploidy in both MV1 and MV3. The 
chromosome number varied from 53 - 69 (X= 64.32 ± SD 2.49) for MV1 and 
from 45 - 74 (X= 57.08 ± SD 4.99) for MV3. Structural chromosomal abnor-
malities were frequent in both cell lines and several unidentified marker-
chromosomes were present (Figs. 2 and 3). In MV1 the numbers of chromosome 
1 and 7 centromere regions, which could be identified in the three fully 
karyotyped cells, were 3, 3, 3 and 3, 3, 3, respectively. For chromosome 1 this 
was confirmed by the C-banding experiments. ISH on metaphase-spreads using 
probes for the centromere region of chromosomes 1 and 7 revealed a major 
population with three spots and a smaller population with two spots for these 
chromosomes, both in the metaphases and in the interphase nuclei on the same 
slides (Fig. 4A, B). 
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Figure 1: Analysis of cell lines MV1 and MV3 by flow-cytometry and ISH 
(A, C): DNA histograms of MV1 cells (A) and MV3 cells (C) that were stained with 
propidium iodide and analyzed by flowcytometry. Chicken red blood cells and human 
lymphocytes were used as standard control. The cell lines showed a similar DNA index. 
DI, DNA index; CNTS, counts. 
(B, D): Frequency distribution in the cell lines MV1 (B) and MV3 (D) of nuclei with the 
indicated number of hybridization spots, obtained by ISH using chromosome specific 
(peri-)centromere probes. Black bars, percentages obtained with pUC 1.77, the 
chromosome 1 specific probe (#lc); hatched bars, percentages obtained with p7dl, the 
chromosome 7 specific probe (#7c). 400 nuclei were counted for each evaluation. 
Differences between the cell lines are described in the text. 
In the 3 fully karyotyped MV3 cells, the number of chromosome 1 centromere 
regions, which could be identified readily was 2, 2, and 3. These cells contained 
a dicentric chromosome 1, which also appeared in the C-banding as a dicentric 
chromosome 1 marker with one centromere of unknown origin (Fig. 4C, D). ISH 
on metaphases showed that this chromosome contained two chromosome 1 
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Figure 2: Karyotype of cell line MV1 
In all cells many clonal marker-chromosomes were detected involving chromosomes 3, 6, 
7, 11, 13, 14, 20 and 22 (t). Furthermore, in every cell several unidentified marker-
chromosomes were present (mar). 
centromere regions (Fig. 4E, F), and that the major fraction of the metaphases 
had three chromosome 1 centromere regions. For chromosome 7 in MV3, ISH 
on metaphase preparations revealed the largest population to contain four spots, 
both in the metaphase spreads and in the present interphase nuclei. Populations 
with three, or more than four spots were also present. Some cells with two spots 
were seen. By G-banding, only two identifiable chromosome 7 centromere 
regions in the three fully karyotyped cells could be detected. Many unidentified 
marker-chromosomes were seen (Fig. 3). 
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Figure 3: Karyotype of cell line М З 
The karyotype of MV3 showed a large complexity and variability. Many (unidentified) 
marker-chromosomes were present in every cell (mar, t). In the analyzed cells no sex 
chromosomes were recognized. 
ISH on cell suspensions 
In contrast to the flow-cytometric data, where the DNA histogram showed a 
similar DNA index for apparently homogeneous cell populations in both lines, 
ISH analyses with chromosome-specific probes for the centromere regions of 
chromosome 1 or 7, showed that there were marked differences between the cell 
lines MV1 and MV3 (Fig. IB, D; Table I). Both aneuploid cell lines were 
heterogeneous as they showed different cell populations. This is reflected by the 
different number of ISH spots in the nuclei of each line (Fig. 5A, B; Table I). 
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Figure 4: ISH on metaphase chromosomes 
(A, B): Example of ISH on a metaphase-spread of cell line MVl, using probe pUC 1.77, 
hybridizing to the peri-centromere region of chromosome 1. A: DAPI- and B: FITC-
image of a metaphase, showing hybridization of the probe to three regions. (C, D, E, F): 
Derivative dicentric chromosome 1 as present in all studied cells of MV3. C: Q-banding 
and D: C-banding of an example of this marker chromosome, E: DAPI- and F: FITC-
image of two chromosomes, one of which shows two spots after hybridization with pUC 
1.77. 
In MV3, we detected an imbalance between the numbers of ISH spots obtained 
with probes specific for either chromosome 1 or 7. In the case of chromosome 1 
the major population showed three spots per nucleus, in contrast to the 
chromosome 7 centromere probe, where the major population contained four 
spots per nucleus. Thirteen percent of the nuclei of the latter contained more than 
four, ranging from 5-11 (Figs. ID, 5C-F). The overall picture for MV3 showed 
four or more spots for chromosome 7 in most nuclei, but showed three or less 
for chromosome 1. A subpopulation with more than four spots, as detected in 
MV3 for chromosomes 1 and 7, could not be traced in MVl (Fig. IB). In MVl 
the major population for both chromosomes 1 and 7 showed three spots per 
nucleus. Nuclei with four spots for either chromosome 1 or 7 were rare in MVl. 
ISH on cell suspensions of cultured normal human melanocytes, which were used 
as a control, showed two spots for the chromosome 1 and 7 centromere sequen-
ces in at least 95% of the nuclei. No nuclei with more than two spots were seen. 
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Figure 5: In situ 
hybridization on cell 
suspension of cell line 
MV3. Bar, 20 μΐη 
(A, C, E): Visualization 
of nuclei in cell line MV3 
by counterstaining of the 
total DNA with DAPI. 
(B, E, F): Same nuclei as 
in а, с and e. Visualiza­
tion of the centromere 
region of chromosome 7, 
using probe p7dl. (A, B): 
Three nuclei with a dif­
ferent number of spots per 
nucleus (four, two, three), 
showing heterogeneity and 
aneuploidy. (C, D): Large 
nucleus showing eight 
ISH spots. (E, F): Two 
nuclei with four spots, as 
found in the major frac­
tion of the nuclei in MV3 
for chromosome 7, and 
one nucleus with five 
spots. 
ISH on paraffin sections 
We applied ISH to paraffin sections, in order to see whether we could detect 
numerical aberrations, aneuploidy and heterogeneity with regard to the 
chromosome 1 and 7 targets in the subcutaneous and lung lesions of the nude 
mice and in the primary tumour and metastases of the patient. 
Using the procedures described in Materials and Methods we were able to obtain 
évaluable data from all tissues studied (Table I, Fig. 6A-E). As expected, no 
signals were observed in murine nuclei (Fig. 6D). In order to obtain optimal 
results, a well-tuned pretreatment prior to ISH was crucial. Compared to the cell 
lines, optimalization was far less easy for the paraffin sections. This is illustrated 
by the range of pretreatments needed, which varied from 5 minutes of enzyme 
digestion, without prior NaSCN incubation, to 60 minutes pepsine treatment after 
NaSCN pre-treatment. This reflects interlesional variability in the accessibility of 
the DNA targets. The need for pepsine digestion also varied within one section. 
As an example, the subepidermal part of the human primary melanoma was much 
less resistent to enzyme digestion than the compact deeper part. In general, as 
reported for other tissues (23,24), incubation with NaSCN shortened the digestion 
time with pepsine, which resulted in a more preserved morphology. In this way a 
better balance between ISH signal and loss of morphology was achieved. Nuclei 
in the paraffin sections could be evaluated with regard to the number of ISH 
spots in their normal architectural context (Fig. 6). Areas of interest in the secti-
ons could easily be selected. Although the melanocytic cells in general contained 
little melanin pigment, there was no problem in differentiating between the DAB-
ISH signals in the nuclei and pigment in remaining parts of the cytoplasma. 
Xenograft lesions in nude mice 
In all the melanocytic tumour lesions in the mice, nuclei showed varying numbers 
of ISH spots for the chromosomes 1 and 7 targets (Table I, Fig. 6A-D). A 
comparison of the subcutaneous tumours of MVI and MV3 showed the presence 
of a population of nuclei with more than four spots, for both the chromosome 1 
and 7 probe in MV3 tumours in contrast to MV1 tumours, to be consistent with 
the spot distribution in the cell lines. In the MV3 tumours for chromosome 7 
there was a trend towards a larger fraction of nuclei with a smaller number of 
spots in the subcutaneous tumour compared with cell line MV3; the imbalance 
between chromosomes 1 and 7 for MV3, observed in the cell line MV3, could 
not be found in the corresponding subcutaneous lesions in the mice. In contrast, 
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Table I: Relative frequency of nuclei with indicated number of spots per 
nucleus, obtained by ISH on melanocytic lesions and cell lines"1" 
1 
Number of spots per 
2 
A. ISH with chromosome #1 specific 
PMd 
MM' 
MVl*f 
EG1* 
MV3*f 
XG3g 
LXG3h 
+ + 
+ + 
± 
+ + 
± 
+ 
+ + 
+ + + 
+ + + 
+ + + 
+ + + 
+ + + 
+ + + 
+ + + 
3 
nucleus 
4 
probe (pUC 1.77)c 
+ + + 
+ + + 
+ + + + 
+ + + 
+ + + + 
+ + + 
+ + + 
B. ISH with chromosome 7 specific probe (p7dl)c 
PM 
MM 
MV1* 
XG1 
MV3* 
XG3 
LXG3 
+ + + 
+ + + 
+ 
+ + + 
± 
+ + 
+ 
+ + + + 
+ + + + 
+ + 
+ + + 
± 
+ + 
+ + + 
+ + 
+ + 
+ + + + 
+ + + 
+ + 
+ + + 
+ + + 
+ + 
+ + 
+ 
+ 
+ 
+ + 
+ + 
+ 
+ 
± 
+ 
+ + + + 
+ + 
+ + 
>4 
+ 
+ 
-
-
+ 
+ + 
+ 
-
-
-
-
+ + 
+ + 
+ 
The materials studied included cell lines (*) and paraffin sections. 
95% or more of cultured melanocytes showed 2 spots for the chromosomes 1 
and 7 centromere region. The majority of keratinocytes in paraffin sections of 
normal skin showed 2 spots. No nuclei with more than 2 spots were seen. 
. = o%, ± = 0-2%, + = 3-10%, ++ = 11-20%, + + + = 21-60%, 
+ + + + = 61-100%. 
PM = human primary melanoma 
MM = human melanoma metastases 
MV1 and MV3 = cell lines MV1 and MV3 
XG1 and XG3 = "xenografts" after subcutaneous inoculation with MV1 or MV3 
in nude mice 
LXG3 = lung metastases in nude mice inoculated with MV3 cells 
for MV3 (chromosome 1) and MV1 (chromosome 7) a proportionally larger 
population of nuclei with four spots or more was observed in the subcutaneous 
tumours than in the corresponding cell lines. 
The spontaneous lung metastases of mice subcutaneously inoculated with MV3 
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cells, showed a similar distribution in the relative frequency of ISH spots as the 
"primary" tumour, both for chromosome 1 and 7 (Table I). Micrometastases 
could be detected by the presence of ISH spots in nuclei (Fig. 6C). Furthermore, 
tumour cell emboli of multiple and single melanoma cells were seen in microvas-
cular lumina (Fig. 6D). 
Human primary melanoma lesion and metastases 
Within the primary melanoma two different areas (a micronodular subepidermal 
area and a deeper larger nodule) could be evaluated. Both areas were aneuploid. 
Subpopulations of nuclei with a given spot number were present in both areas. 
Comparing the two areas, no differences in the relative fraction of these nuclei 
could be detected. In general, nuclei with a higher spot number were larger than 
those with fewer ISH signals. Nuclei were found with one, two, three and four 
spots per nucleus for the chromosome 1 and 7 targets, whereas for chromosome 
1 nuclei with five spots were observed as well (Table I, Fig 6E). The presence of 
these nuclei with five ISH spots contrasts with the absence of such a population 
in the cell line MV1. The relative frequency of nuclei with a given number of 
spots differed for the chromosomes 1 and 7 sequences; nuclei with three spots or 
more were more frequent in the case of chromosome 1. Furthermore, nuclei with 
more than four spots were not detected for chromosome 7. This imbalance was 
not present in cell line MV1 and was reversed for MV3. Although with those 
pretreatments which gave optimal results for the tumour cells, only a few nuclei 
of the overlying epidermis in this lesion were évaluable, these nuclei consistently 
showed no more than two spots. Control experiments on 6 μπι paraffin and 
frozen sections of normal skin showed two spots for both probes in the majority 
of the epidermal nuclei. No nuclei with more than two spots were seen. 
Two different neck lymph node metastases, one of which was used to make the 
cell lines, were evaluated and showed aneuploidy (Table I). The same relative 
fractions of nuclei with a given spot number were observed in these two lesions. 
This distribution also matched that of the primary melanoma. Thus, comparing 
the primary melanoma and the two metastases with regard to the nuclei with 
more than four spots, this subpopulation was present in the case of chromosome 
1 and absent for chromosome 7 in all three lesions. 
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DISCUSSION 
Melanocyte tumour progression can be studied by comparing melanoma cell lines 
with different biological behavior or by comparing (parts of) tissues with a 
different morphology (1). Here, we report on the feasibility of detecting 
chromosome specific repetitive DNA targets of chromosomes 1 and 7 in intact 
nuclei, using non-radioactive in situ hybridization. First, nuclei from cell 
suspensions of two melanoma cell lines, derived from the same patient lesion 
were compared. These lines show different metastatic behavior in nude mice, 
when inoculated subcutaneously. Regarding the total DNA content, flow-
cytometric analysis of these cell lines showed apparently homogeneous cell 
populations in both lines with no differences in ploidy. At the single cell level, 
however, both cell lines showed different subpopulations, when ISH was applied 
using probes which hybridize to repetitive sequences in the (peri-)centromere 
regions of either chromosome 1 or 7. We detected an imbalance in the presence 
of these sequences, as reflected by the number of ISH spots in cell suspensions of 
MV3, but not in those of MV1. Furthermore, only MV3 showed a subpopulation 
with more than four ISH spots. 
Figure 6 (next page): ISH on 6 μιη paraffin sections of melanocytic tissues 
The number of centromere regions per nucleus, for the chromosome under investigation, 
can be evaluated by counting the number of DAB spots per nucleus. Counterstaining of 
the nuclei with hematoxylin. Photographic documentation is complicated by focussing pro­
blems. Per section 200 nuclei were counted. Bar, 20 μηι. 
A: ISH with a chromosome 1 specific probe on a section of a subcutaneous tumour in a 
nude mouse after inoculation of cell line MV1 . The major fraction consists of nuclei with 
two or three spots per nucleus; B: ISH with a chromosome 1 specific probe on a section 
of a subcutaneous tumour in a nude mouse inoculated with cell line MV3. As in the 
suspensions, giant nuclei with a large number of spots could be detected. C: ISH with a 
chromosome 7 specific probe on a section of an area in the lungs of a nude mouse, 
inoculated subcutaneously with cell line MV3, to which human tumour cells have metas­
tasized. Human cells with five spots are visible, whereas the murine lung tissue is negati­
ve; D: ISH with a chromosome 7 specific probe on a section showing a murine pulmonal 
blood vessel containing a tumour embolus of human tumour cells in a nude mouse 
inoculated subcutaneously with cell line MV3; E: ISH with a chromosome 1 specific 
probe on a section of the subepidermal part of the primary cutaneous melanoma. The 
typical tissue architecture of the tumour is preserved. Aneuploidy is visualized. Most 
nuclei showed two or three DAB spots per nucleus. 
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Both cell lines MV1 and MV3 showed a complex karyotype with several (uniden-
tified) marker-chromosomes. With regard to the number of centromere regions of 
chromosomes 1 and 7 in MV1, the number of ISH spots of the major populations 
in the cell suspensions correlated well with the number of regions identified in 
the karyotyped cells. They also correlated well with the results obtained by ISH 
on metaphase spreads. Minor subpopulations could be detected with ISH on 
interphase nuclei. In MV3 the results from ISH on cell suspensions and on 
metaphases confirmed each other. For chromosome 1 and 7 the major populati-
ons showed three and four spots, respectively. Taking the dicentricity of chro-
mosome 1 into account, this was in accordance with the G- and C-banding data 
for chromosome 1. For chromosome 7 aberrant (marker-)chromosomes, which 
could not be identified in the metaphase spreads, might harbour the "missing" 
chromosome 7 centromere regions. In theory, a selection caused by differences in 
the mitotic index during the preparation of metaphase spreads between sub-
populations in MV3 could also explain the difference. 
Compared to flow-cytometric and karyotypic analyses, ISH on interphase nuclei 
allows the assessment of numerical aberrations of specific DNA targets at the 
single-cell level in a large number of unselected nuclei. Aneuploidy, 
heterogeneity, major and minor subpopulations can be detected. The detection of 
numerical differences in situ with regard to specific sequences may reflect 
differing copy numbers of (parts of) the investigated chromosomes and enables 
chromosome counting in non-mitotic cells (21,22). The number of ISH spots in 
the major fraction of nuclei for the chromosome 7 target changed from three, in 
the non-metastasizing cell line MV1, to four in the metastasizing MV3. Sub-
populations with a higher spot number appeared in MV3 for both the 
chromosome 1 and 7 sequences. The process of polyploidization, of which these 
observations may be indicative, was correlated to tumour progression (35). 
In melanoma research aneuploidy, genotypic heterogeneity, the process of 
polyploidization and specific genomic aberrations are hard to study at the single 
cell level in intact tissues. To study the applicability of ISH to formalin-fixed, 
paraffin-embedded melanocyte tissues, we investigated whether differences could 
be traced between the xenografts, obtained by subcutaneous inoculation of either 
MV1 or MV3 cells. We observed the same subpopulations with a given spot 
number for both the chromosome 1 and 7 targets, as were detected in the 
suspensions of the cell lines. Notably, the presence or absence of a population 
with more than four spots in the cell lines correlated well with the data from the 
xenografts. We assume that these aneuploid lesions contain cells with different 
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numbers of ISH spots per nucleus, which would make them heterogeneous. The 
observation that small clusters of nuclei with different spots numbers were seen, 
supports this view. However, the different sizes of the nuclei and the effect of 
cutting through nuclei may lead to an underestimation of the number of spots. 
Thus, all nuclei may, in theory, contain the maximum number of spots detected 
(19,23). Regarding the lung metastases of mice inoculated with MV3, we could 
detect tumour cell emboli in the pulmonal vessels and micrometastases in lung 
parenchyma, based on the presence of ISH signals in nuclei in their natural 
context. Nuclei with varying numbers of ISH spots were seen in a distribution 
similar to that in the primary subcutaneous xenograft. As was expected for the 
human specific probes, no hybridization signals were seen in the murine cells. 
This is useful in studies, where questions may rise as to the origin of cell 
populations, i.e. human cells in laboratory animals (26, 27). 
Further, we studied paraffin sections of the original patients' primary melanoma 
and two lymph node metastases. It is important for the possible detection of 
cytogenetic changes in complex melanocyte lesions harboring different stages of 
progression, that we could compare ISH data from two different areas in one 
section of the primary melanoma, based on the proper preservation of the 
morphology. Thus, ISH on tissue sections has the advantage that single tumour 
cells can be studied in their histological context with respect to numerical 
chromosomal abnormalities. In both the subepidermal and the deeper intradermal 
area of the primary melanoma we found extra (parts of) copies of chromosomes 1 
and 7. There was an imbalance between the two chromosomes studied regarding 
the presence of a population of nuclei with more than four ISH spots. Similar 
changes have been reported in karyotyping studies. Reports from Balaban et al. 
and Parmiter et al. on primary cutaneous melanomas revealed abnormalities of 
chromosome 1 and 7 in most cases, in which histologically both a radial growth 
phase (RGP) and a vertical growth phase (VGP) component were present, but 
which could not be studied separately (6-8). No aberrations of chromosomes 1 or 
7 were found in the case of a RGP primary melanoma and in the RGP part of a 
primary melanoma, in which the RGP and VGP component could be evaluated 
separately (7). Cowan et al. also reported on abnormalities of chromosomes 1 
and 7 in primary melanomas (10). Based on histology, our case is an advanced 
primary melanoma in which aberrations of chromosomes 1 and 7 may be 
expected taking these data from the literature into account. 
We found numerical aberrations of the targeted sequences on chromosomes 1 and 
7 in the patients' metastases. Numerical changes of these chromosomes have been 
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described consistently in the literature (4). Strikingly, the two different metastases 
showed the same distribution of spot numbers, which also matched that of the 
primary melanoma. With respect to the comparison of a primary tumour with its 
metastasis, similar patterns in spot distribution were also found in the MV3-
derived tumours in the mice. In line with the theory of clonal dominance, 
proposed by Kerbel et al. (36), it is tempting to assume that the same 
population(s) which formed the metastases had overgrown the primary tumour 
site. 
The study of melanocytic tumour progression in intact human tissues depends on 
the selection by conventional histology of (parts of) lesions with known biological 
behavior. By using morphological characteristics, different stages can be iden­
tified and compared. As most tissues of interest are archived in paraffin, the ap­
plication of ISH to paraffin sections opens new perspectives for the study of 
genomic changes in melanocytic tumour biology. We were able to evaluate our 
paraffin material by selecting the proper pretreatment and optimal tuning. We 
also obtained results in 6 μπι cryostat sections of the deep frozen material. 
However, finding the right balance, between loss of morphology and the ob­
taining of évaluable ISH signals, was more difficult in comparison with the 
paraffin sections. 
From our study, we conclude that ISH can be applied to detect targeted repetitive 
DNA sequences at the single cell level. The results can be interpreted in terms of 
aneuploidy, heterogeneity and numerical aberrations of (parts of) chromosomes. 
Various sources of cells and tissues can be used, including archived formalin-
fixed, paraffin-embedded materials, which allows for a comparison of various 
stages of progression. ISH on tissue sections enables direct reference to his-
topathological characteristics. The reliable detection of non-repetitive DNA 
targets in melanocytic tissue sections, allowing the in situ detection of deleted 
regions of chromosomes, is under study. We believe that interphase cytogenetics 
will broaden the perspective of integrating genomic and phenotypic characteristics 
of melanocytic tumour progression. Furthermore, it may serve as a diagnostic 
tool in histopathology. 
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ABSTRACT 
As the clinical and differential diagnosis between Spitz naevus and cutaneous 
melanoma clinically and histologically may be very difficult, we have investigated 
whether DNA in situ hybridization may be helpful in resolving this problem. To 
this end routinely processed paraffin sections of 15 typical Spitz naevi, 15 typical 
nodular melanomas, and five cases originally misdiagnosed as Spitz naevus but 
which later metastasized and were reclassified as melanoma were analysed using 
a method previously described (De Wit et al, J Invest Dermatol 1992; 98: 450-
458). 
Microscopical semi-quantitative evaluation revealed that the number of nuclei 
with supernumerary aberrations of the centromere region of chromosome 1, 
suggestive for aneuploidy, was significantly different in Spitz naevi and nodular 
melanoma. The mean number of aberrant nuclei per high power field was 0.41 
and 4.01, respectively (P=0.0001). On applying the results of the typical lesions 
to the equivocal, originally misdiagnosed lesions, three out of five could be iden-
tified as melanoma. 
These results suggest that the application of DNA in situ hybridization may 
contribute to the positive identification of histologically equivocal pigmented 
lesions. The advantages of this technique are that it is cheap, requires little tissue, 
and can be applied on routinely-processed paraffin sections (J Pathol 1994; 173: 
227-233). 
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INTRODUCTION 
In the histopathology of cutaneous melanocyte proliferations the differential 
diagnosis between malignant and benign lesions can be very difficult; this is true 
especially for nodular melanoma versus Spitz naevus (1-4). Not infrequently, 
cases are encountered where even expert opinions differ on routinely stained 
histological slides. There is an evident need for additional techniques to support 
the histopathological diagnosis. Recently we described how DNA in situ hybridi-
zation (DNA-ISH) utilizing probes specific for repetitive DNA targets on specific 
chromosomal regions can be applied on sections of routinely formalin-fixed, 
paraffin-embedded melanocyte lesions (5). Supernumerary aberrations of chro-
mosomal regions could thus be detected in situ; that is, by the visualization of 
more than two regions in one interphase nucleus, in contrast to a normal diploid 
cell (6). The presence of supernumerary aberrations can be interpreted as a 
marker of aneuploidy. According to the literature, a considerable number of the 
malignant melanomas are aneuploid, the percentage of aneuploid lesions increa-
sing with tumour thickness (7). As especially thick melanoma lesions raise pro-
blems in the differential diagnosis with Spitz naevus and in view of the foregoing 
it is of interest that Spitz naevi have been reported as euploid (8-12). We have 
applied DNA-ISH on paraffin sections of routinely processed lesions to inves-
tigate whether it can be used to identify malignant melanomas by means of in situ 
visualization of aneuploidy. This was done on histologically typical malignant 
melanomas and on unequivocal Spitz naevi. More importantly, we studied a num-
ber of primary cutaneous melanocytic lesions initially misdiagnosed as Spitz 
naevus, but which later proved to be malignant melanomas by the subsequent 
development of metastases. The aim was to investigate whether DNA-ISH could 
be of value in the differential diagnosis of malignant melanoma and Spitz naevus. 
MATERIALS AND METHODS 
Unequivocal cases 
Clinical and pathological data on 15 cases of Spitz naevus and on 15 cases of 
nodular melanoma are listed in Tables IA and IB, respectively. These his-
tologically unequivocal cases were selected from the files of the Departments of 
Pathology from the University Hospital Nijmegen and the Canisius-Wilhelmina 
Hospital Nijmegen. As a quality control, the slides were submitted to the 
pathology panel of the Dutch Melanoma Working Party. The original diagnosis 
was confirmed in all cases. 
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Table IA: Clinico-pathological data and DNA-ISH results on 15 his­
tologically typical Spitz naevi* 
case 
No. 
1 
2 
3 
4 
5 
6 
7 
δ 
9 
10 
11 
12 
13 
14 
15 
age 
(yrs) 
20 
22 
4 
21 
7 
17 
24 
21 
31 
41 
6 
5 
37 
14 
5 
sex 
F 
M 
F 
F 
F 
M 
F 
F 
F 
M 
F 
F 
M 
F 
F 
site 
nose 
ear 
cheek 
lower leg 
forehead 
knee 
upper leg 
abdomen 
lower leg 
nose 
elbow 
cheek 
cheek 
back 
cheek 
A 
— 
— 
— 
— 
— 
— 
— 
— 
— 
— 
— 
— 
— 
— 
— 
В 
0.6 
0.4 
0.7 
0.2(1.5)** 
0.4 
0.4 
0.2 
0.3 
0.1 
0.5 
0.9 
0.7 
0.0 
0.1 
0.6 
С 
— 
— 
— 
-(+) 
— 
— 
— 
— 
— 
— 
— 
— 
— 
— 
— 
D 
2(4) 
0 
1 
2 
*: А, В, С, D: DNA-ISH results: 
A: assessment at screening: aneuploidy suspected (+); equivocal (±); aneuploidy not 
suspected (—); B: nuclei with >2 ISH spots: mean number per HPF (10 HPFs 
counted); C: nuclei with >3 ISH spots present (+) or not (—); D: nuclei with >2 ISH 
spots: maximal number observed in one HPF; **: Figures between brackets refer to 
counts including the giant Spitz cells (see text) 
Problematic cases 
In order to evaluate the diagnostic value of DNA-ISH in the differential diagnosis 
of melanoma versus Spitz naevus, 18 problematic cases were traced using the 
Dutch PALGA system. This computerized data system holds histological diag­
noses and keywords on biopsies per individual, entered by 70 pathology 
laboratories in The Netherlands. Five cases were retrieved which fulfilled the 
following criteria: a) the original diagnosis was documented as Spitz naevus, b) 
melanoma metastases occurred (n=3) or there was local recurrence with evident 
malignant morphology (n=2), c) the differential diagnosis of the primary lesions 
was difficult as documented in the pathology report and also after review of the 
slides, d) no other primary melanoma was documented, e) there was enough 
representative tissue left in the paraffin block to perform the experiments. These 
five cases are summerized in Table II. 
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Table IB: Clinico-pathological data and DNA-ISH results on 15 his­
tologically typical nodular melanomas* 
case 
No. 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
age 
(yrs) 
23 
30 
61 
39 
51 
69 
63 
47 
37 
40 
64 
62 
59 
76 
54 
sex 
F 
M 
F 
M 
F 
F 
F 
M 
M 
M 
M 
M 
F 
M 
M 
site 
buttock 
face 
flank 
back 
lower leg 
lower leg 
upper leg 
dorsum foot 
back 
back 
lower leg 
face 
lower leg 
face 
back 
Clark 
level 
III 
IV 
Ш 
Ш 
Г 
V 
V 
Г 
Ш 
rv 
m 
IV 
V 
IV 
in 
Bres-
low" 
3.0 
2.2 
1.8 
1.6 
3.0 
3.9 
5.7 
7.0 
1.5 
5.5 
2.7 
3.0 
4.0 
6.0 
2.9 
A 
+ 
± 
± 
— 
— 
+ 
+ 
± 
— 
+ 
+ 
+ 
+ 
+ 
+ 
В 
2.2 
1.0 
1.4 
0.9 
1.1 
5.2 
3.1 
1.6 
0.6 
2.5 
6.3 
5.8 
8.2 
11.1 
9.3 
С 
— 
— 
— 
— 
— 
-
— 
+ 
— 
+ 
+ 
— 
+ 
+ 
+ 
D 
4 
2 
3 
2 
5 
> 10 
10 
5 
1 
4 
> 10 
8 
> 10 
> 10 
> 10 
': A, B, C, D: DNA-ISH results: 
A: assessment at screening: aneuploidy suspected (+); equivocal (±); aneuploidy not 
suspected (—). 
B: nuclei with >2 ISH spots: mean number per HPF (10 HPFs counted). 
C: nuclei with >3 ISH spots present (+) or not (—). 
D: nuclei with >2 ISH spots: maximal number observed in one HPF. 
*": Breslow thickness in millimeters. 
DNA in situ hybridization 
The DNA in situ hybridization procedure (DNA-ISH) was performed as 
described previously by us in detail (5), with minor modifications. In short, 4 
micrometer paraffin sections were mounted on organosilane (Sigma, St. Louis, 
USA) coated slides, dried, heated and dewaxed. After blocking of endogenous 
peroxidase with H 2 0 2 / methanol, sections were pretreated with NaSCN (80°C) 
or water (37°C). Enzyme digestion was performed using pepsin in HCl, followed 
by dehydration and heating. Differentiation in pepsin treatment time was used to 
obtain an optimal balance between morphology preservation and DNA-target 
accessibility (obtaining of ISH-signal). A biotinylated probe pUC 1.77 was used, 
which hybridizes to a tandem repeat of 1.77 Kb in the pericentromere region of 
chromosome 1 (region lql2) (13). High stringency hybridization conditions were 
used as previously described (5). Visualization of the in situ hybrids was per-
113 
Table Π: Clinico-pathological data and DNA-ISH results on five 
melanomas, initially misdiagnosed as Spitz naevus* 
case 
No. 
1 
2 
3 
4 
5 
age 
(yrs) 
9 
23 
50 
35 
80 
sex 
M 
M 
F 
F 
F 
site 
dorsum foot 
neck 
back 
arm 
cheek 
Clark 
level 
Г 
IV 
Г 
IV 
V 
Bres-
low" 
3.0 
2.2 
1.8 
2.9 
4.1 
A 
+ 
+ 
± 
+ 
— 
В 
5.4 
5.5 
1.1 
3.7 
0.4 
С 
— 
— 
-
— 
— 
D 
>10 
10 
3 
6 
1 
*: A, B, C, D: DNA-ISH results: 
A: assessment at screening: aneuploidy suspected (+); equivocal (±); aneuploidy not 
suspected (—); B: nuclei with >2 ISH spots: mean number per HPF (10 HPFs 
counted); C: nuclei with >3 ISH spots present (+) or not (—); D: nuclei with >2 
ISH spots: maximal number observed in one HPF 
"*: Breslow thickness in millimeters 
formed using an avidin-biotin-complex method and diaminobenzidine (DAB), 
resulting in dark brown spots in the nuclei in the tissue sections at those places 
where the specific DNA targets on the specific chromosomal regions are located 
(ISH-spots). Sections were counterstained with (eosin and) hematoxylin. 
Evaluation 
Based on criteria, established in our laboratory at an earlier stage, sections were 
evaluated as follows (14). The sections of each case were checked to ensure that 
they were representative of the lesion and for preservation of its general architec­
ture. The optimal slide to evaluate semi-quantitatively was considered to be the 
one with well demarcated (by hematoxylin) melanocyte nuclei (preserved mor­
phology) in combination with the visualization of all targeted chromosome-
regions present (clearly visible, discrete, well-separated ISH-spots). All lesionai 
nuclei were first screened for the presence of more than 2 (>2) ISH-spots: two 
observers (PdW, HK) scored the lesions for the presence of nuclei with > 2 ISH-
spots, without counting, into the categories: a) aneuploidy suspected ( + ) , b) 
equivocal (±) , c) aneuploidy not suspected (—). In addition, areas were selected, 
which at screening appeared to have the most nuclei with > 2 ISH-spots. Other­
wise, random high power fields (HPF= x400) were selected. A minimum of 10 
HPFs per lesion were examined and the number of nuclei with > 2 ISH-spots per 
HPF was counted. Non-parametric statistics were applied. 
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RESULTS 
Unequivocal cases 
Table IA lists the data of the DNA-ISH experiments on the 15 histologically 
typical Spitz naevi. On screening, all lesions were scored as "aneuploidy not 
suspected" by both observers. All lesions, except for one (No. 4), had 2 or fewer 
nuclei with >2 spots as a maximum observed in one HPF. Case 4 showed 4 
nuclei with >2 spots in one field (column D). These were nuclei of Spitz's 
multinucleated giant cells, some of which showed >3 spots. Not taking the giant 
cells in this case into account, the mean number of nuclei with >2 spots per 
HPF (10 HPFs counted) varied from 0 to 0.9 (mean 0.41, SD 0.26). A represen­
tative example is shown in Figure IA. 
Table IB lists the data of the DNA-ISH experiments on the 15 histologically 
typical nodular melanomas. On screening the lesions, nine were considered 
clearly "aneuploidy suspected", three were scored "not suspected" and three 
others were "equivocal". These results were significantly different from the 
results of Spitz naevi (Fisher's exact test, p<0.001). There was a correlation 
between the mean number of nuclei with >2 spots per HPF and the global 
assessment at screening (Spearman correlation coefficient: 0.87; p= 0.0001). 
The "not suspected" lesions showed a low mean number of nuclei with >2 ISH-
spots. The mean number of nuclei with >2 spots per HPF (10 HPFs counted) 
ranged from 0.6 to 11.1 (mean 4.01; SD 3.4). This was different from the results 
in Spitz naevi (Mann-Whitney test, p= 0.0001). The data for the melanomas also 
differed from those of the Spitz naevi with regard to the maximal number of 
nuclei with >2 spots seen in one HPF (columns D; Mann-Whitney test, p= 
0.0001)) and to the presence of nuclei with more than 3 spots (columns C; 
Fisher's exact test, p= 0.02). Also, the mean number of nuclei with >2 spots 
per HPF (column B) increased with the Breslow-thickness of the lesion (Spear-
mann correlation coefficient: 0.53, ρ = 0.04). A representative example is 
shown in Figure IB. 
Problematic cases 
Table II gives the data of the DNA-ISH experiments in the five cases of 
melanoma diagnosed in first instance as Spitz naevus. The mean number of nuclei 
with >2 spots per HPF ranged from 0.4 to 5.5. No nuclei with more than 3 
spots were observed. A representative example is shown in Figure 1С. 
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Figure 1: DNA-ISH on melanocytic lesions. 
DNA-ISH on a typical Spitz naevus (A), on a typical nodular melanoma (B) and on a 
melanoma initially misdiagnosed as Spitz naevus (С). In В and С, nuclei with > 2 ISH-
spots per nucleus are present, but not in A. For evaluation criteria see text. Bar = 20 
micrometer. 
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A summary of the results in the different lesions on the mean number of nuclei 
with > 2 spots per HPF is presented in Table III. 
Table ΙΠ: Number of aberrant nuclei per HPF in melanocyte lesions 
studied (summary) 
Number of nuclei 
with > 2 ISH spots 
(mean per HPF) 
> 10 
5 - 10 
2 -5 
1 -2 
0 .5- 1 
0 - 0 . 5 
Typical Spitz 
naevus* 
Typical 
melanoma 
• 
· · · 
· · · · 
· · 
Misdiagnosed 
melanoma 
· · 
• 
• 
• 
* Each circle represents one lesion 
DISCUSSION 
The differential diagnosis between malignant melanoma and Spitz naevus is a 
well-known problem in dermatopathology (1). This problem relates especially to 
the vertical growth phase of primary melanoma. In superficial spreading 
melanoma with a nodular component, the vertical growth phase, a histological 
diagnosis of melanoma can often be made based on the characteristic features of 
the associated horizontal growth phase. On the other hand, in the case of a 
nodular melanoma, the diagnosis has to be made on the vertical growth phase 
alone. In view of these considerations, our study concentrated on the differential 
diagnosis of Spitz naevus and nodular melanoma. A definite diagnosis of malig­
nant melanoma should be soundly based because of clinical implications that 
include: a) re-excision with possible mutilating effects, b) staging procedures, c) 
the follow-up regimen and d) examination of relatives in case of familial mela­
noma. In routine practice, consultation of more experienced (dermato-)patholo-
gists may solve a number of diagnostic problems. However, even expert opinions 
on hematoxylin and eosin stained sections may differ. Several approaches have 
been put forward in such problematic cases in order to establish their malignant 
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nature. Rode et al, using immunohistochemical methods recently described a 
significant difference in mean staining intensity for S100 and NSE, comparing a 
group of Spitz naevi with a group of melanomas (11). 
Most reports on the differential diagnosis between Spitz naevus and melanoma 
have focused on differences in DNA content (8-12). These have included image-
cytometry on disaggregated nuclei or on nuclei in tissue sections, and flow-
cytometry. The results of these studies indicate that Spitz naevi are euploid. In 
contrast, a considerable number of nodular melanomas is aneuploid, which is in 
concordance with data from cytogenetic studies (15-16). To the best of our 
knowledge, no karyotyping studies for Spitz naevi have been reported. This 
reflects the fact that it is impracticable to sample and culture or store fresh 
(frozen) tissue from every pigmented skin lesion in a routine setting. Additional 
diagnostic techniques should therefore be applicable on formalin-fixed, paraffin-
embedded material. 
Here we report on the positive identification of three out of five malignant 
melanomas that had previously been diagnosed as Spitz naevus. This was possible 
using microscopical visualization of aneuploidy by applying DNA-ISH on 
routinely processed lesions. The technique has several advantages. It requires no 
specific expensive equipment. It takes relatively little tissue and can be applied to 
small lesions. Each nucleus can be analyzed separately in its histological context 
because the architecture is preserved. This enables the reliable evaluation of 
known cell types. Since the marker of aneuploidy is visualized as the presence of 
three or more discrete spots within a counterstained nucleus, comparison with a 
normal diploid population is not needed. These factors may be regarded as 
advantages compared with the flow-cytometric and/or image-cytometric analysis 
of aneuploidy. 
To support our data regarding ploidy assessed as by DNA-ISH, the DNA content 
of four Spitz naevi (Table IA: Nos 2, 3, 8 and 9) and 4 nodular melanomas 
(Table IB: Nos 9, 11, 12, and 15) was also assessed using image-cytometric 
analysis on Feulgen-stained tissue sections (data not shown). The ploidy of these 
lesions determined by this technique correlated well with the ploidy assessed by 
DNA-ISH: Spitz naevi showed DNA indices of 1.1 (No. 2), 0.93 (No. 3), 0.95 
(No. 8) and 0.92 (No. 9) and nodular melanomas of 1.0 (No. 9; this case was 
not suspected for aneuploidy at DNA-ISH), 1.6 (No. 11), 1.7 (No. 12) and 2.2 
(No. 15). 
It is remarkable that the detection of supernumerary chromosomal aberrations 
based on only one target, on chromosome 1, already yields diagnostically 
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relevant information. Conceivably, the extension of the number of targets studied 
may improve the efficacy of the DNA-ISH approach. Future investigations should 
explore the appropriate choice and number of such targets. The rationale for 
chosing the lql2 target on chromosome 1 is that this region is very often over-
represented in melanoma, especially in advanced lesions (15-16). As a conse-
quence those lesions which are aneuploid have mainly 3 or more of these targets 
per nucleus. A further practical reason is that the lql2 target is quite large and 
can be visualized better than other targets in paraffin sections. 
The nodular melanomas studied frequently showed aberrant nuclei and nuclei 
with >3 spots were also seen. However, occasional melanomas had counting 
results overlapping with those of the Spitz naevi. This was not unexpected, as a 
proportion of the melanomas have been reported to be euploid/diploid (7). Thus, 
the technique used here does not therefore provide an absolute distinction 
between melanomas and Spitz naevi, but can contribute to the identification of a 
considerable proportion of melanomas. Assessing and counting the number of 
aberrant nuclei in ten HPF provides indirect information on the ploidy of the 
lesion and thus on its nature. Using an arbitrarely chosen lower margin of at least 
three aberrant nuclei per HPF as a mean, out of five originally misdiagnosed 
cases, three would have been correctly designated as melanoma. This result on 
difficult lesions is quite revealing, as these cases represent major diagnostic 
problems in daily practice. With regard to the Spitz naevi, there are no reports 
which provide karyotyping data on these lesions. Flow- and image-cytometric 
studies show that they are diploid, with sometimes few hyperdiploid or polyploid 
cells (8-12). Our data suggest that in Spitz naevi, cytogenetic aberrations may be 
found, although in a very low percentage of cells. One case out of 15 showed a 
pattern which indicates a few polyploid cells within a diploid population. Chi et 
al also found such a pattern in 2 out of 20 Spitz naevi using a cytofluorometric 
analysis (10). 
In conclusion, we have described here a new approach which helps positively to 
identify melanoma cases that are problematic on conventional light microscopy. 
As it is applicable on routinely processed lesions and does not require expensive 
equipment, it may be of practical use in the differential diagnosis between 
melanoma and Spitz naevus. 
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CHAPTER 7 
LOSS OF HETEROZYGOSITY DETECTED BY 
MICROSATELLITE ALLELOTYPING IN THE 
DIFFERENTIAL DIAGNOSIS OF MELANOMA 
VERSUS SPITZ NAEVUS 
Peter E.J. de Wit, Riki W. Willems, Marjolijn J.L. Ligtenberg, 
Goos N.P. van Muijen, Robert M.W. de Waal, Dirk J. Ruiter 
Department of Pathology, University Hospital Nijmegen, 
The Netherlands 
ABSTRACT 
We describe a study in which routinely processed tissues were used as starting 
material to perform allelotyping experiments on Spitz naevi and malignant 
melanomas in order to investigate whether the phenomenon of loss of 
heterozygosity (LOH), as a marker for the presence of so-called early or later 
genetic events, may be used for diagnostic purposes. We used 5 microsatellite 
markers, D3S1293, D6S271, D9S171, D10S187 and D18S70 to detect LOH at 
the chromosomal regions 3p, 6q, 9p, lOq and 18q, respectively. The technical 
procedure using automated fluorescense- based DNA sizing equipment was 
optimised for this application. Criteria for the interpretation of the output 
graphics, based on evaluation by naked eye assisted by calculating allele im-
balance ratios, were established. The overall number of tests évaluable with 
regard to the presence of LOH, was comparable for melanomas (29) and Spitz 
naevi (27). Not-interpretability (34 tests) was due to homozygosity of the markers 
(21), to preferential PCR of a significantly smaller allele (5) or to unknown 
factors, probably related to poor quality DNA (8). While 5 out of 9 melanomas 
showed LOH at at least one locus, no LOH was found in the 9 Spitz naevi 
studied. In melanomas with LOH, either the chromosome 9 marker or 
chromosome 10 marker was always involved. As most mentioned problems can 
be circumvented by the application of more markers, we conclude that our results 
provide evidence that the detection of LOH using fluorescence-based technology 
can be valuable in the differential diagnosis of melanoma versus Spitz naevus, 
which merits a more extended study. 
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INTRODUCTION 
Although dissemination in cutaneous malignant melanoma occurs already at a 
relatively small tumour volume, the prognosis is excellent when this tumor is 
detected and excised at an early stage. Due to physicians and the general 
population being keen on early diagnosis, pathologists are presented with many 
melanocyte lesions for diagnosis (1). In the histopathology of cutaneous 
melanocytic proliferations, the discrimination between malignant and benign 
lesions can be difficult. Regularly, clinically relevant diagnostic difficulties are 
encountered, including the differential diagnosis of melanoma versus Spitz 
naevus. As also pathologists who are experienced in this field have problems 
here, there is a need for additional techniques to support the histopathological 
diagnosis and to minimise the number of so-called "impossible cases" (2). Such 
techniques should preferably be applicable on routinely fixed and embedded 
tissues. 
Besides immunohistochemical and morphometrical studies, most reports dealing 
with the differential diagnosis of Spitz naevus versus melanoma are based on 
differences at the DNA level. In concordance with data from the cytogenetic 
literature, thick melanomas are often aneuploid as determined by flow- or image-
cytometrical techniques, whereas Spitz naevi are reported to be euploid (3-6). 
This difference can be useful for diagnostic purposes and it formed for us the 
basis for a DNA-in situ hybridization study, aiming at the visualisation of 
numerical aberrations of the centromere region of chromosome 1 as an indicator 
of aneuploidy (7). However, already at the light microscopical level using haema-
toxylin & eosin (H&E) stained slides, the most difficult clinically relevant cases 
to diagnose as melanoma are those thick and intermediate-thickness lesions with a 
uniform nuclear appearance, i.e. melanomas with relatively small, non-hyper-
chromatic nuclei, mimicking benign naevi. These melanomas probably form a 
subgroup which are diploid or which have DNA-content-aberrations not 
measurable with current cytometric techniques. In such melanomas it may be 
assumed that, although rather gross numerical aberrations have not (yet) oc-
curred, early genetic changes are present. So, the detection of these early events 
in melanomas (both thin and thick) may serve diagnostic purposes if these events 
are not found in Spitz naevi. 
It has been reported for melanoma that deletions of chromosomal regions on 
chromosomes 9p and lOq, probably harbouring tumour suppressor genes, are 
among these early events (5, 8-11). On the other hand, detection at the nucleotide 
level of later events may, if already present, be of diagnostic value if not 
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occurring in Spitz naevi. Here, amongst others, deletions on chromosomes 3p, 6q 
and l lq have been reported (12-16). The detection of deletions by the study of 
loss of heterozygosity (LOH) has become wider applicable with the introduction 
of microsatellite markers. Microsatellites are small non-coding repetitive DNA 
sequences, highly variable in size, mostly highly polymorphic and widely present 
in the human genome. Using specific primers these sequences can be amplified 
by polymerase chain reaction (PCR) and the applicability to formalin-fixed, 
paraffin-embedded tissues offers possibilities for the study of archived materials 
(17). 
In this study we explored whether LOH might serve diagnostic purposes in 
discriminating melanomas from Spitz naevi. We selected microsatellites based on 
data derived from karyotyping and molecular studies on melanomas (5-16). For 
Spitz naevi no karyotypes are described, while one LOH study was reported in 
the course of this study (18). We explored technical possibilities and problems 
with regard to the use of automated fluorescence-based DNA sizing equipment 
including the output interpretation with regard to the presence or absence of LOH 
(19). Using 5 microsatellite markers we found LOH in melanomas but not in 
Spitz naevi. 
MATERIALS AND METHODS 
Melanomas and Spitz naevi: tissue selection 
For this LOH study we selected nine cases of histopathological unequivocal, 
mostly thick nodular melanomas, not derived from patients with the dysplastic 
naevus syndrome. These cases were selected because the chance of finding DNA 
aberrations here was considered high, which was regarded important with respect 
to the technical aspects to be evaluated. Also it was postulated that by studying 
the selected melanomas, the outcome with regard to the diagnostic efficacy would 
indicate the merit of a more extented study. For comparison, nine cases of Spitz 
naevi were selected, three of which showed an atypical nuclear appearance. 
Characteristics of the lesions selected are summarized in Table I. All lesions 
were from different individuals and taken from the archives of the routine 
pathology practice, implying that all tissues were fixed in buffered formalin (4%) 
with fixation times varying from about 16 to 64 hours. Melanocyte lesions were 
selected which were at least moderately cellular and which had a not too brisk 
lymphocytic infiltrate, in order to reduce the chance of substantial contamination 
of tumour DNA with normal DNA. Contamination by non-tumour cells was 
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estimated microscopically: the selected tumour tissues contained at least 60 
percent tumour cells. Melanomas and Spitz naevi were microdissected without 
paying attention to the presence of areas with a different morphological ap­
pearance, thus incorporating the possibility of mixing different populations from a 
heterogeneous lesion. Although morphological heterogeneity was present in 
melanomas, Spitz naevi had a homogeneous cytonuclear appearance. Depending 
on the size of the tissue of interest, 4-50 consecutive sections of 10 μπι thickness 
were used. For control non-tumourous tissue, normal skin from the same surgical 
excision was used, either (if present) from the paraplast blocs with normal skin 
(negative resection margins) or microdissected, guided by a parallel H&E-stained 
slide, from the same bloc in which the tumour was present (non-tumourous 
lateral margins). For one case (no. 1) a tumour-negative lymph node was used as 
a control. In case of the tumours, the non-tumourous (basal and/or lateral) dermal 
and epidermal parts were removed by microdissection after mounting the sections 
on glass slides. In addition, in relatively thin Spitz naevi, the supra-tumoural 
epidermis was scraped away, in order to avoid substantial contamination with 
keratinocytes. After selection by microdissection, the tissue parts of interest were 
put into a 1.5 ml Eppendorf tube. 
DNA isolation 
The DNA extraction procedure was performed using the Puregene DNA isolation 
kit (Gentrasystems, Triangle Park, USA). The selected tissues were treated for 
18 hours at 55°C with 0.5 mg/ml proteinase К in 500 μΐ cell lysis solution accor­
ding to the recommendations of the manufacturer. Further digestion was per­
formed for 48 hours at 37°C. After cooling-down the samples to room 
temperature, 150 μ\ of protein precipitation solution was added, followed by 
mixing for 20 seconds and centrifugation (14,000xg, 4°C). To the supernatant, 
500 /Л isopropanol (100%) was added followed by gentle mixing and 
centrifugation (14,000xg, 4°C) for DNA precipitation. After washing the pellet 
with 500 μΐ ethanol (70%) at 4°C and centrifugation (14,000xg, 4°C), DNA was 
air-dried. Fifty μΐ of DNA hydration solution was added for DNA solubilisation 
for 60 minutes at 65°C. DNA was stored at 4°C. Since in starting experiments 
with deeply pigmented tumours we obtained sufficient PCR products and also 
because the lesions selected for this study were not very heavily pigmented, we 
did not include a melanin extraction step. 
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PCR-analysis 
Amplification of the targets was performed using standard procedures and 
primers labelled with fluorescent phosphor-amidites, linked to the forward primer 
(commercially obtained from Perkin-Elmer Corporation, Warrington, UK). 
Markers used are listed in Table II together with data on genomic localisation, 
length and degree of heterozygosity. Samples were denatured for 5 minutes at 
93°C and passed through 35 or sometimes up to 40 cycles of amplification 
consisting of 45 seconds denaturation at 92°C, 45 seconds primer annealing at 
50°C, 60 seconds elongation at 72°C and a final extension of 5 minutes at 72°C 
(Mastercycler, Eppendorf, Germany). After PCR and evaluation of the products 
on a agarose gel, samples were denatured with formamide and subjected to 
electrophoreses on a 6% Polyacrylamide gel in a 373 DNA Sequencing System 
(Applied Biosystems, Perkin-Elmer Corporation, Foster City, USA). In this 
system the fluorescence-labeled PCR products were size-separated and detected 
after excitation of the labels. The emitted fluorescence, after filtering, was 
detected by a photomultiplyer system and the banding pattern was analyzed by 
computer software (Genescan, Applied Biosystems, Perkin-Elmer Corporation). 
This multicolour system offers the possibility for running a size standard in the 
sample lane and combines possibilities for quantification of the amplified product 
with a rather large range of response linearity. As an output, electrophoresis 
bands were plotted graphically with fluorescence intensity plotted per basepair 
number. Values were retrieved on the basepair number at the peak position, on 
fluorescence level of the peak top and area (surface) of the peak, allowing a 
quantitative comparison of tumour and non-tumour-derived data. 
Legend to Table I (next page) 
': SSM = Superficial Spreading Melanoma; NM = Nodular Melanoma; SNm = Spitz 
Naevus, mixed spindle and epithelioid; SNe = Spitz Naevus, epithelioid cell 
predominant; SNs = Spitz Naevus spindle cell predominant. 
b
: In millimeters according to Breslow; for Spitz naevi measured similarly as for 
melanomas. 
c: H: homozogous; +: heterozogous with LOH; -: heterozygous and no LOH; * and #: no 
evaluation possible (see Results). 
d: Fraction of informative markers with LOH in the given case. 
e: Not classical appearance: atypical Spitz naevi. 
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Table I: Loss of heterozygosity in melanomas but not in Spitz naevi 
no 
1 
2 
3 
4 
5 
6 
7 
8 
9 
type 
of 
lesiona 
SSM 
NM 
NM 
NM 
NM 
NM 
NM 
NM 
NM 
thick-
ness1" 
7.0 
4.2 
4.5 
7.0 
7.5 
4.2 
4.5 
5.5 
2.15 
LOH per marker 
LOHc 
D3 
S1293 
-
-
-
-
H 
* 
-
+ 
-
14% 
D6 
S271 
# 
-
-
+ 
H 
H 
-
-
-
17% 
D9 
S171 
H 
H 
+ 
H 
H 
-
* 
+ 
H 
66% 
DIO 
S187 
+ 
-
H 
+ 
-
+ 
-
H 
H 
50% 
D18 
S70 
-
H 
-
-
-
+ 
-
-
* 
14% 
LOHd 
1/3 
0/3 
1/4 
2/4 
0/2 
2/3 
0/4 
2/4 
0/2 
10 
11 
12 
13 
14 
15 
16 
17 
18 
SNm 
SNm 
SNee 
SNe 
SNs 
SNm' 
SNe 
SNm 
SNee 
1.1 
2.6 
1.9 
1.4 
3.0 
1.9 
1.2 
1.1 
1.5 
LOH per marker 
-
-
# 
-
* 
-
-
-
-
0% 
-
-
# 
-
-
H 
-
H 
-
0% 
-
-
# 
H 
H 
-
-
* 
-
0% 
H 
-
# 
-
-
H 
# 
-
H 
0% 
-
-
# 
-
-
H 
# 
-
H 
0% 
0/4 
0/5 
0/0 
0/4 
0/3 
0/2 
0/3 
0/3 
0/3 
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Interpretation 
Interpretation of the results was based on evaluation by naked eye of plotted 
graphics assisted by calculating the allelic imbalance ratio between tumour and 
control tissue, using data on peak top level and peak area. 
RESULTS 
The main results of the described experiments are summarized in Table I. In 
figure I plotted graphics are presented for three cases. From all cases DNA could 
be obtained from both the tumour and the control tissue, even if the starting 
material was little. There was a correlation between the estimated amount of 
microdissected tumour cells and the amount of DNA isolated from the tissues. 
PCR- and electrophoresis conditions were adjusted in such a way that optimal 
results were obtained. Per marker (primer set) optimal conditions were es-
tablished by varying the MgCl2 concentration in the PCR. For some samples of 
large lesions the isolated DNA had to be diluted before PCR to obtain optimal 
results. On the other hand, for small amounts of dissected tissue, up to 40 cycles 
had to be used to obtain sufficient product for electrophoresis. The amount of 
tumour DNA and control DNA of a pair was adjusted to similar levels as much 
as possible. The extra extension step at 72°C allowed for a better interpretation 
of the final graphic output. Per case and marker, a repeated experiment under 
optimal conditions was performed with reproducible results. Whereas most data 
were évaluable, some results were obtained which did not allow a conclusive 
interpretation. Five types of results were formulated: 1) homozygous, 2) 
heterozygous with LOH, 3) heterozygous and no LOH, 4) data not interpretable 
with regard to LOH due to a large difference in length between the two alleles 
with highly preferential PCR of the smaller allele, 5) data not interpretable with 
regard to (loss of) heterozygosity for unknown factors, probably representing 
poor quality DNA in combination with PCR-procedure derived factors, resulting 
in non-typical, non-explainable peak patterns. 
With regard to the informativeness of the different markers in the tumours (both 
melanomas and Spitz naevi) the percentage of heterozygosity in évaluable cases 
was 93% for D3S1293; 75% for D6S271; 53% for D9S171; 63% for D10S187 
and 80% for D18S70, which was somewhat higher than reported for the 
chromosome 3 marker but considerably lower for the chromome 9 and 10 
markers (see Table II). This discrepency is probably due to the limited number of 
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lesions evaluated in this study. 
In melanomas 8 out of 29 informative markers showed LOH (28%). LOH for 
marker D3S1293 was found in 1 out of 7 cases (14%). For the markers D6S271, 
D9S171, D10S187 and D18S70 these percentages were 17, 66, 50 and 14 
respectively. Five out of 9 melanomas showed LOH at at least one locus (56%). 
There was no correlation between the estimated degree of contamination of 
tumour cells with non-tumour cells and the absence of LOH. 
In the group of Spitz naevi no LOH was found: none of eight évaluable cases 
showed allelic loss on informative loci, including those with nuclear atypia. The 
total number (27) and the distribution of the informative markers in Spitz naevi 
and also the degree of contamination with non-tumour cells was comparable to 
that found for melanomas. 
Table Π: Genomic localisation, heterozygosity and length of microsatellite 
markers used* 
chromosomal 
region 
heterozygosity 
(%) 
allele length (bp) 
D3S1293 
3p24.2-ter 
80 
116-144 
D6S271 
6q25.2 
85 
166-208 
D9S171 
9p21 
80 
159-177 
D10S187 
10q22-ter 
84 
92-114 
D18S70 
18q23 
83 
111-126 
" based on the genome database: http://gdbwww.gdb.org/ 
DISCUSSION 
In this paper we report on the use of the detection of LOH in diagnostic 
melanocytic pathology. For this purpose microsatellite allelotyping using non­
radioactive, fluorescence-based automated DNA-sizing technology was applied. 
The knowledge on genetic mechanisms related to the initiation and progression of 
human malignancies has increased substantially with studies on the selective loss 
of DNA sequences in tumours in comparison with normal tissues. Loss of genetic 
material in tumours has been taken as evidence for the involvement of tumour 
suppressor genes. The analysis of highly polymorphic microsatellites by PCR 
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facilitated LOH-studies and the small size of these markers was found to be an 
advantage in the studies of archival tissues, since they proved relatively insen-
sitive to autolysis and to routine procedures used in pathology, including formalin 
fixation and paraffine embedding. These characteristics imply that microsatellite 
analysis might also be of interest for diagnostic pathology, moreover because 
only small samples are needed. We investigated whether the detection of LOH 
may serve diagnostic purposes in the differential diagnosis of melanoma versus 
Spitz naevus. This study was designed to explore this hypothesis in a group of 
lesions that in theory would harbour the highest chance of positive results, this in 
order to assess technical aspects next to the diagnostic issue. 
In the course of this study we learned what difficulties are related to the techni-
ques used when applied to formalin-fixed, paraffin-embedded tissue-derived 
DNA. The inherent difficulty of discriminating between presence or absence of 
LOH was noted. This is probably based on problems related to contamination of 
tumour with non-tumourous tissue due to the inevitable presence of normal cells 
in tumour samples. To this end, several factors were taken into consideration at 
the start of this study. Tumour lesions were microdissected guided by parallel 
H&E-stained slides and the relative extent of contamination of the tumour parts 
with lymphocytes and stromal components was estimated. Cases were selected in 
the first place for the absence of a brisk infiltration of lymphocytes or an exten-
sive stromal component. Based on titration experiments using autoradio-graphical 
methods, Gruis et al. described that for a tumour with LOH, a safe margin to 
handle to avoid false negative cases is to require a minimum of 40% of tumour 
cells in the sample (20). However, as we do not know the quality of the tumour 
DNA compared to the control DNA we feel uncertain to formulate that contami-
nation was only a minor problem in our experiments, although lesions were 
selected for an estimated percentage of tumour cells of 60 or more. 
Figure 1 (next page): LOH presence or absence in melanocyte lesions. 
Examples of plotted curves representing electrophoresis patterns, showing fluorescence 
intensity (Y-axis) versus basepair-number (X-axis). The number in the upper rectangle 
represents the basepair number position of the peak, the middle rectangle shows the peak 
top level and the lower rectangle indicates the area of the peak. A: malignant melanoma 
with LOH for marker D9S171 (in the tumour, the 161 bp peak is too small compared with 
the ratio between the peaks in the control); B: melanoma homozygous for marker 
D9S171; C: Spitz naevus without LOH for marker D9S171. 
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In addition, heterogeneity in lesions may be a factor diluting the targeted aberrant 
DNA. In diagnostic practice, these considerations would imply that the absence 
of LOH should always be regarded with care in cases with an estimated small 
percentage of tumour cells. One approach may be a precise quantification of 
contaminating cells in parallel slides. Further, to obtain insight into problems 
related to contamination and heterogeneity, selection procedures using laser 
microdissection equipment may be valuable. In line with this, our results imply 
promising perspectives with regard to the use of microsatellites in studies on 
melanocyte tumour progression, if combined with laser dissection. This because 
in situ techniques to study small deletions in routinely processed tissues are not 
available (21,22). 
Another technical aspect of importance is the PCR procedure. It remains difficult 
to perform reliable quantitative PCR experiments in which the relative amount of 
product of either allele reflects the relative amount of starting material of these 
alleles. To reduce these problems, we always compared PCR products of tumour 
and control DNA pairs that were derived from the same experiment, using the 
same number of cycles and that contained a similar amount of PCR product, as 
judged on agarose gels. Moreover, only data that were reproducible in indepen-
dent experiments were used for analysis. The preferential amplification of the 
smaller allele in cases with a large difference in basepair length of the alleles 
prohibited a conclusive analysis of the possible loss of the larger allele (cases 
marked with an asterix in Table I). Although a minimal difference in length (one 
dinucleotide) would thus be preferable, in the PCR always a product of one 
dinucleotide smaller than the genuine allele is formed. This results in overlapping 
curves for the alleles in such heterozygous cases, complicating the evaluation 
(part of the cases marked ft in Table I). Cases with intermediate differences in 
length of the alleles proved to be best suitable to arrive at a conclusive 
interpretation. 
As expected also some unexplainable and thus uninterpretable results were 
encountered, including all markers tested in case no 12. These results were 
probably due to poor quality of the DNA caused by autolytic degradation or 
formalin fixation (17). Also PCR artefacts may be important here, but, although 
in general more PCR artefacts are introduced when starting with a smaller 
amount of DNA, three cases in our series with the smallest amount of starting 
tissue showed proper curves. Notwithstanding the mentioned problems, it was 
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possible to classify most cases with regard to (loss of) heterozygosity. 
While five out of nine melanomas showed LOH for at least one of five markers 
used, no LOH was found in Spitz naevi. Although we studied only a limited 
number of melanomas, our results are in line with data from the literature, 
especially with regard to the high percentage of LOH found for the 9p and lOq 
markers, underlining the frequent involvement of these regions in melanoma (6). 
Unfortunately, in our study the markers used in these regions (D9S171 and 
D10S187) were homozygous in a rather large proportion of melanomas. We 
assume that if more melanoma cases would have been heterozygous for the 
chromosome 9 marker, more melanoma cases with LOH would have been found. 
So, in diagnostic terms, the sensitivity of the detection of LOH to support the 
diagnosis of melanoma is complicated by homozygosity of the markers. The use 
of more markers per chromosomal region of diagnostic interest may circumvent 
this problem. Also, more results on one relevant region may corroborate each 
other. Like the use of more markers per region, the use of markers on more 
chromosomal regions may improve the sensitivity with regard to the detection of 
LOH. Although in our set it appeared that the study of more regions besides 9p 
and lOq provided no additional information, in the literature melanoma cases are 
described with LOH detected only in regions other than 9p or lOq (6,16). As at 
diagnostic evaluation of a lesion one does not know in which specific stage of 
genomic abnormality a presumed melanoma has arrived, both early markers and 
late markers may harbour diagnostic information. Further studies may clarify the 
additional value of including more early and/or late markers. 
In our group of Spitz naevi we did not find LOH, which would imply a high 
specificity for melanoma of the finding of LOH. In the course of this study, 
Healey et al reported on LOH in 2 out of 27 Spitz naevi, both on chromosome 9p 
(one out of 20 informative cases with marker D9S171 and one out of 14 with 
marker D9S162). No further LOH in Spitz naevi was found by these authors, 
using 12 markers targeting those 7 chromosomal regions (3p, 6q, 9p, 9q, lOq, 
17p and 18q) which in their group of melanomas showed the highest percentage 
of LOH (18). With regard to this it is interesting that our two évaluable atypical 
Spitz Naevi did not show LOH. Nevertheless, as deletions on 9p also otherwise 
seem to be not truly malignancy specific as they were also, although rarely found 
in dysplastic naevi, LOH in regions other than 9p may be less sensitive but more 
specific for melanoma (18). So, both from a diagnostic and cell biological interest 
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a future study might, next to the incorporation of a larger number of unequivocal 
as well as misdiagnosed melanomas and Spitz naevi, also include dysplastic 
naevi, all with a well documented follow-up. With regard to patient care, besides 
the diagnostic benefit, another interesting perspective of LOH detection is the 
identification of additional prognostic factors for melanoma patients, both derived 
from the primary tumour as well as on the basis of the detection of free tumour 
DNA in blood (21,23). 
We conclude on the basis of our results that the detection of LOH through 
microsatellite-allelotyping using fluorescence-based technology may be valuable in 
the differential diagnosis of melanoma versus Spitz naevus, which merits further 
study. 
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SUMMARY 
The melanin pigment in the human skin is produced by melanocytes. Naevocel-
lular naevi may be regarded as benign neoplasms of melanocytes. Malignant 
neoplasms of melanocyte cells are termed "malignant melanoma", synonymously 
used with "melanoma". Two pathways of tumourigenesis in melanoma have been 
proposed: a de novo proliferation of epidermal melanocytes can occur or a more 
gradual progression via melanocyte naevi as an intermediate stage. An inter-
mediate lesion in melanocyte tumour progression between the common acquired 
naevus and melanoma has been recognized and termed "dysplastic naevus". This 
lesion is considered a clinically relevant potential precursor of melanoma. 
Although melanoma is not a "big killer", in young adults it is an important cause 
of death and for various reasons, many clinical and basic research activities have 
focussed on this type of cancer. From a clinical point of view, immunotherapy 
using transduced human cells, sentinel node procedures and refined isolated limb 
perfusion protocols are examples of innovative patient care. With respect to 
tumour biological research, malignant melanoma and its precursors form an 
attractive model because of the possibility to study molecular aspects of tumour 
progression using a series of discrete stages, which can be identified histological-
ly by the pathologist. For the general pathologist melanocyte lesions form a 
substantial part of the daily work, which may be related to an increased interest 
in recognizing melanoma at a curable stage and in recognizing precursor stages. 
Relevant clinico-pathological characteristics of melanoma, the dysplastic naevus 
and another type of naevus i.e. the Spitz naevus, are described in the general 
introduction (chapter 1), since they create a substantial part of the problems 
encountered by diagnostic pathologists. 
In chapter 2, the character and relative extent of difficult areas in melanocytic 
pathology is described as deducted from the cases submitted to the Pathology 
Panel of the Dutch Melanoma Working Group. A consecutive series of 1069 
referral cases, submitted in 1992 through 1994 were analysed. Of the 158 lesions 
classified as invasive melanoma by the referring pathologists, 22 were considered 
to be benign by the panel. Conversely, 108 invasive melanomas (panel diagnosis) 
had originally been considered as benign naevus or melanoma in situ. Most 
diagnostic difficulties were encountered with dysplastic naevi and Spitz naevi and 
the results give guidance to the focussing on efforts to reduce the specific 
problems regarding these lesions. To this end, in this thesis histomorphological, 
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as well as immunohistochemical, DNA-in situ hybridization (DNA-ISH) and 
allelotyping approaches are described. 
Chapter 3 describes the attempt made, through an interobserver study among 
experts in the field of melanocyte pathology in Europe, to come up with a set of 
best reproducible histomorphological parameters in melanocyte lesions leading to 
the highest chance of obtaining a reproducible, although still arbitrary histological 
"boundary" between dysplastic naevi and common acquired naevi. This is 
important because the histological identification of a dysplastic naevus may 
indicate that, like melanoma itself, the patient has an increased risk of developing 
a (subsequent) melanoma, possibly in the context of the dysplastic naevus 
syndrome, the latter potentially also of importance for the family of the patient. 
Although there is still discussion on the histological criteria which are obligatory 
for the diagnosis of a dysplastic naevus, basically, the selection and weight of a 
feature for a diagnostic purpose rests on its validity in terms of the discriminatory 
value (efficacy) and the reproducible recognition among observers. To investigate 
this, ten (dermato)pathologists studied fifty cutaneous melanocyte lesions 
including common naevocellular naevi, dysplastic naevi, melanomas in situ and 
invasive primary melanomas. Using a standardized form, 20 defined his-
topathological features were scored (semi)quantitatively. Concordance of diag-
nosis, efficacy and reproducibility of features were investigated. Dysplastic naevi 
were distinguished well from the other entities (mean P0 0.87). Agreement on the 
degree of atypia of dysplastic naevi was low. The reproducibility of the scoring 
was best for the following features: irregular nests, lymphohistiocytic infiltrate, 
marked junctional proliferation and large nuclei. The overall values of these 
features to discriminate between dysplastic naevi and non-dysplastic naevi were 
better than for the other features studied. Using the presence of at least 3 of the 4 
features as a condition for the diagnosis of dysplastic naevi, values for sensitivity, 
specificity, positive and negative predictive values were 0.86, 0.91, 0.96 and 
0.73, respectively. On the basis of the results these features seemed best suited as 
histological criteria for the diagnosis of dysplastic naevi. 
The dysplastic naevus as a simulant of melanoma is another histopathological 
problem. Especially the differentiation between the deeper dermal part of a 
malignant melanoma versus the naevus remnant underlying a micro invasive, 
radial growth phase melanoma is a clinically relevant problem as it has major 
impact on the Breslow thickness and thus on prognosis and clinical management. 
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As a basis towards a possible application in this differential diagnosis, chapter 4 
presents a study on the expression of the epidermal growth factor receptor 
(EGFR) on melanocyte cell lines and tissues at the protein and mRNA level, in 
order to determine the use of EGFR as a possible progression marker. EGFR 
expression in six human melanoma cell lines was compared by utilizing the 
monoclonal antibodies 2E9, 425 and 225, applying four immunocytochemical 
staining procedures. A three-step immunoperoxidase method using the 
monoclonal antibody 2E9 proved the most sensitive. Staining intensities, es-
timated semi-quanti tati vely, correlated well with the quantitative data obtained by 
multiple point ligand binding assays which showed that EGFR expression in the 
highly metastasizing cell lines MV3 and BLM was at least 40 times higher than 
in the cell lines IF6, 530, M14 and Mel57 which do not or only sporadically 
metastasize after subcutaneous inoculation into nude mice. Expression on the 
mRNA level by Northern blot analysis was also in agreement with these results. 
Immunohistochemical staining of a large series of human cutaneous melanocytic 
lesions showed differential EGFR expression in various stages of melanocytic 
tumour progression: 19% of common naevocellular naevi, 61% of dysplastic 
naevi, 89% of primary cutaneous melanomas and 91% of melanoma metastases 
showed staining of melanocytic cells. It was concluded that EGFR expression 
increases in melanocytic tumour progression. 
Chapters 5-7 concern approaches which can be used to reduce the number of 
cases with an unpredictable behaviour in the differential diagnosis of melanoma 
versus Spitz naevus. To this end, DNA-ISH and allelotyping experiments were 
performed using routinely processed, formalin-fixed, paraffin-embedded tissues. 
In chapter 5 a study on the feasibility of DNA-ISH on melanocytic cell lines and 
tissues is described, in order to be able to study genomic changes and 
heterogeneity during melanocytic tumour progression. The possibility to detect 
numerical aberrations with respect to the (peri-)centromere regions of 
chromosomes 1 and 7 in intact nuclei of two human melanoma cell lines with 
different metastatic behavior in nude mice, was studied. In addition, paraffin 
sections from xenograft lesions were used, obtained by inoculation of these cell 
lines into nude mice (subcutaneous tumours and spontaneous lung metastases). 
Paraffin sections from the original primary cutaneous melanoma (with a 
subepidermal and a dermal part) and two loco-regional metastases were also 
studied, one of which was the source for the cell lines. With regard to the cell 
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lines, the ISH analysis correlated well with data obtained by ISH on metaphase 
spreads. Differences between the lines, which could not be detected by flow-
cytometric or conventional karyotyping analysis, included data suggestive of a 
polyploid subpopulation and an extra copy of chromosome 7 in the metastasizing 
cell line. The polyploid population could be detected also in the paraffin sections 
of the corresponding subcutaneous xenografts and lung metastases in the mice. 
Both areas in the patients' primary melanoma could be evaluated separately and 
showed similar supernumerary aberrations of the chromosome-specific targets. 
These abnormalities matched those found in both metastases. The results demon-
strated that DNA-ISH can be used to visualize genomic abnormalities at the 
single cell level in melanocyte nuclei in their natural context, which made it a 
possible tool in the histopathology of melanocytic lesions. 
In chapter 6, a study is described on the possible implementation of DNA-ISH in 
the histological differential diagnosis between Spitz naevus and malignant 
melanoma. To this end routinely processed paraffin sections of 15 typical Spitz 
naevi, 15 typical nodular melanomas, and five cases originally misdiagnosed as 
Spitz naevus but which later metastasized and were reclassified as melanoma 
were analysed using DNA-ISH. Microscopical semi-quantitative evaluation 
revealed that the number of nuclei with supernumerary aberrations of the 
centromere region of chromosome 1, suggestive for aneuploidy, was significantly 
different in Spitz naevi and nodular melanomas. The mean number of aberrant 
nuclei per high power field was 0.41 and 4.01, respectively. On applying the 
results of the typical lesions to the equivocal, originally misdiagnosed lesions, 
three out of five could be identified as melanoma. These results suggested that 
the application of DNA-ISH may contribute to the positive identification of 
melanomas in the differential diagnosis with Spitz naevus. 
In chapter 7 a study is described in which routinely processed tissues were used 
as starting material to perform allelotyping experiments on Spitz naevi and 
malignant melanomas in order to investigate whether the phenomenon of loss of 
heterozygosity (LOH), as a marker for the presence of so-called early or later 
genetic events, may be used for diagnostic purposes. Five microsatellite markers, 
D3S1293, D6S271, D9S171, D10S187 and D18S70 were used to detect LOH at 
chromosomal regions 3p, 6q, 9p, lOq and 18q, respectively. The technical 
procedure using automated fluorescense-based DNA sizing equipment was 
optimised for this application. Criteria for the interpretation of the output 
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graphics were established, based on evaluation by naked eye assisted by cal-
culating allelic imbalance ratios. The overall number of tests évaluable with 
regard to the presence of LOH, was comparable for melanomas (29) and Spitz 
naevi (27). Not-interpretability was due to homozygosity of the markers (21) or 
to preferential PCR of a significantly smaller allele (5) or to factors not known, 
probably related to poor quality DNA (8). While 5 out of 9 melanomas showed 
LOH at at least one locus, LOH was not found in the 9 Spitz naevi studied. In 
melanomas with LOH, either the chromosome 9 marker or chromosome 10 
marker was involved. As most mentioned problems can be circumvented by the 
application of more markers, it was concluded that the results indicate that the 
detection of LOH may be valuable in the differential diagnosis of melanoma 
versus Spitz naevus, meriting further study. 
Summing up, in order to handle specific problems in melanocyte pathology, in 
this thesis molecular and morphological approaches are described. Some results 
of the studies are already implemented while others are of interest for future 
implementation in diagnostic melanocytic pathology. 
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SAMENVATTING 
Het melanine pigment in de menselijke huid wordt geproduceerd door 
melanocytes Naevocellulaire naevi (moedervlekken) kunnen worden beschouwd 
als goedaardige nieuwvormingen van melanocyten. Kwaadaardige nieuwvormin-
gen van melanocytaire cellen worden "maligne melanoom" genoemd of kortweg 
"melanoom". Voor de ontstaanswijze van melanomen worden twee routes 
voorgesteld: één direct vanuit epidermale melanocyten en een andere middels een 
stapsgewijze progressie via melanocytaire naevi. Bij melanocytaire 
tumorprogressie is een intermediaire afwijking tussen een naevus naevocellularis 
van het gebruikelijke type en een melanoom beschreven, die "dysplastische 
naevus" is genoemd. Deze laesie wordt beschouwd als een mogelijke voorloper 
van het melanoom. Ook wordt deze als een indicator voor een verhoogd risico op 
het ontstaan van een melanoom gebruikt bij het klinisch onderzoek. Ofschoon het 
melanoom niet een "big killer" is, is het bij jonge volwassenen een belangrijke 
oorzaak van overlijden en wordt er om verschillende redenen veel klinisch en 
basaal onderzoek verricht aan dit type kanker. Vanuit klinisch opzicht zijn im-
munothérapie middels vaccinatie met genetisch gemanipuleerde cellen, beperkte 
lymfklierdissectie (schildwacht-lymfklier-excisie) en geïsoleerde perfusie van de 
ledematen voorbeelden van innovatieve patiëntenzorg. Ook bij het tumor-
biologisch onderzoek vormen het melanoom en de voorloper stadia een aantrek-
kelijk model vanwege de mogelijkheid tot het bestuderen van moleculaire 
aspecten in een reeks opeenvolgende stadia, die histologisch door de patholoog 
geïdentificeerd kunnen worden. Voor de algemeen patholoog vormen 
melanocytaire afwijkingen een substantieel deel van het dagelijkse werk, 
waarschijnlijk ook samenhangend met een toegenomen aandacht voor het herken-
nen van melanomen in een curatief behandelbaar stadium alsook voor het herken-
nen van voorloper stadia. Relevante klinisch-pathologische kenmerken van het 
melanoom, de dysplastische naevus en een ander type naevus, te weten de Spitz 
naevus, worden beschreven in de algemene inleiding (hoofdstuk 1) omdat deze 
afwijkingen een substantieel deel uitmaken van de problemen bij melanocytaire 
afwijkingen waarmee pathologen geconfronteerd worden. 
In hoofdstuk 2 wordt de aard en de relatieve omvang beschreven van diagnos-
tische problemen bij melanocytaire afwijkingen op basis van een reeks gevallen 
die werd toegezonden aan het pathologen-panel van de Nederlandse Melanoom 
Werkgroep. Een opvolgende reeks van 1069 gevallen uit 1992, 1993 en 1994 
145 
werd geanalyseerd. Van de 158 afwijkingen die door de inzendende pathologen 
geclassificeerd werden als melanoom, werden er 22 door het panel als goedaardig 
beschouwd. Omgekeerd bleken er 108 melanomen (panel diagnose) 
oorspronkelijk beschouwd te zijn als een naevus of als een melanoma in situ. De 
diagnostische problemen deden zich vaak voor bij dysplastische naevi en Spitz 
naevi. Op basis hiervan kan nascholing en aanvullend onderzoek gerichter gedaan 
worden. Het in dit proefschift uitgevoerde histomorfologische als ook immunohis-
tochemische, DNA-in situ hybridisatie (DNA-ISH) en allelotyperingsonderzoek is 
tegen deze achtergrond verricht. 
Hoofdstuk 3 beschrijft een interobserver studie bij Europese pathologen die 
ervaren zijn in het veld van de melanocytaire pathologie. Het doel was om de 
best reproduceerbare parameters, zoals gebruikt bij de diagnostiek van naevi, te 
onderkennen. Door gebruik te maken van deze parameters bestaat immers de 
hoogste kans op het verkrijgen van een reproduceerbare, alhoewel nog steeds 
arbitraire histologische grens tussen een dysplastische naevus en een naevus 
naevocellularis van het gebruikelijke type. Dit is belangrijk omdat de his-
tologische diagnose "dysplastische naevus" net zoals de diagnose "melanoom" 
aangeeft dat de patiënt een verhoogd risico heeft op het ontwikkelen van een 
(volgend) melanoom, mogelijk in de context van een dysplastisch naevus 
syndroom. Dit laatste is mogelijk ook van belang voor de familie van de patiënt. 
Hoewel er nog steeds discussie gaande is over de histologische criteria die 
obligaat zijn voor de diagnose dysplastische naevus, is de waarde van een 
kenmerk voor een diagnostische toepassing gelegen in de bruikbaarheid, dat wil 
zeggen a) in het onderscheidend vermogen (efficacy) en b) in de reproduceerbare 
herkenning door verschillende waarnemers. Om dit te onderzoeken bestudeerden 
tien (dermato)-pathologen vijftig melanocytaire huidlaesies waaronder naevocel-
lulaire naevi van het gebruikelijke type, dysplastische naevi, melanomas in situ en 
invasieve primaire melanomen. Gebruikmakend van een gestandaardiseerd 
formulier werden twintig goed omschreven histopathologische kenmerken 
(semi)kwantitatief gescoord. Onderzocht werden overeenkomst in diagnose 
alsmede efficacy en de reproduceerbaarheid van de kenmerken. Dysplastische 
naevi werden goed onderscheiden van de andere entiteiten (gemiddelde P0 0.87). 
De overeenstemming over de mate van atypie in dysplastische naevi was echter 
laag. De reproduceerbaarheid was het beste voor de volgende kenmerken: 
irregulaire nesten, lymfohistiocytair infiltraat, duidelijke grensvlak activiteit en 
grote kernen. Op basis van juist ook deze kenmerken bleken dysplastische en 
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niet-dysplastische naevi goed onderscheiden te kunnen worden. Indien de aan-
wezigheid van tenminste drie van de vier genoemde kenmerken gebruikt werd als 
een voorwaarde voor de diagnose dysplastische naevus bedroegen de 
gevoeligheid, specificiteit en positieve en negatieve voorspellende waarde 
respectievelijk 0.86, 0.91, 0.96 en 0.73. Op basis van deze resultaten werden 
deze kenmerken beschouwd als de meest geschikte bij het diagnostiseren van 
dysplastische naevi. 
De dysplastische naevus kan door de aanwezigheid van cellulaire en architecturele 
atypie sterk op een melanoom lijken, hetgeen de histopathologische diagnostiek 
compliceert. Met name het onderscheid tussen een dieper dermaal deel van een 
melanoom versus een naevusrest gelegen onder een micro-invasief horizontaal 
groeiend melanoom is klinisch relevant omdat het van grote invloed is op de 
Breslow-dikte en dus op de prognose en het klinisch beleid. Als een mogelijke 
bijdrage om te komen tot de juiste diagnose wordt in hoofdstuk 4 een onderzoek 
beschreven waarin de expressie van de epidermale groei factor receptor (EGFR) 
in melanocytaire cellijnen en weefsels op eiwit en mRNA niveau werd nagegaan, 
teneinde de waarde van EGFR als een mogelijke progressie merker te bepalen. 
De EGFR expressie in zes humane melanoom cellijnen werd vergeleken, gebruik-
makend van de monoclonale antilichamen 2E9, 425 en 225, terwijl vier im-
munocytochemische kleuringsprocedures werden toegepast. Een drie staps-im-
munoperoxidase methode met gebruikmaking van het 2E9 antilichaam was het 
meest gevoelig. De semikwantitatief ingeschatte aankleuringsintensiteiten cor-
releerden goed met de kwantitatieve gegevens die verkregen waren middels een 
"multiple point ligand binding assay", die aantoonden dat EGFR expressie in de 
sterk metastaserende cellijnen MV3 en BLM tenminste 40 keer zo hoog was als 
in de cellijnen IF6, 530, M14 en Mel57, die na subcutane inspuiting bij naakte 
muizen niet of alleen sporadisch uitzaaien. De expressie op mRNA niveau 
volgens een Northern blot analyse was eveneens in overeenstemming met deze 
resultaten. Immunohistochemische kleuring van een grote reeks humane 
melanocytaire huidlaesies toonde een differentiële EGFR expressie in verschil-
lende stadia van melanocytaire tumorprogressie: 19% van de naevocellulaire 
naevi van het gebruikelijke type toonde aankleuring van de melanocytaire cellen, 
terwijl dit 61% was voor de dysplastische naevi, 89% voor de primaire huid-
melanomen en 91% voor de melanoom metastasen. Er werd geconcludeerd dat de 
EGFR expressie toeneemt bij melanocytaire tumorprogressie. 
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De hoofdstukken 5, 6 en 7 betreffen benaderingswijzen die gebruikt kunnen 
worden om bij de lastige differentiaal diagnose tussen het melanoom en een Spitz 
naevus, het aantal niet of moeilijk te classificeren gevallen te reduceren. Hiertoe 
werden DNA-ISH en allelotyperingsexperimenten uitgevoerd, gebruikmakend van 
routinematig verwerkte formaline-gefixeerde en paraffine-ingebedde weefsels. 
In hoofdstuk 5 werd de mogelijkheid tot het toepassen van DNA-ISH op 
melanocytaire cellijnen en weefsels onderzocht, tegen de achtergrond van de 
mogelijkheid tot het bestuderen van genetische afwijkingen en heterogeniteit bij 
melanocytaire tumorprogressie. Bestudeerd werd de mogelijkheid om numerieke 
afwijkingen van de centromeer regio's van chromosoom 1 en 7 aan te tonen in 
intacte kernen van twee humane melanoomcellijnen met een verschillend metas-
taseringsgedrag in naakte muizen. Daarnaast werden paraffinecoupes gebruikt van 
materiaal afkomstig van tumoren verkregen door inspuiten van de cellijnen bij 
naakte muizen (subcutane tumoren en spontane longmetastasen). Ook werden 
paraffinecoupes van het oorspronkelijke primaire huidmelanoom (met een 
subepidermaal en een dermaal gedeelte) bestudeerd alsmede twee loco-regionale 
metastasen, waarvan er één het uitgangsmateriaal vormde voor de cellijnen. Voor 
wat betreft de cellijnen correleerde de ISH-analyse goed met gegevens gekregen 
middels ISH op metaphase preparaten. Verschillen tussen de cellijnen die niet 
konden worden gedetecteerd met flow-cytometrische of conventionele 
karyotyperingsanalyse waren een polyploide subpopulatie van tumorcellen en een 
extra copie van chromosoom 7 in alleen de metastaserende cellijn. De polyploide 
cellen konden ook gedetecteerd worden in paraffinecoupes van de cor-
responderende subcutane tumor en longmetastasen in de muizen. Beide gebieden 
in het primaire melanoom van de patiënt konden afzonderlijk geëvalueerd worden 
en toonden soortgelijke numerieke afwijkingen van de bestudeerde chromosoom 
regio's. Deze afwijkingen kwamen overeen met die in de beide metastasen. De 
resultaten toonden aan dat DNA-ISH gebruikt kan worden om genetische afwij-
kingen te visualiseren op het niveau van de enkele cel in melanocytaire kernen in 
hun natuurlijke context, hetgeen DNA-ISH een potentiële aanvullende techniek in 
de histopathologic van melanocytaire laesies maakt. 
In hoofdstuk 6 is een studie beschreven naar de mogelijke implementatie van 
DNA-ISH bij de histologische differentiaal diagnostiek tussen Spitz naevus en 
melanoom. Hiertoe werden coupes gebruikt van vijftien typische Spitz naevi, 
vijftien typische nodulaire melanomen en vijf gevallen die oorspronkelijk diagnos-
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tiseerd waren als Spitz naevus maar die later bleken te metastaseren en dus 
uiteindelijk geclassificeerd werden als melanoom. Deze gevallen, waarvan de 
weefsels routinematig verwerkt waren, werden geanalyseerd met behulp van 
DNA-ISH. Een microscopische, semikwantitatieve evaluatie toonde dat het aantal 
kernen met getalsmatige afwijkingen van de centromeer regio van chromosoom 1, 
hetgeen suggestief is voor aneuploidie, significant verschillend was in Spitz naevi 
en nodulaire melanomen. Het gemiddelde aantal afwijkende kernen bij hoge 
vergroting was 0.41, respectievelijk 4.01. Bij toepassing van deze resultaten op 
de oorspronkelijk incorrect geclassificeerde laesies konden drie van de vijf 
geïdentificeerd worden als melanoom. Deze resultaten wijzen erop dat de 
toepassing van DNA-ISH kan bijdragen aan het identificeren van een melanoom 
bij de differentiaal diagnose met een Spitz naevus. 
In hoofdstuk 7 is een studie beschreven waarin ook routinematig behandelde 
weefsels werden gebruikt als uitgangsmateriaal om allelotyperingsexperimenten te 
doen op Spitz naevi en maligne melanomen teneinde oriënterend te onderzoeken 
of het verschijnsel van verlies van heterozygotie (LOH), als kenmerk voor de 
aanwezigheid van zogenaamde vroege of late genetische veranderingen, voor 
diagnostische doeleinden gebruikt kan worden. Hiertoe werden vijf microsatelliet 
merkers, te weten D3S1293, D6S271, D9S171, D10S187 en D18S70 gebruikt om 
LOH aan te tonen op de chromosoomregio's 3p, 6q, 9p, 10q en 18q. De tech-
nische procedure, waarbij gebruik gemaakt werd van geautomatiseerde op 
fluorescentie gebaseerde DNA-metingsapparatuur, werd voor deze toepassing 
geoptimaliseerd. De criteria voor de interpretatie van de uiteindelijke curves, 
welke werden geëvalueerd met het blote oog, ondersteund door het berekenen 
van de imbalans ratio tussen allelen, werden vastgesteld. Het totaal aantal testen 
dat evalueerbaar was voor wat betreft de aanwezigheid van LOH, bleek ver-
gelijkbaar voor melanomen (29 testen) en Spitz naevi (27 testen). Het niet 
interpreteerbaar zijn van een test was te wijten aan homozygotie van de markers 
(21 testen), preferentiële PCR van een significant kleiner allei (5 testen) of aan 
onbekende factoren, die waarschijnlijk te maken hadden met slechte kwaliteit van 
het geïsoleerde DNA (8 testen). Vijf van de negen melanomen toonden LOH van 
tenminste één locus, terwijl geen LOH gevonden werd in de negen onderzochte 
Spitz naevi. Bij de melanomen met LOH was altijd of de chromosoom 9 of de 
chromosoom 10 merker betrokken. Aangezien meerdere van de genoemde 
problemen kunnen worden verholpen door gebruik te maken van extra merkers, 
werd geconcludeerd dat het detecteren van LOH waardevol kan zijn als hulpmid-
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del bij de differentiaal diagnose van melanoom versus Spitz naevus, hetgeen 
verder onderzoek rechtvaardigt. 
Samenvattend zijn in dit proefschrift moleculaire en morfologische 
benaderingswijzen beschreven die van waarde kunnen zijn om specifieke 
problemen in de melanocytaire pathologie op te lossen. Sommige van de 
verkregen resultaten zijn inmiddels geïmplementeerd terwijl andere interessant 
zijn om verder te valideren voor een toekomstige toepassing in de diagnostische 
melanocytaire pathologie. 
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1. Bij het stellen van de histopathologische diagnose maligne melanoom op de 
kinderleeftijd moet grote terughoudendheid betracht worden. 
(dit proefschrift; Spatz et al., Int J Cancer 1996; 68: 317-324) 
2. De histopathologisch bepaalde grens tussen een naevus naevocellularis van 
het gebruikelijke type enerzijds en een dysplastische naevus anderzijds kan 
het beste getrokken worden op basis van de volgende kenmerken: a. sterk 
toegenomen grensvlakactiviteit; b. onregelmatige nesten; с grote kernen; d. 
lymfohistiocytair infiltraat. 
(dit proefschrift) 
3. Immunohistochemische en biochemische analyses zijn complementair bij het 
onderzoek van eiwitten in weefsels. 
4. DNA-In Situ Hybridisatie en genetische analyse van verlies van 
heterozygotie kunnen bijdragen tot het diagnostiseren van een maligne 
melanoom door de patholoog. 
(dit proefschrift) 
5. Moleculaire diagnostiek en prognostiek in de oncologie vergt bundeling van 
krachten vanuit meerdere disciplines, waaronder zeker de pathologie. 
6. Kinderen die een leukemie en de behandeling daarvoor overleefd hebben 
moeten gecontroleerd worden op (pre-)maligne melanocytaire afwijkingen 
van de huid. 
(De Wit et al., Med Pediatrie Oncol 1990; 18: 336-338; Curtis et al, NEJM 
1997, 336: 897-904) 
7. Bij een krimpend budget krijgt het woord kwaliteitszorg een accent­
verschuiving van verzorging naar bezorgdheid. 
8. Zwijgen is alleen dan goud indien deze tijd gebruikt wordt om na te denken 
over wat men moet gaan zeggen. 
9. De fixatie van veel pathologen op fixatie-technieken is niet pathologisch. 


